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ABSTRACT 
Shared Molecular Features of Inherited and Sporadic ALS/FTD 
Erin G. Conlon 
Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) are two 
devastating neurodegenerative diseases in urgent need of therapeutic intervention. The 
last seven years has been a period of great progress in understanding these disorders 
separately and as a disease spectrum. Most notable is the discovery of the 
hexanucleotide GGGGCC expansion in the C9ORF72 (C9) gene, which is the greatest 
known cause of inherited and sporadic forms of these two diseases. In response to this 
groundbreaking discovery, we set out to elucidate the molecular mechanisms of C9 
pathogenesis with a focus on the expanded RNA transcripts derived from the C9 
expansion. Our two primary goals have been to contribute to the worldwide efforts to 
understand the primary toxic insults of this mutation that will ultimately shape 
therapeutic development, and to identify molecular criteria that can be used to define 
new links between these diseases and undetermined genetic factors. 
In the introduction, we review the broad conceptual links between RNA binding 
proteins (RBPs), mRNA regulation, and neurodegeneration. This review, published in 
Genes and Development, contains substantial discussion of ALS, FTD, and C9, as well 
as related neurodegenerative, neuromuscular and repeat expansion diseases. In 
addition to providing a detailed history of molecular mechanisms proposed for these 
disorders, this section serves as a justification for our focus on the C9 RNA, RBP 
sequestration, and altered splicing that we describe in the following chapters. 
Chapter two consists of our 2016 Elife paper on sequestration of the RBP 
hnRNP H and resulting splicing changes in C9ALS-FTD afflicted individuals. In this 
paper, we sought to identify the most biochemically sound candidate for the proposed 
RBP sequestration hypothesis. We found that the splicing factor hnRNP H binds with 
high affinity to the repeat sequence and likely has a role in regulating the transition of 
the repeat RNA from linear to G-quadruplex (G-Q) conformation. Importantly, we 
identified functional deficiency of this protein in patient brains, as evidenced by 
dysregulation of known hnRNP H splicing targets, and loss of soluble hnRNP H.
Chapter three consists of recently submitted work on the molecular links 
between C9ALS/FTD, and sporadic ALS/FTD at large. Building upon our findings in 
C9ALS-FTD, we have sought to ask whether the changes to hnRNP H we predicted 
would occur in C9 expansion carriers as a result of the repeat RNA might also occur 
independent of this expansion. We found that indeed half of all patients in a cohort of 
50 sporadic ALS, ALS-FTD, and FTD brains demonstrated hnRNP H sequestration and 
accompanying splicing changes, a pattern we refer to as like-C9. Like-C9 patients may 
be thought of as phenocopies of C9 expansion carriers, in that they not only present 
with similar clinical symptoms, but also possess remarkably similar molecular 
signatures of RBP dysfunction. While the genomic origins of like-C9 remain unknown, 
we propose that they are suggestive of repeat expansions analogous to C9, much like 
what is seen in DM1 and DM2, and HD and HDL2 (discussed in Ch. 1). This work has 
provided the foundation for our ongoing search for novel genomic expansions that 
confer increased susceptibility to ALS/FTD. 
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Abstract 
Neurodegeneration is a leading cause of death in the developed world and a natural 
albeit unfortunate consequence of longer-lived populations. Despite great demand for 
therapeutic intervention, it is often the case that these diseases are insufficiently 
understood at the basic molecular level. What little is known has prompted much 
hopeful speculation about a generalized mechanistic thread that ties these disparate 
conditions together at the subcellular level and can be exploited for broad curative 
benefit. In this review we will discuss a prominent theory supported by genetic and 
pathological changes in an array of neurodegenerative diseases: that neurons are 
particularly vulnerable to disruption of RNA binding protein dosage and dynamics. We 
will synthesize the progress made at the clinical, genetic, and biophysical levels and 
conclude that this perspective offers the most parsimonious explanation for these 
mysterious diseases. Where appropriate, we will highlight the reciprocal benefits of 
cross-disciplinary collaboration between disease specialists and RNA biologists, as we 
envision a future in which neurodegeneration declines and our understanding of the 
broad importance of RNA processing deepens. 
 
Introduction 
Alternative transcript processing is an effective mechanism to generate functional 
diversity from a fixed volume of genetic information. Such types of justifications are 
often called upon to rationalize the lack of correlation between the number of genes in 
an organism’s genome and its perceived complexity. Nowhere is this more pertinent 
than in studies of the human brain, the most cellularly and functionally complex organ 
amongst all living things. While much research has focused on how cis-acting 
elements within alternatively processed transcripts provide instructions for the 
multitude forms they can take, the mechanisms through which these signals impart 
different meaning in a context-dependent manner depends heavily on their trans-acting 
effectors, RNA binding proteins (RBPs). RBPs seldom act alone but rather form 
extensive protein-protein and protein-RNA interactions in an immense number of 
permutations that allow for spatial and temporal control of gene expression in 
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response to a range of stimuli. Given the scope and intricacy of functions the human 
central nervous must regulate, it is thus not surprising that disruption of precise RBP 
stoichiometry, through mutations and pathological events, lead to a wide range of 
neurological and neurodegenerative diseases. In this review we will discuss recent 
findings and recurrent questions regarding the widening role of RBPs in human 
neurodegenerative diseases. For further insight into this topic, we refer the reader to a 
number of excellent related reviews (Cooper et al. 2009; Vanderweyde et al. 2013; 
Nussbacher et al. 2015; De Conti et al. 2016; Cookson 2017). 
 
RNA metabolism in the brain, a heightened demand 
The human brain contains a remarkable number of cells, currently estimated at 170 
billion, with an approximate 1:1 ratio of neurons:non-neurons, or glia (Azevedo et al. 
2009).  Neurons, the targets of neurodegeneration, come in countless varieties, 
differing in position (Fig. 1), size, neurotransmission and electrophysiological 
properties, yet they are united by several key features such as their polarization, ability 
to form networks with other neurons, and enormous energy demands (Herculano-
Houzel 2012; Sharpee 2014).  
While our analysis will focus primarily on genetically determined neurodegeneration, 
the greatest risk factor for neurodegeneration is normal ageing (Bishop et al. 2010). 
This underscores the point that neurodegeneration is a gradual, age-dependent 
process that may exploit another unique feature of neurons, which is their persistent 
metabolic activity across long lifespans (Magistretti and Allaman 2015). The molecular 
mechanisms put forward for neurodegenerative diseases must always strive to explain 
how accumulative damage due to inherited/germline mutations can manifest decades 
later in highly specific neuronal loss. Likewise, an important aspect of faithful disease 
modeling is the consideration of how different genetic variants lead to earlier onset and 
faster progression; as the factors that result in more serious disease may be of 
therapeutic interest as well as informative of the diseases themselves (Van Damme et 
al. 2017).  
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Alternative mRNA processing greatly increases the dimensions of gene expression 
beyond the on/off duality through splicing, polyadenylation, targeted localization and 
post-transcriptional silencing, and the cells in the brain take great advantage of these 
different strategies to diversify their repertoires. For example, it has been shown that 
the brain undergoes particularly high levels of alternative splicing relative to other 
human tissues, and also tends to follow more distinctive patterns (Yeo et al. 2004). 
Analogous types of analyses have similarly revealed that brain tissues are unique in 
alternative polyadenylation choices (Zhang et al. 2005). In recent years, more classes 
of RNAs, including miRNAs (Wang et al. 2012), eRNAs (Kim et al. 2010) and lincRNAs 
(Sauvageau et al. 2013; Wu et al. 2013), have been demonstrated to contribute to the 
fine-tuning of gene expression in the brain that specify its distinctive proteome and 
capacity for adaptive responses. While splicing will make up the majority of our 
discussion, in reality it’s impossible to consolidate the many ways RNA, and by 
association RBPs, make neurons unique. 
The outcomes of alternative splicing can have important biological relevance in the 
brain. This can include, for example, determining isoform expression patterns of 
receptors and channels critical to neurotransmission (Grabowski and Black 2001). 
Sometimes these brain-specfic events are regulated by binding of brain-restricted 
splicing factors such as NOVA (Jensen et al. 2000) or neural polypyrimidine tract 
binding protein (nPTB; Coutinho-Mansfield et al. 2007; Licatalosi et al. 2012). Yet for 
many specific neuronal splicing events, and for splicing events in general, splice site 
choices rely on the concerted action of many indispensable factors that are 
ubiquitously expressed (Chan and Black 1997; Chou et al. 1999). Thus it is seen that 
alternative RNA processing is driven by the competition inherent in the dynamic 
concentrations of RBPs with respect to other protein factors and the abundance of 
high-affinity sequences they bind (Dreyfuss et al. 1993; Chen and Manley 2009).  
 
Early Clinical examples 
Disease has been one of our biggest teachers when it comes to the importance of 
RBPs in defining neural identity. Just as classical ablation studies have enabled 
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researchers to map the contribution of different brain regions, naturally occurring 
human encephalopathies have unlocked molecular signatures of the brain’s function.  
Paraneoplastic Syndromes 
The neuronal RBPs Hu and Nova-1/2 were discovered as the targets of high-titer 
antibodies present in the sera of cancer patients with paraneoplastic neurologic 
disorders (PND). These proteins represent the misexpressed pathological culprits 
behind paraneoplastic encephalomyelitis/sensory neuronopathy (PEM/SN) and 
paraneoplastic opsoclonus-myoclonus ataxia (POMA), respectively (Darnell 1996). 
PNDs arise due to ectopic expression of brain-specific proteins in tumors, for instance 
in small cell lung cancer (PEM/SN and POMA) and breast and fallopian cancer (POMA) 
(Yang et al. 1998). The abnormal expression of these brain-restricted proteins causes 
the immune system to mount an attack on these antigens; thus, in the case of POMA, 
releasing auto-antibodies that attack Nova-1 in the regions of the brain and spinal cord 
where they are expressed in a highly restricted manner (Zhou et al. 2014). The 
generation of Nova-1 null mice highlighted the tissue-specific relevance of this protein, 
as the animals exhibited progressive motor dysfunction in their short lifespans before 
dying within 10 days postnatally, and importantly, displayed defects in specific splicing 
events critical to the affected cells and developmental period (Jensen et al. 2000). 
Subsequently, Nova-1 was the first protein to be subjected to CLIP analysis. CLIP, 
short for Crosslinking-Immunoprecipitation, enables profiling of the RNAs associated 
with a protein in vivo, and has been instrumental in much of the research we will 
discuss. For Nova-1, this effort led to the striking observation that three-quarters and 
one-third of Nova-1 splicing targets function in neuronal synapses and inhibition, 
respectively (Ule et al. 2003).  
The main symptoms of POMA are indicative of lower motor dysfunction (Buckanovich 
et al. 1993). However it has been noted that symptoms of POMA sometimes include 
atrophy of the cerebellum, a region not expressing Nova-1. Furthermore, POMA 
antisera are reactive against regions of the brain outside the limits of Nova-1 
expression. These inconsistencies led to the discovery of a highly similar protein, 
Nova-2 (Yang et al. 1998). Subsequent CLIP analysis of Nova-2 demonstrated a role in 
	   6	  
both brain-specific splicing and alternative polyadenylation (Licatalosi et al. 2008). 
Decreased Nova activity has been found in brains from a pooled cohort of 
Frontotemporal Dementia (FTD) and Alzheimer’s disease patients (Tollervey et al. 
2011b).  
  
Spinal Muscular Atrophy (SMA) 
Spinal Muscular Atrophy (SMA) is a juvenile-onset neurodegenerative disorder marked 
by the loss of lower motor neurons (MNs) from the anterior horn of the spinal cord. In 
its most extreme form, it is the most common monogenic cause of infant mortality 
(Prior 2010). The disease is caused by homozygous loss-of-function mutations in the 
gene SMN1, which together with the nearly identical SMN2 gene (unique to humans), 
encode the protein survival of motor neuron (SMN), a protein chaperone for 
spliceosomal factor biogenesis (Pellizzoni 2007; So et al. 2016). While SMN is not an 
RNA binding protein itself, its interaction with gemin proteins is critical for the efficient 
assembly of Sm proteins and snRNAs into snRNPs (Kolb et al. 2007). SMN thus 
resides upstream of the proper functioning of many RBPs by orchestrating the splicing 
process they participate in. 
While SMN in an essential protein in organisms from S. pombe to humans, its range of 
suboptimal levels in patients is the defining factor in the spectrum of differentially 
severe forms of SMA. This has prompted much inquiry into why MNs are seemingly 
more susceptible than other cells to low SMN levels (Kolb et al. 2007; Simone et al. 
2016; Tu et al. 2017).  
SMA is classified into three types based on age of onset and disease severity (Simone 
et al. 2016). The different clinical manifestations reflect the overall amounts of SMN 
protein (Lefebvre et al. 1997), which are determined by the mutation (deletion versus 
partial loss of function) in SMN1 (Tu et al. 2017), SMN2 gene copy number (Taylor et al. 
1998; Harada et al. 2002), and amount of full-length SMN2 produced (Fig. 1). Full-
length SMN2 represents the minority of total SMN2 produced, due to a translationally 
silent single nucleotide difference distinguishing exon 7 of SMN1 from SMN2. This 
polymorphism generates a novel exonic splicing silencer in the latter (or perhaps also 
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disrupts a splicing enhancer in the former; (Cartegni and Krainer 2002)) that is bound 
repressively by the RBPs hnRNP A1 and Sam68 (Kashima and Manley 2003; Pedrotti 
et al. 2010). MNs have been shown to express lower levels of exon 7-containing SMN2 
than other cells in the spinal cord, which is negatively reinforced in an SMN1-deficient 
context where splicing is most compromised (Ruggiu et al. 2012). Development of 
antisense oligonucleotides (ASOs) that promote exon 7 inclusion and increase full-
length SMN protein levels (Hua et al. 2007) and can rescue severe SMA mice when 
injected neonatally (Hua et al. 2011) thus represents a major therapeutic breakthrough. 
This technology led to the development of Biogen’s SpinrazaTM, the first FDA-approved 
therapy for SMA (Ottesen 2017), and has increased the hope that ASOs may be 
successful at mitigating other neurodegenerative diseases. 
A key question when disease-linked changes in gene expression arise from mutations 
affecting a transcription/RNA processing factor is the identity of the critical gene 
target(s) that lead to disease, and this is certainly true with SMN. A number of studies 
(Zhang et al. 2008; Lotti et al. 2012; Doktor et al. 2017) have pointed to defects in 
splicing of a class of introns known as U11/U12 introns. These introns represent less 
than 1% of all introns, and differ at their consensus 5’ donor and 3’ acceptor sites, 
requiring a spliceosome with distinct snRNPs for intron removal. Splicing of U11/U12 
introns is less efficient than is splicing of standard introns, which is thought to be a 
rate-limiting factor in the expression of genes that contain a U11/U12 intron (Turunen 
et al. 2013). Interestingly, a rare class of genes with more than one U11/U12 intron is 
the voltage-gated ion channel superfamily of genes (Wu and Krainer 1999), which 
themselves are mutated in neurodegenerative and neuromuscular disease (Andavan 
and Lemmens-Gruber 2011), suggesting that selectively compromised splicing of 
these transcripts may have disease relevance. Recently it was shown in mice that SMN 
deficiency leads to intron retention, particularly amongst U11/U12 introns, which can 
be reversed by increasing SMN levels (Jangi et al. 2017). While the affected genes 
were not similar in function, their pre-mRNA structures were, as they tended to have 
weaker 5’ and 3’ splice site, be GC-enriched, and contain more R-loop structures, to 
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which SMN has been independently been shown to be recruited (Zhao et al. 2016; 
Jangi et al. 2017).  
Efforts are ongoing to determine whether there is indeed a select repertoire of splicing 
changes associated with SMN deficiency from which one can rationalize disease 
features, or if SMN depletion leads to global splicing disruption that manifests 
differently depending on the splicing factors in a given cell type. While these 
mechanistic questions still remain, the evidence that SMN is indeed critical for MN 
survival builds. As was shown in SMA and control patient-derived iPSC-MNs, even 
amongst this cell population, there is variability in SMN levels in individual cells, and 
those with the lowest levels are the fastest to die, even when they were derived from 
healthy controls. Furthermore, while increasing SMN levels promoted survival of iPSC-
derived MNs in the face of stress, the same was not true for cells differentiated into 
cortical neurons (Rodriguez-Muela et al. 2017). While the special function of SMN in 
MNs remains a mystery, it is noteworthy that loss of nuclear Gems, a hallmark of SMA, 
has also been observed in Amyotrophic Lateral Sclerosis (ALS) (Shan et al. 2010; 
Yamazaki et al. 2012; Tsuiji et al. 2013), raising the possibility that SMN disruption may 
occur indirectly in this adult-onset MN disease. 
snRNP assembly/splicing is not the only process of mRNA biogenesis that SMN has 
been implicated in. Evidence for a role in axonal mRNA transport provides an intriguing 
link to pathology, as the degeneration of axon terminals at neuromuscular junctions is a 
disease hallmark (Dombert et al. 2014). MNs have remarkable architecture, with a large 
cell body and extremely long axons that are very far removed from the nucleus and 
soma. Axons undergo many changes during development and in response to stimuli 
and injury that require responses at the level of protein expression, with high spatial 
and temporal resolution; this is enabled by local protein translation (Jung et al. 2012). 
SMN has been shown to localize to axons in a complex with several mRNA binding 
proteins including FMRP (Piazzon et al. 2008), HuD (Fallini et al. 2011) and hnRNP R 
(Dombert et al. 2014). Additionally, compartmentalized siRNA-mediated knockdown of 
SMN was observed to cause differential effects in the somatodendritic and axonal 
compartments, with the latter displaying downregulation of genes involved in axonal 
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growth (Saal et al. 2014).  Decreased SMN at axon terminals might lead to loss of 
important gene regulation at the synapse, and it will be interesting to see if this 
impinges on early clinical changes to the motor circuitry in MNs and other cells (Mentis 
et al. 2011). 
 
Mutations affecting RBPs in cis 
Amyotrophic Lateral Sclerosis (ALS) 
SMA is an excellent example of an RNA processing-centric mechanism, as disease is 
demonstrably controlled by SMN levels, and is thus a straightforward case of loss-of-
function (LOF). Several points differentiate ALS and SMA: First, while both diseases 
have some systemic dysfunction, ALS affects lower MNs in the spinal cord in addition 
to upper MNs in the motor cortex, and symptoms of dysfunction in both regions are 
necessary to make a diagnosis (Rowland and Shneider 2001) (Fig. 1). Second, ALS 
primarily affects adults, with an average age at onset of 60 years (Svetoni et al. 2016), 
although in some more aggressive forms of disease patients are afflicted in early 
adulthood or adolescence (Swinnen and Robberecht 2014). Third, ALS is nearly always 
fatal, usually after an average disease duration of 3-5 years (Rowland and Shneider 
2001) while patients with less severe forms of SMA have normal lifespans (Zerres et al. 
1997). In adults, a significant fraction of ALS patients exhibit an array of cognitive, 
behavioral and language defects that can result in diagnosis of FTD, thus placing them 
along an ALS-FTD spectrum (Ling et al. 2013). Finally, ALS is often defined by two 
dichotomies that attempt to simplify its complex etiology: One, the familial/sporadic 
division, separates patients on the basis of belonging to a lineage where ALS is 
recurrent (~10%) or not (~90%), while the other delineates patients based on the 




Aggregations are hallmarks of many but not all neurodegenerative diseases, and 
aggregated TDP-43 inclusions represent the single greatest unifying factor throughout 
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ALS molecular pathology. TDP-43 proteinopathy is also predominantly associated with 
Frontotemporal Lobar Dementia subtype Ub+/TDP+ (FTLD-U/FTLD-TDP), a 
pathological form of the heterogeneous dementia marked by the loss of cortical (and 
other) neurons. There is considerable intra-family and clinical overlap between ALS and 
FTD, particularly FTLD-TDP, and the two diseases are thought to be different clinical 
manifestations of a common pathological mechanism (Al-Chalabi et al. 2012). The 
presence of aggregated TDP-43 in both familial and sporadic ALS, with or without 
accompanying TDP-43 mutations (as described below), represents a central paradox in 
the effort to characterize the molecular events that are necessary and/or sufficient to 
cause disease (Blokhuis et al. 2013). 
TDP-43 is a ubiquitously expressed, critical protein. It is highly conserved across 
species (Ayala et al. 2005) and genetic knockout leads to embryonic lethality in mice 
(Kraemer et al. 2010). TDP-43 negatively regulates its own mRNA expression by 
binding its 3’UTR, an interaction that requires a C-terminal Gly-rich region (Ayala et al. 
2011; Polymenidou et al. 2011). Tight regulation of TDP-43 levels is thus important to 
the cell; one consequence of elevated TDP-43 expression is increased skipping of 
exon 9 in the mRNA encoding the cystic fibrosis transmembrane regulator (Buratti et al. 
2001), amongst other similar roles in splicing inhibition. Overexpression of TDP-43 can 
be toxic in a wide array of cell, yeast and animal models (Ash et al. 2010; Li et al. 2010; 
Wils et al. 2010; Armakola et al. 2011), thus making it even harder to disentangle the 
effects of mutant versions of the protein in any context that alters overall levels of the 
protein. As this highlights, changes in TDP-43 abundance are not detrimental to MNs 
alone, again prompting speculation that MNs are more intrinsically sensitive to 
alterations in RBP concentration (Sephton and Yu 2015). 
The identification of TDP-43 as the major component of the hallmark neuronal 
cytoplasmic inclusions in ALS enabled several important discoveries regarding the 
nature of pathological TDP-43. These include the protein’s nuclear clearance, post-
translational cleavage and hyper-phosphorylation (Arai et al. 2006; Neumann et al. 
2006). Whereas pure loss of SMN is sufficient to at least explain the outcome of SMA, 
and loss of nuclear TDP-43 has been argued to underlie disease (Vanden Broeck et al. 
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2014), the aggregation and modifications that TDP-43 undergoes pose novel gain-of-
function (GOF) that may be toxic, a subject of considerable inquiry. Identification of 
TDP-43 also led to the discovery of causative mutations in the gene that encodes it, 
TARDBP, thus strongly supporting a causal role in disease (Kabashi et al. 2008; 
Sreedharan et al. 2008) (Fig. 2). Nonetheless, the uncanny pathological similarities 
between TARDBP mutants (themselves highly diverse) and patients with mutations in 
other ALS genes, or with sporadic forms of disease, makes it difficult to determine 
whether TDP-43 proteinopathy represents the cause or effect of the underlying 
pathology of these syndromes (Banks et al. 2008).  
Currently there are ~55 identified TARDBP mutations associated with ALS. These are 
primarily dominant missense mutations found mostly in familial ALS, but also in some 
sporadic cases (accounting for about 2% of all ALS) and rare FTD patients (Buratti 
2015). The vast majority of these mutations cluster in the C-terminus of the protein, 
which is sometimes referred to as an hnRNP interacting domain (Ayala et al. 2005; 
Buratti et al. 2005). The C-terminus is also found in an ~25 kDa proteolytic fragment, 
along with a portion of the second of two RNA recognition motifs (RRMs). Only two 
rare mutations have been found in the RRMs, both in RRM1 (Buratti 2015). While the 
mutated amino acids are close to residues important for RNA binding (Lukavsky et al. 
2013), they are not suspected to influence RNA recognition (Sun and Chakrabartty 
2017). The heavily mutated C-terminal region of the protein is rich in glycine (Gly-rich) 
and glutamine/asparagine (Q/N) residues (Fig. 2). The entire C-terminal region of about 
160 amino acids is considered low-complexity in that it is highly enriched in only four 
amino acids, glycine, glutamine, serine and asparagine, which are similar to the 
residues enriched in yeast prion domains (March et al. 2016). Some mutations are 
predicted to increase propensity for phosphorylation (Kabashi et al. 2008) and 
spontaneous aggregation (Johnson et al. 2009), while others are proposed to influence 
amyloid-like states that are available to TDP-43 via a short stretch of mostly Q/N 
(Fuentealba et al. 2010; Budini et al. 2012; Mompean et al. 2016). These observations 
suggest that while changes in splicing and gene expression may be seen in disease, 
they are not due to differences in RNA recognition. Instead, mutations may indirectly 
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affect the profiles of RNAs that are bound through increased aggregation, and/or 
impaired nuclear import (Buratti 2015), or through disruption of protein interactions, 
although some common mutations in the hnRNP interaction region have been shown 
not to influence binding to one interacting protein, hnRNP A2 (D'Ambrogio et al. 2009) 
(Fig. 2).  
Proving that ALS/FTD is associated with TDP-43 LOF would require a clear 
understanding of what TDP-43’s major functions are and how the protein behaves in 
the cell. TDP-43 binds long stretches of UG-rich RNA through its two RRMs (Lukavsky 
et al. 2013) in homodimeric form (Kuo et al. 2009). These sequences are often enriched 
near TDP-43 regulated exons (Buratti et al. 2001), but are also found in deep intronic 
positions downstream of skipped exons (Polymenidou et al. 2011; Tollervey et al. 
2011a). The UG binding motif has been confirmed in vivo by CLIP in both cell culture 
and human post-mortem brain (Xiao et al. 2011; Tollervey et al. 2011a). Interestingly, 
despite the axiomatic cytoplasmic aggregation in the FTLD-TDP patients studied, CLIP 
from both nuclear and cytoplasmic fractions revealed that neither control nor patient 
brains demonstrated much cytoplasmic RNA binding, but instead both were enriched 
for intronic regions and noncoding transcripts such as NEAT1 and MALAT1. 
Furthermore, the finding that bound RNAs are enriched for multiple dispersed TDP-43 
binding motifs suggests possible cooperative binding of multiple molecules to UG 
repeats that are spread out over 100 nt distances (Tollervey et al. 2011a).  
Loss of TDP-43 function due to nuclear clearance can lead to particular splicing 
signatures of disease (Polymenidou et al. 2011; Xiao et al. 2011; Ling et al. 2015) or to 
defective transport of distally targeted mRNAs (Ishiguro et al. 2016). Intriguingly, it has 
been postulated that an important function of TDP-43 is the repression of cryptic 
exons  (Fig. 1), and increased inclusion of such exons was found in post-mortem 
ALS/FTD individuals (Ling et al. 2015), to the potential detriment of cell survival (Tan et 
al. 2016). While this result presents an important observable metric of TDP-43 LOF in 
disease, such cryptic exons are not exclusively regulated by TDP-43 and are bound by 
a number of other RBPs whose concentrations may vary in patients (Humphrey et al. 
2017).  
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The patterns of cleavage that TDP-43 undergoes are an interesting feature of disease. 
However, its contribution has been called into question due to the minor prevalence in 
the spinal cord (Igaz et al. 2008). One proposed explanation for the toxicity of the C-
terminal fragments (Zhang et al. 2009) is that their lack of a nuclear localization signal 
(NLS) prevents them from entering the nucleus, thus leading to their buildup and 
aggregation in the cytoplasm; indeed, an NLS-tagged 25-kDa fragment is less toxic 
and aggregation-prone than the fragment without an NLS (Kitamura et al. 2016). 
Furthermore, the ability to bind RNA may underlie the organization of TDP-43 
oligomers, and loss of RNA binding capability in truncated versions might promote 
aggregation (Kitamura et al. 2017). Once formed in the cytosol, these aggregates can 
then trap full-length TDP-43, disrupting its normal nucleo-cytoplasmic shuttling and 
leading to nuclear depletion (Winton et al. 2008). However, the existence of these 
fragments in the brains of patients with both mutant and wild-type TDP-43 alike 
suggest cleavage is not specifically driven by mutations (Li et al. 2015).  
 
FUS 
The discovery of TDP-43 pathology and mutations established RBP dysfunction as a 
major theme in ALS/FTD. The knowledge that RBPs can harbor ALS mutations led to 
the concerted sequencing efforts that identified mutations in another RBP, TLS/FUS, or 
FUS (Kwiatkowski et al. 2009; Vance et al. 2009) (Fig. 2). FUS was originally identified 
as site of the most common translocation event leading to liposarcoma (hence the 
name Fused in liposarcoma/translocated in liposarcoma) (Crozat et al. 1993;  Rabbitts 
et al. 1993). FUS is a member of the TET/FET family of proteins, which includes two 
other similar proteins, EWS and TAF-15, is ubiquitously expressed, and has many 
proposed cellular functions, ranging from transcription to RNA processing to DNA 
damage repair (Tan and Manley 2009; Wang et al. 2013). The protein’s ability to shuttle 
between the nucleus and cytoplasm might have important consequences for synaptic 
mRNA transport (Fujii et al. 2005; Masuda et al. 2015). Structurally, FUS consists of an 
N-terminal domain comprised of a QGSY-region and the first of three RGG-repeat 
regions, and an RRM and Zn-finger motif account for its ability to bind nucleic acids. 
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An NLS, which harbors a majority of characterized ALS mutations (see below), is 
located at the extreme C-terminus (Fig. 2). 
Like TDP-43, FUS has been characterized as both an RNA and DNA binding protein. 
With respect to RNA, while an affinity for UG-rich RNA sequences has been observed 
(Lerga et al. 2001; Lagier-Tourenne et al. 2012), it has also been argued that FUS does 
not have a specific binding recognition motif, but rather binds RNAs promiscuously, 
with greater binding occupancy on highly expressed RNAs (Wang et al. 2015). The lack 
of a consensus FUS binding motif was echoed by CLIP experiments, which identified a 
predisposition for binding to stem-loop structures (Hoell et al. 2011). Like TDP-43, FUS 
has been found to bind to long introns, with potentially important regulatory 
implications (Lagier-Tourenne et al. 2012; Rogelj et al. 2012). The brain is a site of 
increased transcriptional activity of genes with long introns, as expression of longer 
genes is overrepresented in neural tissue (Gabel et al. 2015). A co-transcriptional 
requirement of FUS and TDP-43 for processing long introns may therefore underlie a 
critical function of these proteins that is specific to the brain (Zylka et al. 2015).  
FUS has also been implicated in DNA binding. Early studies suggested an ability to 
bind single-strand DNA, perhaps reflecting a function in DNA repair and/or 
transcription (Tan and Manley 2009). DNA FUS-responsive elements were later found 
enriched within promoter regions of genes shown to respond transcriptionally to FUS 
levels (Tan et al. 2012). One such gene, MECP2, biologically interesting due to its 
relationship to the neuroregressive disease Rett syndrome, was found to be misspliced 
in cells transfected with mutant, but not wildtype, FUS (Coady and Manley 2015). 
Interestingly, the splice isoform of MECP2 promoted by mutant FUS was found to have 
increased RNA stability yet express lower protein levels. The mRNA was found to be 
present with mutant FUS in cytoplasmic aggregates by both biochemical analysis and 
FISH, suggesting that the transcript is sequestered. These results suggest that mutant 
FUS aggregation can affect the stability and translation of mRNA targets through direct 
sequestration of RNAs, and pre-mRNA splicing through sequestration of splicing 
factors (Coady and Manley 2015). 
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FUS aggregates are detected in ALS, although less frequently than TDP-43. Of the 
approximately 3% of ALS cases that do not have TDP-43 aggregation, FUS is 
analogously aggregated in ~ 50% of these (Mackenzie et al. 2007). However, unlike 
with TDP-43, FUS pathology never presents without FUS mutations, more than 50 of 
which have been described (Nolan et al. 2016). Whereas disease-causing TDP-43 
mutations are clustered in the C-terminal G-rich and Q/N regions, FUS mutations occur 
throughout the protein, although the most common and well-described are in the C-
terminal NLS (Shang and Huang 2016; Svetoni et al. 2016). Such mutations have been 
proposed to influence the cytoplasmic aggregation and nuclear clearance of the 
protein. These pathological features also occur in the roughly 10% of FTD patients with 
an atypical FTLD-U pathological subtype whose inclusions are TDP-43 negative 
(Neumann et al. 2009). These patients do not carry mutations in FUS, reminiscent of 
ALS-TDP and FTLD-TDP cases where wild-type TDP-43 is mislocalized and 
aggregated (Mackenzie et al. 2010).  
As with TDP-43, there is debate surrounding the relative contributions of gain- and 
loss- of function mechanisms with respect to how both FUS mutations and aggregates 
impact disease. One characteristic of FUS-ALS is that the gene harbors several 
mutations that lead to especially aggressive juvenile-onset forms of disease, such as 
the P525L mutation (Sharma et al. 2016), a deletion in exon 14 (Belzil et al. 2012), and 
the recently described Y526C mutation (Corcia et al. 2017). An important question is 
whether these juvenile mutations affect the same functions and biochemical properties 
of FUS as mutations that lead to more classical ALS, such as R521C, but to a more 
severe degree. In support of this, it was found that mice expressing P525L mutant FUS 
displayed greater aggregation and higher cytoplasmic to nuclear FUS ratio than mice 
expressing the less severe R521C FUS (Sharma et al. 2016). FUS cytoplasmic 
aggregation has been shown to influence the profile of the RNAs it is associated with, 
as mutant FUS binds less to intronic nuclear RNA than wild-type does, and makes 
many more associations with 3’ UTRs.  (Hoell et al. 2011). In a recently described 
mouse model, FUS lacking an NLS exhibited mislocalization to the cytoplasm that led 
to changes in gene expression and splicing that largely mirrored those caused by FUS 
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ablation. However, mislocalization also led to upregulation of genes involved in mRNA 
translation and to a subset of unique splicing changes that may reflect disruptions to 
other RBPs as a consequence of the cytoplasmic FUS aggregation (Scekic-Zahirovic 
et al. 2016). It was also shown that both depletion and cytoplasmic mislocalization of 
FUS led to perinatal lethality due to respiratory insufficiency; however, mislocalization 
alone further resulted in perinatal MN death (Scekic-Zahirovic et al. 2016). In another 
mouse model, widespread post-natal elimination of FUS from the central nervous 
system as well as MN-specific elimination resulted in mice with normal post-natal 
survival without MN loss or denervation compared to control animals (Sharma et al. 
2016). These results argue in favor of a mechanism in which FUS is pathogenic through 
a gain of mutant and/or cytoplasmic function. 
RBPs and membraneless organelles 
While LOF contributions to pathogenesis cannot be ruled out, the expanding evidence 
for GOF has prompted more biochemically-focused research into the structure and 
interactions of mutant and wild-type FUS. This is due, in part, to the sequencing of 
large cohorts of patients and controls that has led to identification of (presumed) ALS-
causing mutations in so-called intrinsically disordered regions (IDRs; Ticozzi et al. 
2009; Corrado et al. 2010). Due to the rarity of these mutations, in-depth post-mortem 
analyses and identification of FUS pathology have been lacking. Additionally, the 
presence of these rare variants in sporadic patients makes the case for causality 
weaker than if they were seen as driving a recurrent phenotype in families. Despite 
these reasons to retain skepticism, mutations in the FUS Prion-like and Gly-rich 
regions offer a new opportunity for unification with the rapidly expanding topic of 
liquid-liquid phase separation (LLPS). The idea that mutant versions of TDP-43 and 
FUS lead to alterations of the biophysical properties of their IDRs has been gaining 
traction as part of a larger effort to characterize intracellular phase transitions 
undergone by membrane-less organelles such as stress granules (SGs) and P bodies 
(Brangwynne et al. 2015).  
The formation of liquid droplets that partition as a separate phase from the surrounding 
medium are of interest because they are mediated by low-complexity domains (LCDs), 
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also known as IDRs. These include the QGSY- and RGG-rich domains of FUS and the 
Gly- and Q/N-rich domains of TDP-43, which have been shown to be important for SG 
formation (Liu-Yesucevitz et al. 2010; Bentmann et al. 2012) (Fig. 2). The natural 
conformational heterogeneity of these domains permits them to make diverse 
combinations of charge-charge, dipole, and pi-stacking interactions along the 
polypeptide backbone over short and long ranges. This predisposition to make self-
interactions rather than solvent interactions has the potential to drive compaction and 
thus phase separation. Consequently, as concentrations of critical protein components 
rise, so does formation of these proteinaceous droplets, enabling spatial separation of 
important biochemical processes such as the partitioning of nucleic acids (Nott et al. 
2016), which can also help drive formation of these species (Brangwynne et al. 2015; 
Shorter 2016).  
Several types of membrane-less granules may be relevant to RBPs and ALS/FTD. For 
example, TDP-43 (Liu-Yesucevitz et al. 2010; McDonald et al. 2011) and FUS (Baron et 
al. 2013) have both been found in SGs. These structures form in response to cellular 
stress as a means to temporarily halt translation of mRNAs not needed to respond to 
the situation at hand, and can thus be viewed as temporary RNA storage sites. P 
bodies on the other hand, while sharing some properties with SGs, are sites of mRNA 
degradation (Decker and Parker 2012; Li et al. 2013). RNA transport granules are 
another important class of membrane-less organelles with specific neuronal relevance 
in localized mRNA expression (Kiebler and Bassell 2006). Their ability to fuse into 
droplet states has become of great interest for disease because the properties driving 
this protective aggregation, which can involve phase transitions of mutant FUS and 
TDP-43, can also lead to amyloid-like states (Fang et al. 2014; Murakami et al. 2015). 
This can be imagined as a transition from liquid droplets to hydrogels to irreversible 
amyloid fibers, giving rise to a gradient in rigidity (Fig. 2).  
The ability of SGs to form rapidly and reversibly is an important aspect of their role in 
maintaining RNA homeostasis. Important work on the molecular events that initiate SG 
formation in yeast implicated a prion-like Q/N-rich region of the protein Lsm4p in 
conferring the ability to aggregate reversibly (Decker et al. 2007). Despite the emphasis 
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on the unstructured nature of IDRs, it has been proposed that transient, partially-
populated folded conformations, facilitated by particular amino acid stretches, may be 
disrupted by mutations, for instance in TDP-43  (Conicella et al. 2016). TDP-43 
fibrilization is thought to seed aggregates of itself (Furukawa et al. 2011), and to cross-
seed aggregations of other proteins (Fang et al. 2014). Such fibrillization by LCD-
containing proteins is not necessary for phase-separation and formation of granules, 
but it has been shown to increase in these conditions (Molliex et al. 2015). The ability to 
study the properties driving hydrogel formation and phase separation was augmented 
by the discovery that these molecules can be selectively precipitated using 
compounds such as biotinylated isoxazole (Han et al. 2012; Kato et al. 2012). Through 
application to extracts from different cells and tissues, it was shown that RNA-based 
granules contain many RBPs such as translation factors, ribosomal proteins, helicases 
and 3’ UTR-binding factors, but that there are core RBPs, such as SRSF5, PTBP1, 
Pur-alpha and hnRNPs, that are essential to these granules, as treatment with RNAses 
revealed that the LCDs themselves, and not the RNAs, provide the basis for 
aggregation (Han et al. 2012). However, the coexistence of RBDs and LCDs within the 
same proteins suggest that coalescence via association with the same RNAs serves to 
drive local concentrations to the point of phase transitions (Molliex et al. 2015; Zhang 
et al. 2015). Intriguingly, one of these essential granule proteins that exhibited greater 
enrichment after RNAse treatment is Matrin-3 (MATR3) (Han et al. 2012), which is 
infrequently mutated in familial ALS (Johnson et al. 2014) (Fig. 1). Matrin-3 is a DNA 
and RNA-binding protein with a role in promoting mRNA stability (Salton et al. 2011), 
and has also been suggested to associate with TDP-43 (Ling et al. 2010), although the 
interaction was shown to be RNA-dependent (Johnson et al. 2014). While the precise 
nature of Matrin-3 in cellular granules with other disease-related proteins in unclear, 
such findings reinforce the convergence of different ALS genes in the same physical 
processes. 
The focus on LCDs in RNA granules has provided a number of additional insights 
which will not be discussed in this review. These studies helped foster the view that 
disease is somehow triggered by injury, persistent stress, or activity-dependent 
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demands from which cells with mutant TDP-43 or FUS are slow or unable to recover 
(Wolozin and Apicco 2015). Differential exposure to environmental toxins, damage and 
stressors can therefore be seen as important modifiers of disease and may explain the 
incomplete penetrance of some ALS-causing variants (Harms et al. 2015). This line of 
research has also underscored the fact that aggregation is an intrinsic property of 
LCD-containing proteins, but also a liability when taken to the extremes of 
concentration (Guo and Shorter 2015). Along these lines, several studies have 
investigated how mutant forms of FUS (Patel et al. 2015) and TDP-43 (Liu-Yesucevitz 
et al. 2014), as well as more rarely mutated proteins such as hnRNP A1/2 (Kim et al. 
2013; Shorter and Taylor 2013) and EWS (Couthouis et al. 2012), perturb the dynamics 
of aggregate formation, dissipation and strength. While great advances in our 
understanding of the different states accessible to RBPs under different conditions of 
crowding have been made using cell-free systems (Han et al. 2012; Kato et al. 2012) 
and structural biology (Mompean et al. 2015; Conicella et al. 2016), it will be important 
to see how these insights translate into in vivo systems and therapeutic targets. 
Mutations affecting RBPs in trans 
Microsatellite expansions in protein-coding regions 
RNA is not merely a passive carrier of genetic information acted upon by proteins, but 
an important actor as well. RBPs have evolved to deal with the complexities associated 
with RNA, particularly its propensity to fold, sometimes nonproductively (Herschlag 
1995), and its high demand for precise localization relevant to gene expression and 
catalysis. Just as it seems a combination of mutant and relocalized RBPs can cause 
aggregation and effect changes in RNA and gene expression, excess repetitive RNAs, 
or those with highly stable structures (Mooers et al. 2005; Bernat and Disney 2015; 
Ciesiolka et al. 2017), can sequester RBPs in aggregates, leading to deficiencies in 
their normal functions (Jiang et al. 2004; Morriss and Cooper 2017) (Fig. 1). The 
convergence of multiple mutations that cause diseases of the neuraxis on mechanisms 
of RNA and RBP homeostasis suggest that disruption of these pathways represent the 
most parsimonious candidate for a central mechanism in these diseases (La Spada 
and Taylor 2010). Furthermore, the fact that all known nucleotide expansion disorders 
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take their tolls specifically via neurodegenerative and neuromuscular disorders 
(Budworth and McMurray 2013) reinforces the argument that the regulation of RNA 
metabolism is held to stricter standards in the nervous system. 
The first disease-linked nucleotide microsatellite expansions were discovered over 25 
years ago. These were in fragile X syndrome of mental retardation (FXS) and X-linked 
spinal and bulbar muscular atrophy (SBMA; La Spada and Taylor 2010). Both diseases 
reflect X-linked triplet-repeats, poly-CGG in the FMR1 gene (Verkerk et al. 1991) and 
poly-CAG in the AR gene (La Spada et al. 1991), in FXS and SBMA, respectively (Fig. 
1). These repeats were initially categorized as encoding poly-amino acid tracts leading 
to proteins with higher tendency to misfold and aggregate (Ashley et al. 1993; Sisodia 
1998; Stenoien et al. 1999). This remains the prevailing notion in one of the most 
common inherited diseases and best-known poly-glutamine (polyQ) CAG microsatellite 
disorders, Huntington’s disease (HD; (Ross and Tabrizi 2011; Arrasate and Finkbeiner 
2012). PolyQ aggregation is a recurring theme in neurodegeneratve diseases, 
implicated in possible phase separation of RNA granules (Zhang et al. 2015) and cross-
seeding aggregates of proteins with Q/N regions (Furukawa et al. 2009; Fuentealba et 
al. 2010). However, whether aggregation of expanded polyQ proteins is entirely 
responsible for the pathogenesis of these disorders has been called into question 
(Klement et al. 1998; Saudou et al. 1998), and the observation that mutant Huntington 
aggregates are most prevalent in spared neuronal populations (Kuemmerle et al. 1999) 
has helped foster the view that aggregates may be protective in these and other 
diseases (Ross and Poirier 2005).  
The polyQ paradigm has been challenged by recent work on the toxicity of the repeat-
containing RNA itself (Nalavade et al. 2013; Marti 2016). For example, it has been 
proposed that the CAG repeat RNA forms stable hairpin structures with an 
endogenous neighboring CCG tract, and sequesters the RBP Muscleblind-like 1 
(MBNL1) in intranuclear aggregates (de Mezer et al. 2011), leading to altered splicing of 
MBNL1 targets (Mykowska et al. 2011). The hairpin structures are additionally thought 
to induce cleavage by the RNA-silencing complex endonuclease DICER, generating 
short RNAs that lead to silencing of downstream targets (Krol et al. 2007) (Fig. 1).  In 
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further support of RNA toxicity, a disorder closely resembling HD, Huntington disease 
like-2, is caused by a CTG expansion in the junctophilin-3 gene (Holmes et al. 2001) 
that has been shown to give rise to RNA foci that also sequester MBNL1 (Rudnicki et 
al. 2007), reminiscent of other diseases (see also below). However, it has also been 
shown in transgenic mice that polyQ pathology arises from antisense CAG transcripts 
(Wilburn et al. 2011). Thus the combined toxicities of RNA and poly-Q may have a 
synergistic effect in disrupting RBP function through different modes of sequestration 
and by placing stress on the cell’s autophagic mechanisms (Cortes and La Spada 
2014). 
Several observations have contributed to the view that expanded polypeptides cannot 
be the only mechanism behind triplet repeat diseases. For example, with regard to 
FXS, the CGG repeat in FMR1 is outside the open reading frame, in the 5’ UTR (Ashley 
et al. 1993), suggesting that the expansion might lead to decreased gene expression 
(Bell et al. 1991). However, recent advances in understanding repeat-associated non-
AUG (RAN) translation have reopened the debate about whether expansions in non-
coding regions can be translated, to generate short repetitive polypeptides (Cleary and 
Ranum 2014; Sellier et al. 2017). The ubiquity of this mechanism across a multitude of 
triplet, quadruplet and higher-order nucleotide expansions suggests a dual role of RNA 
as the toxic molecule itself and the intermediary to one, with important inputs from 
specific RBPs factoring into both.  
Microsatellite Expansions and RBP Sequestration 
Perhaps the most well established RNA GOF mechanism is the one described for 
myotonic dystrophy types 1 and 2 (DM1 and DM2; (Udd and Krahe 2012). DM1 and 2 
are dominantly inherited disorders affecting multiple organs, characterized by muscle 
weakness, myotonia, cataracts, cardiac arrhythmias and neuropsychological 
symptoms (Thornton et al. 2017), and are the most common forms of adult muscular 
dystrophy (Caillet-Boudin et al. 2014). The distinction between DM1 and DM2 refers to 
their causative genes. The mutation leading to DM1 is a CTG expansion in the 3’ 
noncoding region of the gene encoding the dystrophia myotonica protein kinase 
(DMPK; (Brook et al. 1992), while DM2 refers to a phenotypically similar disorder due to 
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a CCTG expansion in an intervening sequence of the gene encoding CCHC-type zinc 
finger nucleic acid binding protein (CNBP; Liquori et al. 2001) (Fig. 1). The two encoded 
proteins share no functional overlap arguing against the idea that DM pathogenesis 
can be explained by loss of protein function (La Spada and Taylor 2010). Instead, RNA 
transcribed from these genes forms intranuclear foci that overlap with the proteins 
MBNL1, 2, and 3 (Jiang et al. 2004) and CUG-binding protein 1 (CUGBP1; Timchenko 
et al. 2001). In vitro, purified MBNL1 binds to extended hairpin structures consisting of 
G-C basepairs and U-U mismatches (Michalowski et al. 1999) with high affinity that is 
similar for both short (CUG4) and long (CUG90) repeat RNAs, and higher for short CCUG 
repeat RNAs (Warf and Berglund 2007). However, it has been argued that CUGBP1 
does not bind the double-stranded RNA hairpins that predominate (Michalowski et al. 
1999) and SELEX experiments identified enrichment of the trinucleotide UGU, not CUG 
(Marquis et al. 2006), raising some doubts about the in vivo sequestration of CUGBP1. 
That the observed foci, and biochemical evidence of binding, reflect functional 
sequestration of these proteins has been demonstrated in patients and cell models 
(Kanadia et al. 2003). Examples of missplicing of genes targeted by MBNL and CUGBP 
include events that directly correlate to disease phenotypes (Philips et al. 1998; 
Kuyumcu-Martinez and Cooper 2006). Furthermore, knockout of mouse Mbnl1 results 
in a phenotype that recapitulates several, but not all, aspects of disease (Kanadia et al. 
2003), reflecting the fact that human disease is the result of compound splicing factor 
disruption (Lee et al. 2013).  
 The potential for RAN translation in DM1/2 has also been investigated. In DM1, this 
been demonstrated in cell culture when repeat constructs lacking an ATG start codon 
are overexpressed, presumably requiring the hairpin-forming propensity of the CUG 
repeats (Zu et al. 2011). While low levels of poly-Q aggregates were observed in tissue 
from DM1 transgenic mice and human DM1 patient myoblasts and skeletal muscle, 
whether or not these species contribute to disease has not been further pursued. No 
such potential for homopolymeric products exists in DM2, and although DM1 is 
sometimes more clinically severe than DM2 (Zu et al. 2011), the fact that both repeat 
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expansions cause such similar phenotypes suggests that the mechanism is primarily 
RNA-driven. 
  An important issue in repeat expansion disorders is whether the number of expanded 
repeats correlates with any observable metrics of disease, such as age of onset, 
disease duration, or molecular features such as splicing dysregulation. In DM, 
expansion length roughly correlates with disease severity (Brook et al. 1992), although 
there is no apparent relationship between expansion length and the severity of splicing 
defects (Nakamori et al. 2013). However, confidence in such relationships is 
complicated by somatic instability of repeat length (Savic Pavicevic et al. 2013). 
Establishing the significance of such correlations will depend on the development of 
simpler more accurate methods for measuring repeat length (Yum et al. 2017). Along 
with these endeavors, ongoing DM research has a broad curative focus, from 
developing DM gene silencing therapies (Thornton et al. 2017), to understanding the 
structure and role of extended hairpins and loops formed by the repeat sequences 
(Dere et al. 2004; Yuan et al. 2007; deLorimier et al. 2017) and how their modular 
structure may be therapeutically targeted (Garcia-Lopez et al. 2011; Childs-Disney et 
al. 2012; Childs-Disney et al. 2014).  
RNA-centric mechanisms in C9ORF72 ALS-FTD 
The advances made in DM have provided an important paradigm for subsequent 
repeat expansion discoveries. Most notable is the GGGGCC hexanucleotide expansion 
in the previously unstudied gene C9ORF72 (C9), which is by far the most common 
known cause of ALS and FTD, and the best proof for the continuous nature of the two 
disorders (Renton et al. 2011; DeJesus-Hernandez et al. 2011). A tremendous amount 
of effort has gone into defining several non-mutually exclusive disease mechanisms 
suggested by this mutation (Haeusler et al. 2016; Taylor et al. 2016), yet the relative 
contributions of each mutation is unclear in vivo. C9-ALS/FTD is similar to most other 
forms of ALS in that it is marked by TDP-43 pathology, but also has a distinct class of 
Ub+/p62+ cytoplasmic inclusions containing dipeptide repeat (DPR) proteins made by 
RAN translation (Kearse and Todd 2014; Schipper et al. 2016). Why C9 causes some 
people get pure ALS or FTD or a mixture of both is a mystery. Further complicating 
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matters, C9 has also been associated with Parkinson’s disease (PD; Wilke et al. 2016) 
and schizophrenia (Galimberti et al. 2014), and neuronal loss and gliosis have been 
described quite broadly throughout the brain and spinal cord in C9 ALS (Cooper-
Knock et al. 2014). 
DPR pathology has been a major focus of C9ALS-FTD research. For instance, it 
presents an intriguing link to the low-complexity sequences and hydrogel properties 
involved in RNA granule formation. One possibility is that DPRs may actually disrupt 
cellular functions by interacting with proteins involved in membraneless organelles and 
cytoskeletal intermediate filaments (Lin et al. 2016). DPRs may also provide a useful 
diagnostic biomarker (Lehmer et al. 2017) and their demonstrated ability to spread 
between cells (Westergard et al. 2016) offers a simple explanation for the observation 
that ALS tends to spread from a region of onset to other parts of the nervous system 
(Brettschneider et al. 2015). However, an understanding of how expanded RNA repeats 
make DPRs is lacking (Freibaum and Taylor 2017). Furthermore, antibodies against 
poly-DPRs derived from multiple frames of the GGGGCC expansion recognize short 
epitopes that could be present in unrelated proteins, such that detection on filter-
bound/membrane assays may be misleading. Meanwhile, more informative 
visualization of foci in post-mortem human tissue is fraught with preservation, fixation 
and background technicalities. While toxicity of DPRs has been shown in model 
organisms and cell culture (Wen et al. 2014; Lopez-Gonzalez et al. 2016), this could 
reflect non-physiological effects resulting from overexpression. Understanding how 
DPRs are made (Green et al. 2016), and how abundant they truly are in degenerating 
regions (Gomez-Deza et al. 2015), will be important in order to gauge how critical they 
are to the pathology of the ALS/FTD spectrum. 
Despite these caveats, DPR pathology and its mysterious origins may be linked to the 
structures formed by the RNA repeats and the proteins that bind them. The C9 repeats 
are notable for their ability to form highly stable G-quadruplex (G-Q) structures, which, 
interestingly, have been implicated in translational control (Bolduc et al. 2016; Song et 
al. 2016), and suggested to serve as internal ribosomal entry sites (Morris et al. 2010). 
Expanded, long arrays of G-Q-forming sequences may give rise to complex mixtures of 
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G-Q structures and linear G-tract RNA, which have been reported to bind RBPs such 
as hnRNP H (Conlon et al. 2016), nucleolin (Haeusler et al. 2014), other known G-Q 
binders (Brazda et al. 2014), as well as many other proteins (Haeusler et al. 2016) (Fig. 
1). The ability of G-Qs to self-interact (Petraccone 2013), combined with the potential 
for self-interaction amongst LCDs of proteins that experience high local concentration 
as a result of RNA binding, such as the Gly-rich domains of TDP-43 and other hnRNPs, 
may drive formation of compact RBP/RNA aggregates.  
Numerous proteins have been suggested to bind to the C9 repeat RNA. However, 
functional sequestration of only one, hnRNP H, has been documented in post-mortem 
C9 patient brains, where it was detected in intranuclear aggregates and a large fraction 
was found to be insoluble in extracts. Importantly, this correlated with mis-splicing of 
many known hnRNP H target exons (Conlon et al. 2016). hnRNP H levels affect splicing 
of hundreds of targets (Huelga et al. 2012), including many encoding proteins involved 
in splicing, among them TDP-43 and FUS (Uren et al. 2016). Thus hnRNP H deficiency 
may result in splicing errors that extend beyond exons that hnRNP H interacts with 
physically. hnRNP H regulates splicing of several transcripts that encode proteins 
important to the proper functioning of neuromuscular junctions, which are vulnerable to 
denervation in ALS  (Ohno et al. 2017). One of these transcripts, ACHE, which encodes 
acetylcholinesterase, contains an important hnRNP H-regulated exon (Nazim et al. 
2017) that is misspliced in C9ALS in a manner consistent with hnRNP H deficiency 
(Conlon and Manley, unpublished data). However, whether or not missplicing can 
account for the complex traits associated with C9ALS/FTD is not known. Beyond 
splicing, hnRNP H deficiency may affect polyadenylation choices in C9 brains (Bagga 
et al. 1998; Prudencio et al. 2015) as well as increase the overall global level of RNA G-
Qs. This latter possibility reflects a recently proposed role of hnRNP H in keeping RNA 
G-Qs unwound (Guo and Bartel 2016), and hnRNP H deficiency could thus reinforce 
C9-derived G-Q based aggregates and promote folding of other genomic G-Qs. 
Nucleotide expansions occur in multiple neurodegenerative diseases 
G-Qs have been linked to additional expansion-related neurodegenerative diseases, for 
example FXS (Fry and Loeb 1994; Simone et al. 2015). However, the significance of 
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these G-Qs is unclear, as the CGG repeats in FMR1 are predicted to form a relatively 
unstable G-Q structure due to the weakness of two tetrad stack G-Qs compared to 
three or four (Mullen et al. 2012). CGG expansion in FMR1 causes two distinct 
disorders depending on the length of the expansion: FXS in the case of long (>230 
repeat) expansions, and Fragile X Tremor Ataxia Syndrome (FXTAS) in so-called 
premutation carriers (60-230 repeats; Jin and Warren 2000). In the former case, the 
long 5’ UTR expansion forms a CpG island, results in transcriptional silencing and 
therefore reduced levels of FMRP. Supporting the significance of the G-Qs, FMRP is 
capable of binding transcripts containing them (Darnell et al. 2001; Vasilyev et al. 
2015), which can facilitate their translocation, in some cases, to synapses (Zhang et al. 
2014; Stefanovic et al. 2015). In FXTAS patients, FMR1 is not completely silenced and 
the expansion is actively transcribed into a repeat-containing RNA that has been 
reported to bind multiple RBPs, such as hnRNP A2/B1, MBNL1 (Iwahashi et al. 2006), 
Sam68 (Sellier et al. 2010), Drosha, DGCR8 (Sellier et al. 2013) and more (Galloway and 
Nelson 2009). Evidence for the functional significance of this binding to human disease 
is somewhat limited; however overexpression of hnRNP A2/B1 and CUGBP1 (Sofola et 
al. 2007) or Pur-alpha (Jin et al. 2007) in Drosophila models of FXTAS can suppress the 
neurodegenerative phenotypes. Only one protein, Sam68, has been shown to be 
functionally sequestered in humans, demonstrated by altered splicing of Sam68 
responsive transcripts in brains of FXTAS patients (Sellier et al. 2010). 
 Whether or not the bifurcated nature of FXS and FXTAS resulting from different 
lengths of the same expansion applies to other disorders, such as C9 ALS/FTD, is not 
known. The ability to directly measure expansion lengths, especially G-C rich 
expansions, with confidence based upon sequencing data (Dolzhenko et al. 2016) is an 
important technological challenge. When solved, such information will hopefully prove 
useful in determining whether expansion length correlates with clinical presentation 
and/or molecular events such as splicing defects. 
Repeat expansions are highly represented amongst spinocerebellar ataxias (SCA). 
SCAs are a heterogeneous class of disorders marked by cerebellar atrophy, 
incoordination of gait and loss of balance, among other noncerebellar symptoms (Sun 
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et al. 2016). Many of these are caused by trinucleotide repeats, particularly CAG, which 
occurs in SCAs 1, 2 3, 6, 7, 8, 12, and 17 (La Spada and Taylor 2010). The gene 
responsible for SCA2, ATXN2, contains a CAG polyQ expansion in its 5’ coding region 
that is between 36-52 repeats in disease, making it one of the shortest known CAG 
expansions (Pulst et al. 1996). Interestingly, intermediate lengths of CAG (27-33 
repeats) in ATXN2 have been shown to increase the risk of ALS (Elden et al. 2010; 
Sproviero et al. 2017). The function of Ataxin-2 is still unclear, although it has been 
shown to have roles in mRNA stability (Yokoshi et al. 2014), P-bodies and stress 
granules (Nonhoff et al. 2007), and can associate with TDP-43 in an RNA-dependent 
manner (Elden et al. 2010). Decreased ATXN2 expression can suppress TDP-43 
toxicity in yeast, flies (Elden et al. 2010) and mice (Becker et al. 2017), suggesting that 
ASOs targeting ATXN2 transcripts may be a viable therapeutic strategy in human ALS 
cases with TDP-43 pathology (Becker et al. 2017). 
Higher order repeats are seen in several genes, such as an ATTCT expansion in the 
ATXN10 gene responsible for SCA10 (Handa et al. 2005), a TGGAA expansion in 
SCA31 (Sato et al. 2009) and a GGCCTG expansion in NOP56, responsible for SCA36 
(Kobayashi et al. 2011). It is notable that the UGGGCC repeats of the SCA36 
expansion are so similar to the GGGGCC repeats from C9, and thus would also 
presumably form G-Q structures and associate with a similar set of RBPs, although 
this has not been investigated. SCA36 presents as a “pure” SCA marked by ataxia and 
cerebellar degeneration, as well as by progressive loss of upper and lower MNs, which 
separates it from other SCAs that are predominantly cerebellar and suggests that 
SCA36 is a disorder at the intersection of SCA and MND (Ikeda et al. 2012). Despite 
loss of MNs from the anterior horn of the spinal cord, TDP-43 inclusions were not 
detected in surviving neurons of affected individuals, further differentiating this disorder 
from ALS (Ikeda et al. 2012). 
Comparison of C9 ALS/FTD and SCA36 at the molecular level might yield interesting 
insights into what causes these two disorders to have a mixture of clinical overlaps and 
differences. At the most basic level, the two repeat expansions have different 
underlying repeat sequences. The difference of one G->U per repeat might have 
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several consequences related to the proteins that bind the expanded RNA and their 
binding affinities, resulting in different degrees of sequestration. Furthermore, repetitive 
(G)4(N)2 tracts are predicted to give rise to more stable G-Q structures than (G)3(N)3 
tracts due to the greater number of stacked planar quartets and shorter loops, which 
may influence the permanence of RNA foci and their aggregation properties. The 
expansions are also in different genes, and reduced C9 or NOP56 protein levels may 
influence the ALS/FTD and SCA36 phenotypes, respectively. Last, while the potential 
RAN translation products of the NOP56 expansion have not been studied (Arias et al. 
2014), one frame of each the sense and antisense transcripts can hypothetically give 
rise to a gly-pro DPRs, which are commonly found in C9 carriers, and one frame of the 
antisense can give rise to arg-pro DPRs; both are thought to be toxic (Mizielinska et al. 
2014). Such connections, while speculative, may inform the hunt for novel repeat 
expansions that are not as clearly and extensively linked to disease as C9 and NOP56. 
It is the hope that predictive biomarkers, such as patterns of RBP sequestration and 
splicing, as well as DPRs, might provide evidence for unknown (potentially G-Q-
forming) expansions. 
 
Concluding Remarks: RBP dosage as the central mechanism in 
neurodegenerative diseases 
The examples discussed in this review reflect the increasingly compelling view that 
neurodegeneration can arise from alterations in RBP dosage. If we are to draw any 
aggregate conclusions from the model of SMA, the pleiotropic nature of ALS/FTD and 
the contested mechanisms of TDP-43, FUS, and C9ORF72 mutations, it is that 
neurons, and perhaps especially motor neurons, simply cannot tolerate diminished 
RBP function. It is hard to imagine a way to reconcile TDP-43 aggregation in sporadic 
ALS and FTD, and FUS aggregation in sporadic FTD, without acknowledging their 
centrality to a common disease mechanism. We also note that a significant class of 
ALS without TDP-43 pathology is caused by mutations in Superoxide Dismutase 1 
(SOD1), and the mechanism of disease is not believed to involve RBPs or their 
aggregation (Ling et al. 2013). Our reductionist treatment of these complex, 
	   29	  
heterogeneous diseases is not intended to minimize the contributions of other 
mechanisms, but rather to consolidate the ideas pertaining to the broad topic of RBP 
aggregation. Perhaps in thinking of this disease in such terms, we will become poised 
to draw new parallels between the aggregates we’ve discussed here and the SOD1 
aggregates that characterize SOD1 mutation-affected patients (Bruijn et al. 1998).  
It is our hope that as RBPs emerge as causative factors in more neurodegenerative 
and neurological disorders, such as TIA-1 in Alzheimer’s (Vanderweyde et al. 2012), 
that the potential for therapeutic intervention will be positively impacted by the 
collaborative efforts of neurologists, pathologists, and RNA biologists. From the 
vantage point of basic research, we may find that long sought answers to basic 
questions about RBP dosage in alternative splicing, polyadenylation, and mRNA 
transport will come from the study of these unfortunate ailments. Through attempts to 
answer the question of how gene expression specifies cellular (neuronal) identity, we 
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Figure 1: Overview of Diseases and Genes Covered 
Top-down schematic of neurodegeneration illustrating the tissue-wide phenomena and 
the genetic and molecular changes that occur at the subcellular level. 
Left: Approximate sites of pathology and degenerating neurons in diseases covered in 
this review, including Amyotrophic Lateral Sclerosis (ALS), Spinocerebellar Ataxia Type 
36 (SCA36), Spinal Muscular Atrophy (SMA), Frontotemporal Dementia (FTD), 
Huntington’s Disease (HD), Huntington’s Disease-Like 2 (HDL2) and Myotonic 
Dystrophy Types 1 and 2 (DM1 & DM2).  
Right: Mutations at the DNA result in a variety of changes at the level of RNA 
processing, such as (i.) repression of cryptic splicing, (ii.) formation of exonic splicing 
silencers, (iii.) formation of hairpin structures that trigger RNA silencing pathways and 
sequester proteins, (iv.) formation of stable G-quadruplex structures (G-Qs) that can 
form aggregates with RBPs, (v.) mutations in RBPs that affect their RNA processing 
functions, (vi. & vii.) formation of aggregation-prone poly-glutamine (polyQ) and 
dipeptide repeat (DPR) proteins. Genes harboring mutations are categorized as being 
RBP-encoding genes (TARDBP, FUS, hnRNP A1/A2B1, EWSR1 and MATR3 in ALS), 
noncoding expansions (C9ORF72 in ALS-FTD, FMR1 in Fragile X syndrome and Fragile 
X-associated Tremor/Ataxia syndrome, NOP56 in SCA36, and DMPK and CNBP in 
DM1 and DM2, respectively) or coding expansions (HTT in HD, JPH3 in HDL2, ATXN2 
in Spinocerebellar Ataxia Type 2 and ALS, and AR in X-linked Spinal and Bulbar 
Muscular Atrophy). Nucleotide repeat units for each noncoding and coding expansion 
are in quotations. 
 
	   59	  
 
Figure 2: Functional Domains of the RNA Binding Proteins (RBPs) TDP-43 and 
FUS and their Cellular Roles 
Domain architecture of the disease-related proteins TDP-43 and FUS, with emphasis 
on the Prion-like Domains (PrLD) that contribute to liquid-liquid phase separation, 
represented by a liquid droplet. Various cellular roles of these proteins, including 
nuclear-cytoplasmic shuttling, pre-mRNA processing, hnRNP interactions, mRNP 
granule formation, and Amyloid-like fibrillization are diagrammed, with the domains 
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Abstract 
 
An expanded GGGGCC hexanucleotide in C9ORF72 (C9) is the most frequent known 
cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).  It has 
been proposed that expanded transcripts adopt G-quadruplex (G-Q) structures and 
associate with proteins, but whether this occurs and contributes to disease is 
unknown.  Here we show first that the protein that predominantly associates with 
GGGGCC repeat RNA in vitro is the splicing factor hnRNP H, and that this interaction 
is linked to G-Q formation. We then show that G-Q RNA foci are more abundant in C9 
ALS patient fibroblasts and astrocytes compared to those without the expansion, and 
more frequently colocalize with hnRNP H. Importantly, we demonstrate dysregulated 
splicing of multiple known hnRNP H-target transcripts in C9 patient brains, which 
correlates with elevated insoluble hnRNP H/G-Q aggregates. Together, our data 
implicate C9 expansion-mediated sequestration of hnRNP H as a significant 
contributor to neurodegeneration in C9 ALS/FTD. 
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Introduction 
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two 
related syndromes that occur alone or together in families, and sporadically in 
individuals. Expansion of a hexanucleotide, GGGGCC (G4C2) in an intervening 
sequence separating two putative first, noncoding exons in the gene C9ORF72 (C9) 
(DeJesus-Hernandez et al., 2011; Renton et al., 2011) is the most frequent known 
cause of both disorders. How this expansion leads to disease is unclear, although 
several non-mutually exclusive mechanisms have been suggested. The existence of 
ribonucleoprotein inclusions involving the RNA binding proteins TDP-43 or FUS in the 
brains and spinal cords of nearly all ALS patients and the occurrence of ALS-causing 
mutations in their respective genes (Ling et al., 2013) suggest that defects in RNA 
processing lead to neurodegeneration. In the case of C9ALS, sequestration of RNA-
binding proteins by the transcribed G4C2 expansion is a proposed pathogenic 
mechanism, and it has been shown that RNA from this locus forms intranuclear foci in 
the brains of affected individuals (Donnelly et al., 2013). However, while a number of 
proteins have been suggested to bind the transcribed repeats (Haeusler et al., 2014; 
Lee et al., 2013; Cooper-Knock et al., 2014), the functional significance of such binding 
is not well established. It has also been shown that poly dipeptide repeat (DPR) 
proteins are translated from repeat-containing transcripts, and DPRs may contribute 
toxic effects of their own (Mori et al., 2013b; Kwon et al., 2014; Wen et al., 2014).  
While the mechanism(s) of C9-mediated neurodegeneration is (are) unknown, 
two properties of the pathogenic mutation are noteworthy: First, expansion length is 
variable, with expansions above an indeterminate threshold (~30-40, but up to several 
thousand) causing disease (Nordin et al., 2015). Second, the sequence of the 
expansion favors formation of an especially stable G quadruplex (G-Q) structure, which 
consists of planar tetrad arrays of four non-sequential guanosine residues connected 
by Hoogsteen hydrogen bonds. Two or more of these planar arrays then interact 
through pi-pi stacking, stabilized by a central monovalent cation, generally potassium 
(Davis, 2004). Independent G-Qs can stack upon each other, forming higher order 
multimers. This is relevant to sequences that have many repetitive G-Q motifs in a 
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series, such as is in telomeres and in expanded regions like C9 (Patel et al., 2007; 
Martadinata et al., 2011; Payet and Huppert, 2012; Kobayashi et al., 2011).  
Several factors influence G-Q stability. For example, stability is greater for RNA 
versus equivalent DNA structures, reflecting the presence of 2’ hydroxyls that 
participate in H-bonds within the RNA quadruplex (Collie et al., 2011). Furthermore, 
four quartet G-Qs, such as the O. nova telomeric sequence (GGGGTTTT)n, are 
substantially more stable than their three quartet human telomeric counterparts, which 
in turn are more stable than G-Qs with two quartets (Lee et al., 2008; Mullen et al., 
2012).  The fact that RNA G-Qs, and more so those with four quartets such as the C9 
expansion, are so exceptionally stable is important when considering toxic function 
arising from repeat RNA in ALS/FTD.  It has been proposed that G-Q formation is a 
significant aspect of the toxicity of the repeats in ALS/FTD (Haeusler et al., 2014; 
Simone et al., 2015), but whether such structures are indeed prevalent in C9 ALS/FTD 
patient brains, and if so, whether, and how, they are pathogenic in ALS/FTD has not 
been determined. 
Here we provide insights into the molecular behavior of multimeric RNA G-Qs 
encoded by C9 repeats, which suggest how they may contribute to neurodegeneration 
in ALS/FTD.  Using a sensitive UV-crosslinking assay, we identified the splicing factor 
hnRNP H as the predominant C9 RNA binding protein in a brain cell-derived nuclear 
extract, and show how this interaction reflects association with G-Q containing 
repeats. Significantly, using G-Q- and hnRNP H-specific antibodies for 
immunofluorescence, we observed more G-Q structures and increased hnRNP H 
colocalization in C9 patient-derived cells than in control cells. We detected aberrant 
alternative splicing of multiple known hnRNP H splicing targets in C9 patient brains, 
and show that this correlated with increased levels of insoluble G-Q associated hnRNP 
H in these same brain samples. Intriguingly, the magnitude of splicing deregulation we 
observed in these specimens also roughly correlated with disease severity. Our results 
thus support a model in which the G4C2 repeat expansions in C9 RNA form stable G-Q 
structures that sequester hnRNP H in insoluble aggregates, which in turn lead to 
changes in hnRNP H-target exon inclusion in a variety of disease-relevant transcripts. 
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 Results 
Characterization of C9 protein binding    
We first wished to identify protein(s) that bind C9 repeat RNA, and to investigate 
the effects of RNA structure on binding. While previous studies have identified a 
number of possible C9 RNA binding proteins (Haeusler et al., 2014; Lee et al., 2013; 
Cooper-Knock et al., 2014; see Discussion), we investigated this in a way that allowed 
us not only to analyze direct binding with sensitivity and selectivity, but also to 
determine the possible influence of G-Q formation on binding. To this end, we 
incubated 32P CTP-labeled in vitro transcribed RNAs containing ten C9 repeats (10R), 
typically at a concentration of ~1 nM, in nuclear extract prepared from U87 
glioblastoma cells (NE) and exposed the samples to UV light. Crosslinked RNA-protein 
complexes were digested with RNAse A, T1, a mixture of both, or nothing, and 
resolved by SDS-PAGE. We consistently observed two predominant bands, one of 
~60-65 kDa and one ~75 kDa (Fig. 1a). Unexpectedly, these species were unaffected 
by RNAse A, T1 or both (Fig. 1a, lanes 2-5), with the only difference being that in the 
absence of RNAse, a band appeared at the top of the gel, possibly reflecting higher-
order aggregates that failed to migrate into the gel (lane 2). Notably, although the RNA 
alone ran as a single band of the predicted size on denaturing urea PAGE (Fig. 1b, 
lanes 1 and 5, bottom), on SDS PAGE the free RNA gave rise to two bands, one at the 
expected MW of the full-length RNA (~20-25 kDa, based on protein markers), and a 
lower band that migrated faster (~15 kDa) (Fig. 1a, lane 1). The fact that RNAse had no 
effect on the mobility of the crosslinked doublet suggested that the shifted RNA was in 
fact still full-length and thus resistant to RNAse. Given that the free RNA also resolved 
into two bands, we hypothesized that the two higher MW species resulted from 
crosslinking of the same protein to two differentially mobile full-length RNAs.  
We next wished to investigate why free RNA resolved into two bands on SDS 
PAGE, and whether these species might explain why the crosslinked RNA also 
appeared as two bands. It has been reported that transcripts containing multiple 
independent G-Qs can give rise to distinct species on native gels due to multiple 
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folded conformations (Payet and Huppert, 2012). To test whether the RNAs we 
detected represent different G-Q conformations, we immunoprecipitated (IPed)10R in 
either water or G-Q stabilizing conditions of 200 mM KCl and 500 uM pyridostatin 
(PDS) using the G-Q specific antibody BG4 (Biffi et al., 2013), and resolved the IPed 
RNA by nondenaturing (Fig. 1b, top) or denaturing (Fig. 1b, bottom) PAGE. On 
denaturing PAGE, full-length RNA was detected following IP, consistent with the 
presence of G-Q (lane 5, bottom). On nondenaturing PAGE, both products were 
recovered following IP (lane 5, top), indicating that both species contain G-Qs. Pre-
incubation of the RNA in KCl and PDS enhanced the efficiency of IP (lane 5 versus lane 
4); however, G-Q stabilization was not necessary for recognition of 10R by BG4, as we 
observed minor recovery of 10R in water, visible upon longer exposure (Fig. 1, figure 
Supp. 1, lane 4). We conclude that the two 10R species resolved by nondenaturing 
PAGE reflect two distinct G-Q states, e.g., one in which four G4C2 tracts form one G-Q, 
and the other in which eight tracts form two G-Qs (Fig. 1c).  
We next wished to determine whether the crosslinked doublet was in fact due to 
two differentially mobile G-Q structures bound to one protein. To this end, we 
attempted to denature RNA structures by heating in water to 95OC either 10R or a 
derivative (10R-7dG) in which GTP was replaced during transcription with the G-Q 
destabilizing GTP analog 7-deaza GTP (7dG). RNAs were then added to NE, 
crosslinked, treated with RNAses and the pattern following SDS PAGE compared to 
RNA that had been kept on ice prior to crosslinking (Fig. 1d). Heating 10R slightly 
reduced the appearance of the crosslinked doublet, leading to a corresponding 
increase of a band at ~50 kDa (compare lanes 1 and 3). More striking results were 
observed with 10R-7dG. Even in the absence of heating, crosslinking to produce the 
high MW doublet was substantially reduced relative to 10R (lane 2), supporting the 
view that these species represent protein binding to G-Q RNA. Strikingly, heating 10R-
7dG abolished appearance of the doublet and produced strong crosslinking that gave 
rise to the ~50 kDa species (lane 4). (A weaker band was detected just below the 50 
kDa species; as described below, the two are very likely related).  Notably, the only free 
RNA (at the bottom of the gel) that underwent significant RNAse degradation was 
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heated 10R-7dG (lane 4), consistent with the idea that RNAse resistance reflects stable 
G-Q structures.  
It is conceivable that the identity of the labeled nucleotide could influence the 
pattern of crosslinking, and using a different label could thus provide additional insights 
into the interactions described above. We therefore repeated the above experiments 
with 32P-GTP instead of 32P-CTP in the transcription reaction, generating 10R-G and 
10R-G-7dG, and used these RNAs for crosslinking as above (Fig. 1e). Unheated 10R-G 
reproduced the doublet pattern observed with 10R (lane 3).  However, heated 10R-G 
resulted in the nearly complete loss of the doublet and appearance of increased 
amounts of the 50 kDa species (and fainter band beneath), as well as a reduction in 
intensity of the upper free RNA species (lane 5). With unheated 10R-G-7dG we 
observed much higher levels of 50 kDa bands than with 10R (compare lanes 2 and 4). 
When 10R-G-7dG was heated, only the 50 kDa bands remained, and the free RNA 
underwent significant degradation, similar to what was observed with 10R-7dG 
(compare lanes 4 and 6). To extend these results, we incubated 10R-G and 10R-G7dG 
in 0.1 M KCl before heating, reasoning that stabilization of G-Qs might counteract 
denaturation. Indeed, crosslinking to 10R-G incubated in 0.1 M KCl led to less 
crosslinking at 50 kDa and reappearance of the higher MW doublet (compare lane 7 to 
lane 5). Likewise, heating 10R-G7dG in 0.1 M KCl reduced appearance of the 50 kDa 
band, while also resulting in a faint higher MW doublet (lane 8). These results both 
strengthen our hypothesis that the crosslinked species all arise from interaction with 
the same protein, and also indicate that the identity of the labeled nucleotide can 
indeed influence crosslinking and/or protection from RNAse.  
HnRNP H is the major crosslinked protein 
We next wished to identify the crosslinking protein(s) described above. Several 
lines of evidence, including the size of the "denatured" crosslinked species (~50 kDa) 
and known affinity for poly(rG), led us to hypothesize that it may be the splicing 
regulator hnRNP H (Caputi and Zahler, 2002; Chou et al., 1999; Dardenne et al., 2014; 
Fisette et al., 2012). To determine whether the crosslinked band(s) observed above 
represent(s) RNA bound to hnRNP H, we employed crosslinking followed by IP with 
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anti-hnRNP H antibodies. With10R-G and 10R-G7dG (Fig. 2a) we once again detected 
crosslinked species at 50 kDa (lanes 2 and 6, respectively), both of which were IPed by 
hnRNP H antibodies (lanes 4 and 8, respectively). With 10R-G, and to a lesser extent 
10R-G7dG, we again observed that a significant portion of the crosslinked complex 
failed to migrate into the gel (lanes 2 and 6). Significantly, these species were also 
recovered with hnRNP H antibody (lanes 4 and 8) but not with beads alone (lanes 3 
and7). Some crosslinked doublet was visible with 10R-G (lane 2), although no doublet 
was IPed (lane 4; see below). We also performed crosslinking and IP with the 32P-CTP-
labeled RNA (Fig. 2b). With 10R-7dG, the major and minor 50 kDa crosslinked species 
described above were IPed, but the more abundant higher MW species again were not 
(lane 8). With 10R, the higher MW doublet was again the major species detected, and 
was also not IPed (lanes 2-4). Nonetheless, we believe this doublet does in fact 
represent hnRNP H, but the structured nature of the RNA that enables the complex to 
resist RNAse degradation (Fig. 1a) also obstructs recognition by hnRNP H antibody 
(see also below). Note that the band just beneath the 50 kDa species may represent 
the highly related protein hnRNP H2, which would be predicted to IP with the hnRNP H 
antibody (Stark et al., 2011). 
The above data provided evidence that the 50 kDa species arose from 
crosslinking of hnRNP H and related proteins, but were inconclusive regarding the 
higher MW doublet. Although the data is consistent with the doublet also arising from 
hnRNP H crosslinking, we utilized two additional approaches to investigate this further. 
First, we purified hnRNP H1- 6XHIS from E. coli (H1; Fig. 2c) and performed UV-
crosslinking assays with H1 incubated with 10R-G that was digested with RNAse A/T1 
or not, and compared the results with the pattern in NE (Fig. 2d). In this case, to 
enhance potential G-Q formation and thus detection of the doublet, we included 50 
mM KCl in the buffer. Crosslinking with NE followed by RNAse treatment produced a 
combination of the doublet and ~50 kDa species (lane 3). Notably, the amount of 
doublet was much greater, and the amount of the 50 kDa species much less, than 
when crosslinking was performed in the absence of KCl (compare with Fig. 1e, lane 5). 
Crosslinking with purified H1 followed by RNAse treatment led to a single species 
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running slightly above 50 kDa (lane 1), reflecting the ~4 kDa affinity tag on H1. 
However, when products were not treated with RNAse, both H1 and NE produced 
highly similar patterns of doublets, as well as lower mobility species that failed to 
migrate into the gel, likely reflecting larger multimers as observed above (Fig. 2b, lane 
3). Notably, when we heated the RNA even more stringently (to 100O C) and omitted 
KCl (Fig. 2e), we observed a much simpler pattern, essentially showing only the 50 kDa 
(NE, lane 3) or 54 kDa (H1, lane 4) species.  
As a second approach to determine whether the crosslinked doublet reflects 
hnRNP H crosslinking, we asked whether siRNA-mediated depletion of hnRNP H 
reduces formation of these products. To this end, we prepared two U87 cell NEs, one 
treated with an siRNA targeting hnRNP H (siH) and the other with a negative control 
siRNA (siNC). We were unable to deplete HnRNP H completely, but reduced its levels 
in siH NE to roughly 45% relative to siNC NE (Fig. 2F, top right; silver stained gel (lower 
right) confirmed equivalent protein concentrations in two NEs). We then performed UV 
crosslinking with 10R-G in both NEs. Importantly, both species in the crosslinked 
doublet, as well as the band at the top of the gel, were significantly reduced in siH NE 
relative to the amount detected in siNC NE (Fig. 2F). We conclude that hnRNP H is the 
predominant, and perhaps only, protein in U87 NE to crosslink to 10R and that the 
variations in mobility reflect differential G-Q formation and/or stability. 
We next examined hnRNP H binding to C9 RNA by another method, gel shift 
assays. This approach allowed us to estimate the affinity of hnRNP H for C9 RNA, as 
well as examine any quantitative preference for the folded versus unfolded 
conformation. For this, we used RNAs with four G4C2 repeats, as the ten repeat RNAs 
produced complex patterns in these assays. RNAs were transcribed with GTP or 7-
deaza-GTP to generate 4R and 4R-7dG and gel shift assays were performed with 
increasing concentrations of purified recombinant H1 (Fig. 2, figure Supp. 1). From 
these assays, we estimated the KD for the interaction between H1 and 4R to be 
75.5±14 nM, while the affinity of H1 for 4R-7dG was significantly higher, with a KD of 
13.5±3.0 nM. Notably, we observed the appearance of supershifted RNA-protein 
complexes with both RNAs at higher concentrations of H1. This may reflect multiple H1 
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molecules binding to a single RNA, and is perhaps related to the higher-order 
structures observed in UV-crosslinking experiments. These results suggest that hnRNP 
H binds either to 4R RNA in both folded and unfolded conformations but with different 
modes of recognition and affinities, or preferentially to linear G-tracts, as has been 
found for the third qRRM domain of the highly related protein hnRNP F (Dominguez et 
al., 2010; Samatanga et al., 2013). Either mechanism, however, has relevance to the 
interaction of hnRNP H with the C9 repeats, as expanded transcripts are predicted to 
be composites of G-Qs and linear G-tracts. While determining the precise mode of 
binding will likely require structural studies, these results provide evidence that hnRNP 
H binds the C9 repeats with sufficient affinity for the interaction to be physiologically 
significant.    
Excessive G-Q structure accumulate in C9 patient derived cells 
We next wished to determine the possible relevance of C9 G-Q formation to 
ALS. Previous efforts to visualize GGGGCC repeat foci in cells have relied on in situ 
hybridization (Donnelly et al., 2013; Cooper-Knock et al., 2014). However, this 
approach on the one hand may underestimate the extent of repeat foci because of the 
difficulties denaturing putative G-Q structures, while on the other provides no 
information on the structure of the repeats. We therefore asked instead whether an 
excess of G-Q structures exists in cells from ALS patients with the C9 expansion 
(C9ALS). We used the (Flag-tagged) BG4 antibody to visualize G-Qs by 
immunofluorescence of fibroblasts and astrocytes from C9ALS patients and from 
healthy individuals without neurological symptoms (all patient derived samples 
described in Supp. File 1). 
To quantitate BG4 foci, we developed the program “BG4 Count” in Matlab (see 
Materials and Methods). The program displays only the BG4 foci (red) that coincide 
with DAPI staining in patient and control fibroblasts (Fig. 3a) and astrocytes (Fig. 3b). 
We chose to limit our analysis of BG4 to DAPI-positive areas in order to avoid counting 
artifacts, since the majority of G-Q staining occurs in the nucleus and because DAPI 
staining in the cytoplasm can indicate presence of nucleic acids. Omitting BG4 but not 
FLAG antibody resulted in no staining in the red channel (Fig. 3, figure Supp. 1). Due to 
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potential variability in staining between experiments, we analyzed each experiment 
separately, normalizing the average counts per cell in each cell line to the average 
control cell in each experiment, providing a fold change relative to control. From four 
separate staining experiments with fibroblasts, we compared 16 normalized values 
from seven C9ALS patients comprising a total of ~1,860 cells to 12 values from five 
control lines comprising a total of 1,350 cells using an unpaired t-test, with all C9ALS 
fibroblasts comprising one group, and all control fibroblasts another. This indicated 
that, on average, patient cells contained 1.8 times as many G-Q foci as control cells, 
with a false discovery rate of less than 0.1% (Fig. 3c). Likewise, comparison of one 
C9ALS patient astrocyte line and one control over three separate experiments (210 and 
227 total cells, respectively) revealed that patient cells had 2.0 times as many foci, with 
a false discovery rate of less than 5% (Fig. 3c). 
We also compared the total area of foci in patient and control cells. Comparison 
of the average stained areas across the sets of cells through an unpaired t-test 
revealed that patient fibroblasts contained on average 2.8 times as much stained area 
per cell than did control fibroblasts, with a false discovery rate of less than 0.1%, while 
patient astrocytes had 2.3 times as much area, with a false discovery rate of less than 
1.0% (Fig. 3d). We conclude from these experiments that BG4 foci are larger and more 
numerous in cells from C9ALS patients than from healthy controls. 
We next wished to provide evidence that at least a fraction of the BG4 foci 
detected were RNA and not DNA. BG4 can recognize both DNA and RNA G-Qs, and 
both have been detected in cells (Biffi et al., 2013; Biffi et al., 2014). Treatment of 
astrocytes with RNAse A prior to BG4 antibody incubation in fact reduced the number 
of BG4 foci per cell, by 27% in the control patient cells and by a striking 76% in the 
C9ALS cells (relative to untreated control and C9 cells, respectively; Fig. 3, figure 
Supp. 2). Given that the untreated C9ALS astrocytes in this experiment had 2.7 times 
as many foci per cell as untreated control cells, RNAse A treatment thus reduced both 
patient and control to nearly equivalent numbers of foci per cell (112 and 125 foci per 
cell, respectively), indicating that the excess of BG4 foci observed in the patients is in 
fact attributable to RNA G-Qs.  
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hnRNP H colocalizes with G-Q aggregates in C9 patient derived cells, but not in 
control cells 
We next investigated whether G-Q foci colocalize with hnRNP H and if so, 
whether this occurs more frequently in C9ALS patient cells than in controls. To address 
this, we first analyzed the same sets of fibroblasts and astrocytes by 
coimmunofluorescence in the nucleus (Fig. 4a and b) or DAPI-positive cytoplasm (Fig. 
4c and d; see below). We counted each of the individual colocalization events, and 
then divided these values by the total number of cells (210 C9ALS and 227 control). 
The approximate incidence of nuclear and cytoplasmic colocalizing foci detected in 
C9ALS astrocytes was 6.2 and 8.1%, respectively, and 0.4 and 2.6% in the control 
cells (Fig. 4e). The one nuclear colocalization event we detected in the control 
astrocytes was much smaller and less distinct than any of the events detected in the 
C9ALS astrocytes (Fig. 4f). In fibroblasts, we counted 17 instances of high 
colocalization in the nuclei of C9ALS fibroblasts (Fig. 4g), and 24 in the cytoplasm (Fig. 
4h), or 0.9% and 1.3%, respectively, for the ~1,860 cells we counted. No nuclear 
colocalization events were observed in any of the ~1,350 control fibroblasts, while 
cytoplasmic colocalization was observed in ~0.2% of cells (Fig. 4i).  
Although the incidence of colocalization events detected in the above 
experiments was small, likely reflecting technical difficulties in visualizing the 
overlapping foci, the differences between patient and control cells were highly 
significant. One potential explanation for the low frequency of overlapping G-Q/hnRNP 
H foci we observed is that an excess of BG4-reactive RNA masked hnRNP H within 
RNA-bound aggregates. In support of this, when we counted colocalization events 
after RNAse A treatment in 44 patient astrocytes we found roughly the same rate of 
cytoplasmic colocalization events (9% after treatment as compared to 8.1% before), 
but more than three times as many nuclear colocalization events (20% after treatment 
compared to 6.2% before) (Fig. 4 figure supp. 1). No colocalization events, nuclear or 
cytoplasmic, were detected in control astrocytes after RNAse A treatment. We 
conclude that C9ALS cells contain hnRNP H/G-Q foci that are virtually absent in 
control non-ALS cells. 
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A related possibility is that some hnRNP H/G-Q foci were refractive to BG4 
staining.  We therefore also counted hnRNP H foci not overlapping with BG4 in the 
fibroblasts and astrocytes analyzed above, and again found that the C9ALS cells had 
more foci than the controls. Specifically, C9ALS astrocytes had nonoverlapping hnRNP 
H foci in 18% of cells and control astrocytes had foci in 10% of cells (Fig. 4e), while 
C9ALS fibroblasts had hnRNP H foci in 2.5% of cells and 1.1% of control fibroblasts 
had foci (Fig. 4i). 
We next wished to extend these results to a more physiological context, ALS 
patient brains. For this, we used post-mortem spinal cord sections from two C9ALS 
patients and two nonALS controls (Supp. File 1) for immunostaining with hnRNP H 
antibodies. (BG4 staining was not possible due to high variability and background.) We 
counted instances of nuclear hnRNP H foci that were larger than 0.5 microns in any 
dimension, which was approximately the lower limit for measurement of discernable 
puncta. Motor neurons (MNs) were identified based on their location in the ventral 
horn, size, and low DAPI signal. In the 36 C9ALS MNs we detected, we counted a total 
of 46 large hnRNP H foci, representing possible C9 RNA/hnRNP aggregates (see 
below). In contrast, in 19 nonALS MNs, we detected only three large hnRNP H foci. We 
conclude that hnRNP H distribution is significantly altered in disease-relevant MN 
populations in C9ALS patients. 
C9ALS patient brains show missplicing of hnRNP H target transcripts relative to 
healthy brains 
We next investigated whether the G-Q/hnRNP H association has functional 
consequences in ALS patient brains. We hypothesized that binding of hnRNP H to the 
C9 repeats leads to local depletion of hnRNP H, and the consequent deregulation of 
splicing targets. Such a mechanism would be similar to that which occurs in myotonic 
dystrophy type 1 and 2 (Wheeler and Thornton, 2007). In the case of the C9 repeats, 
sequestration of hnRNP H would most frequently result in increased skipping of 
cassette exons whose inclusion is mediated by concentration-dependent binding of 
hnRNP H to G-runs enriched in the immediate downstream intron (Xiao et al., 2009). To 
investigate this possibility, we first searched RNA-seq datasets from hnRNP H 
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knockdown (KD) and CLIP experiments (Xiao et al., 2009) to identify potential hnRNP H 
targets of interest to the ALS/FTD disease continuum. We selected 13 exons (listed in 
Table 2) whose inclusion appeared significantly reduced upon hnRNP H KD (Xiao et al., 
2009). Targets were selected on the basis of direct links to ALS/FTD or other 
neurological diseases (e.g. ATXN2, KIF1C, PEX19, ARRB2), or because of documented 
involvement in pathways implicated in ALS/FTD such as excitotoxictiy (GABBR1, 
CABIN1), protein degradation (PSMD4, BAT3), cytoskeletal remodeling and 
neuritogenesis (PPP1R12C) and RNA metabolism (PAN2, RNH1, DAZAP1). For 
comparison, we also analyzed three cassette exons, in the genes WDR45, MELK and 
PFKM, that are regulated by the splicing factor SRSF2 (Zhang et al., 2015a) but whose 
response to hnRNP H KD had not previously been studied.  
We analyzed alternative splicing events in C9ALS and non-ALS control 
cerebellum. We used cerebellum because it undergoes significant atrophy across the 
ALS/FTD disease spectrum (Tan et al., 2014), and also because of tissue availability 
and RNA quality. We purified total RNA from postmortem cerebellum of fourteen 
individuals, six without neurological symptoms (ages 54-89, avg. age= 67 years), one 
sporadic SOD1 ALS case (age 52), and seven C9ALS patients (ages 58-73, avg. age= 
63 years) (Supp. File 1). Due to the fundamental pathological, and likely mechanistic, 
differences between SOD1- and C9-ALS we grouped this SOD1 patient with the 
nonALS patients.  For comparison, we also prepared RNA from U87 cells that were 
treated with siRNA against hnRNP H or a negative control siRNA (Fig. 5a). We 
performed 32P-RT-PCR for all samples, amplifying across alternatively spliced cassette 
exons (diagrammed Fig. 5b) and quantitated the proportion of exon-inclusion products. 
We then determined a mean percent inclusion for each patient or KD condition based 
on three or four independent repeats (Fig. 5c-l, Fig. 5, figure Supp. 1), grouped each 
patient as control or C9ALS and compared the values using an unpaired t-test, with 
significance set at p<0.05.  
We first verified splicing changes in the siRNA-treated U87 cells. We found 
decreased exon inclusion following KD for 12/15 hnRNP H target transcripts (Fig. 5d-l; 
Fig. 5, figure Supp. 1b-d), while three were unchanged (Fig. 5, figure Supp. 1 a, e and 
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f). Unexpectedly, two of the three SRSF2 target exons, in WDR45 (Fig. 5c) and PFKM 
(Fig. 5, figure Supp. 1 f), showed increased inclusion upon hnRNP H KD. Although 
neither of these exons appeared among those detected by hnRNP H-CLIP-seq (Xiao et 
al., 2009), the skipped exon in WDR45 contains two potential G-Q motifs that could 
serve as hnRNP H binding sites, while the PFKM exon also contains several G-runs. In 
contrast to the activating effect observed when hnRNP H binds intronic elements, 
hnRNP H generally represses inclusion when it binds exonic sites (Fig. 5b) (Xiao et al., 
2009), consistent with our results. 
We next compared the inclusion values of the 15 hnRNP H and three SRSF2 
target exons between control non-ALS and C9ALS samples. Strikingly, 11 of the 12 
hnRNP H targets and one of the two SRSF2 targets that changed following KD in U87 
cells displayed similar changes in the C9ALS samples compared to controls (Fig. 5c-l, 
Fig. 5, figure Supp. 1 b and c; note that for two exons, in ARRB2 and KIAA1542, p 
values were 0.065 and 0.081, respectively). The hnRNP H target exon in CABIN1 and 
the SRSF2 target in PFKM displayed no difference between controls and C9 patients 
(Fig. 5 figure Supp. 1 d and g), nor did two of the three hnRNP H target exons that 
were unaffected following KD (Fig. 5, figure Supp. 1 e and f). However, the target exon 
in DAZAP1 that did not change following hnRNP H KD was significantly more excluded 
in C9ALS relative to control (Fig. 5, figure Supp. 1 a). The unaffected SRSF2 target 
transcript, MELK, was not detected in brain tissue (Fig. 5, figure Supp. 1 h). 
Widespread splicing dysregulation has been previously reported in the brains of 
C9ALS patients, with motif analysis suggesting hnRNP H as a potential driver of the 
reported changes (Prudencio et al., 2015). To extend our analysis, we examined RNA-
seq from patient brains (Prudencio et al., 2015) and hnRNP H KD (Xiao et al., 2009) to 
identify events common to the two datasets. We performed 32P-RT-PCR on nine 
cassette exon targets that were found significantly altered in both datasets. For two 
genes, UQCRB and UBE2I, we could detect only exon exclusion (Supp. File 2), while 
another, TCEB1, varied greatly in overall expression across our cohort of patients, and 
could not be accurately quantified (data not shown). For the other six targets we 
confirmed that the regulated exon was more included in patients than controls in 
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transcripts from HNRPDL, OS9 and RPL10 (Fig. 5, figure Supp. 2 a-c) and more 
excluded in patients than controls in RBM38, PCBP2 and SIGMAR1 transcripts (Fig. 5, 
figure Supp. 2 d-f), all entirely consistent with the results of the hnRNP H KD RNA-seq 
(Supp. File 2).  
We next investigated whether the affected exons we have described are indeed 
direct targets of hnRNP H. To address this, we examined previous hnRNP H CLIP-seq 
data (Xiao et al., 2009; Katz et al., 2010) to determine whether hnRNP H physically 
binds in the vicinity of the regulated exons (Fig. 5, figure Supp. 4). Indeed, we found 
CLIP tags within 200 bps of 17 out of 18 exons that differed between nonALS and 
C9ALS, with the only exception being the exon in ATXN2, for which CLIP tags were 
present within 500 bp. These observations strongly support a direct role of hnRNP H in 
these misregulated splicing events. 
In addition to the direct involvement of hnRNP H, it is possible that secondary 
effects may contribute to the splicing changes detected in C9ALS. For example, 
changes in expression of splicing factors with hnRNP H-regulated exons, such as 
RBM38, PCBP2 and HNRPDL, could alter splicing. Similarly, levels of the splicing factor 
hnRNP A1, which has been suggested to bind the C9 repeats (Cooper-Knock et al., 
2014; Zamiri et al., 2014), have been suggested to influence roughly one third of the 
events that change upon hnRNP H depletion (Huelga et al., 2012). We therefore asked 
whether cassette exons that are regulated by hnRNP A1 are misspliced in C9ALS 
relative to nonALS brains. We performed 32P-RT-PCR across six exons affected by 
hnRNP A1 KD: three that undergo more skipping following hnRNP A1 depletion and 
three that are more included (Huelga et al., 2012) (Fig. 5, figure Supp. 3 a-f). Only one 
exon, in ZCCHC17, differed significantly, and it was more excluded in C9ALS patients 
relative to nonALS, opposite the outcome that would be predicted if hnRNP A1 levels 
were reduced. Notably, the regulated exon in ZCCHC17 had hnRNP H CLIP tags, ~100 
bp downstream, likely coinciding with a potentially G-Q forming intronic sequence (Fig. 
5, figure Supp. 4). Only one other gene, G2AD (AP1G2), had CLIP tags in or near the 
regulated exon, overlapping a polyG exonic motif ~70 bp downstream (Fig. 5, figure 
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Supp. 4). This exon was indeed included less in C9ALS patients (p= 0.096), again 
opposite the effect predicted for hnRNP A1 depletion (Supp. File 2). 
We next asked whether each C9ALS patient displayed a similar extent of exon 
exclusion for all of the affected transcripts. To investigate this, we determined the 
mean percent exon inclusion of the 16 significantly misspliced hnRNP H target exons 
and the single SRSF2 and hnRNP A1 targets for each patient, and ordered the patients 
from lowest to highest average inclusion. We reasoned that if there was variation, the 
patient in which hnRNP H function was most reduced would have the lowest inclusion 
values, while the patient with the least functional reduction would have the highest 
exon inclusion values, for all of the genes, except for WDR45, HNRPDL, RPL10 and 
OS9, which we hypothesized would display the opposite trend. Using linear regression, 
we plotted a best-fit line for each gene (Fig. 5m), and indeed found that for every gene 
except WDR45, HNRPDL, RPL10 and OS9 a straight line with a positive slope could be 
drawn (values listed in Supp. File 2), demonstrating that the patient with the lowest 
average inclusion had the lowest percent inclusion for all genes tested. As expected, 
the lines for WDR45, HNRPDL, RPL10 and OS9 all had negative slopes. Interestingly, 
this trend also reflected disease duration, i.e., time from onset of symptoms until death, 
for each patient, a rough indicator of disease severity (Supp. File 1). Shorter disease 
duration correlated with greater changes in exon inclusion, suggesting that hnRNP H 
splicing dysregulation is a marker of clinical progression.  
hnRNP H forms insoluble aggregates with G-Qs in C9 patient brains  
We next investigated whether the G-Q/hnRNP H foci we detected by 
immunostaining of patient cells sequester sufficient amounts of hnRNP H to bring 
about the splicing changes we detected in C9ALS brains. To address this, we analyzed 
motor cortex (Brodmann Area 4) from the seven C9ALS patients and seven controls in 
our cohort by biochemical fractionation with Sarkosyl-containing buffers, a method 
used previously to detect protein aggregates from the brains of Alzheimer’s patients 
(Ren and Sahara, 2013), followed initially by western blotting for hnRNP H (Fig. 6a). We 
quantified the abundance of hnRNP H in each fraction, summing them to find the 
amount of total hnRNP H, and determined the percentage of insoluble hnRNP H from 
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two independent experiments. We plotted these values for C9ALS patients and 
nonALS controls and compared them using a t-test (Fig. 6b). The average percentage 
of insoluble hnRNP H was 30.0% in nonALS and 56.1% in C9ALS (p= 0.013). We 
conclude that there is 1.9 times as much insoluble hnRNP H in the motor cortex of 
C9ALS patients as compared to control, providing evidence that hnRNP H 
sequestration by C9 repeats occurs in the brains of ALS patients to a biochemically 
significant level.  
We hypothesized that the change in distribution of hnRNP H reflects formation 
of insoluble aggregates with C9 G-Q RNA. To provide evidence for this, we performed 
co-IP with BG4 and the resuspended insoluble pellets from motor cortex from five 
C9ALS patients and five controls, followed by western blotting for hnRNP H, and for 
comparison, for SR proteins, including SRSF1 and SRSF2, which reportedly bind the 
C9 repeats (Fig. 6c). We performed three independent co-IP experiments, and 
quantified the amount of hnRNP H that co-IPed with BG4 in C9ALS and non-ALS 
controls. We found, on average, 2.7 times as much hnRNP H co-IPed from the C9ALS 
samples as from the nonALS controls (Fig. 6d) (p= 0.0007). We obtained similar results 
when we performed no BG4, beads-alone controls and subtracted the hnRNP H 
signals without antibody from the signal with BG4 for each sample: 2.8 times as much 
hnRNP H co-IPed from the C9ALS samples as from the nonALS controls (Fig. 6, figure 
Supp. 1). Using an antibody that recognizes a common phospho-epitope on all SR 
proteins, we did not detect co-IP of any SR proteins (Fig. 6c). We conclude that hnRNP 
H forms aggregates with G-Qs in the brains of C9ALS patients, providing additional 
evidence that hnRNP H is indeed sequestered by C9 G-Q RNA, and to an extent 
sufficient to bring about the observed splicing dysregulation. Below we discuss how 
the effects on splicing, and the aggregation itself, may be relevant to the ALS/FTD 
disease spectrum.   
 
Discussion 
A number of studies over the last few years have identified proteins capable of 
interacting with the C9 repeats in vitro and which could potentially become 
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sequestered by expanded transcripts in vivo. While a majority of these studies did not 
consider how G-Q formation might affect protein binding, some took explicit 
consideration of the G-Q structure formed by the repeats (Haeusler et al., 2014; Reddy 
et al., 2013; Zamiri et al., 2014), while another rejected G-Q-binding candidates by 
discarding proteins that exhibited similar binding to scrambled targets that would also 
form entirely GC G-Qs (Donnelly et al., 2013). The list of possible C9 repeat binding 
proteins currently includes hnRNP A3 (Mori et al., 2013a), SRSF1 (Lee et al., 2013; 
Reddy et al., 2013; Zamiri et al., 2014), Pur alpha (Rossi et al., 2015; Xu et al., 2013), 
ADARB2 (Donnelly et al., 2013), SRSF2 (Cooper-Knock et al., 2014; Lee et al., 2013), 
hnRNP H (Cooper-Knock et al., 2014; Lee et al., 2013), hnRNP A1 (Cooper-Knock et 
al., 2014; Zamiri et al., 2014), ALYREF (Cooper-Knock et al., 2014), nucleolin (Haeusler 
et al., 2014) and RanGAP (Zhang et al., 2015b). Of these proteins, only SRSF1, hnRNP 
H and nucleolin have been suggested to bind RNA G-Qs (von Hacht et al., 2014); 
however, the known binding specificities of SRSF1 and nucleolin appear inconsistent 
with high affinity binding to GGGGCC repeats (Tacke and Manley, 1995; Ghisolfi-Nieto 
et al., 1996), and our results did not provide evidence for SR proteins binding C9 RNA. 
Moreover, many of these studies initially found an excessive number of candidates, in 
the hundreds, which required further refinement (Cooper-Knock et al., 2014; Donnelly 
et al., 2013; Haeusler et al., 2014; Mori et al., 2013a).  
The above studies paint a complex and somewhat confusing picture of 
GGGGCC repeat recognition by RNA binding proteins. What distinguishes our findings 
from these earlier ones is that, as assayed by sensitive UV crosslinking, we 
consistently observed predominant binding of a single protein, which most often 
appeared as multiple bands due to the folded structure of the ten repeat RNA. Our 
conclusion that hnRNP H is the major C9 binding protein is consistent with studies 
implicating it in in C9ALS (Lee et al., 2013) as well as in G-Q binding (Dardenne et al., 
2014; Fisette et al., 2012; von Hacht et al., 2014). Moreover, a meta-analysis of 
independent RNA pulldown studies identified hnRNP H1 or the highly related hnRNP 
H3 as the proteins most consistently found associated with C9 RNA (Haeusler et al., 
2016). Thus our conclusion that hnRNP H is the major C9 repeat binding protein 
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provides compelling evidence not only for what may be an emerging consensus, but 
also for the functional significance of this interaction to ALS/FTD. 
Our data is also entirely consistent with the known properties of hnRNP H as a 
splicing regulator.  KD of hnRNP H followed by RNA-seq revealed that exons that 
respond with significantly lowered inclusion show enrichment of G-runs within 70 
bases downstream of their 5’ splices site (Xiao et al., 2009). Moreover, a positive 
correlation between the extent of the change in inclusion and the number of G’s in 
these G-runs was observed, and larger changes in splicing following KD were detected 
for exons with relatively weak 5’ splice sites. Thus when hnRNP H is depleted, or 
sequestered as we propose, these types of exons would be the most severely 
compromised. Indeed, sequencing of RNA from C9ALS patient brains revealed global 
changes in alternative splicing, particularly skipping of exons that are proximally 
enriched for putative hnRNP H binding motifs (Prudencio et al. 2015). Our work 
provides a mechanism to explain these findings, and implicates G-Q formation and 
hnRNP H sequestration in the pathogenesis of ALS/FTD. 
Exon skipping is the most common form of alternative splicing, and hnRNP H 
levels influence a significant number of these events. While it is unknown which, if any, 
of the splicing changes we detected are disease relevant, all of the target genes we 
analyzed encode proteins that can be mechanistically linked to ALS/FTD. For example, 
ATXN2 encodes a polyglutamine protein associated with spinocerebellar ataxia 2 
(Imbert et al., 1996) and contains an expansion that also confers increased 
susceptibility to ALS in sporadic (Elden et al., 2010), and possibly C9 (van Blitterswijk 
et al., 2014), cases.  Additionally, GABBR1 encodes one of the subunits of the 
heterodimeric GABA receptor B (GABABR). When exon 19 is skipped, as we observed 
in patient brains, a frameshift occurs, likely reducing levels of GABBR1 protein. GABA 
is the major inhibitory neurotransmitter in the mammalian CNS (Gassmann and Bettler, 
2012) and reduced GABA-mediated inhibition may contribute to excitotoxic cell death 
in ALS (Brockington et al., 2013), which may provide a molecular basis for the 
potentially pathogenic finding of cortical hyperexcitability in C9ALS patients 
(Geevasinga et al., 2015). Additionally, several of the other hnRNP H-regulated genes 
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we identified, such as PAN2 (Udagawa et al., 2015), PEX19 (Murakami et al., 2013) and 
PSMD4 (Gorrie et al., 2014), have been indirectly implicated in ALS.  
A critical question is whether the hnRNP H sequestration we have described 
plays a direct, causal role in ALS. While there is no conclusive data establishing 
causality for any of the multiple mechanisms proposed to explain the toxicity of the C9 
repeats, our data and that of others (Cooper-Knock et al., 2015) suggest that the 
extent of splicing dysregulation, in our case specifically of hnRNP H targets, is 
inversely correlated with disease duration, or directly correlated with disease severity.  
While analysis of larger cohorts is necessary to confirm this correlation, our findings 
support a causal role of hnRNP H deficiency in ALS/FTD.  
An interesting question is how the C9 repeats, by sequestration of hnRNP H or 
indeed any proposed mechanism, lead to neurodegeneration in an age-dependent 
manner. We hypothesize that slight alterations in expression of the genes described 
above, and perhaps other hnRNP H-regulated transcripts, together contribute to 
ALS/FTD pathology. We propose that over time, RNA transcribed from the C9 repeats 
eventually accumulates to levels sufficient to titrate cellular supplies of hnRNP H, thus 
leading to splicing defects of target transcripts. Some of these changes, such as with 
genes we have analyzed, would be “driver” events, others, perhaps most, would be 
“passenger” events that do not contribute to disease. While deleterious consequences 
arising from missplicing might be tolerated or avoided in dividing cells that can 
regenerate before hnRNP H levels become sufficiently low, longer-lived, postmitotic 
neurons would not have the advantage of clearing RNA-protein aggregates, which may 
themselves have toxic consequences for the cell. We predict that in neurons, 
sequestration of hnRNP H becomes more severe with time and continuing C9 
transcription, until functional levels become low enough to deregulate splicing, 
providing an explanation for the age dependence of ALS/FTD.  
Toxic protein aggregates are hallmarks of many neurodegenerative diseases. 
Within the ALS/FTD spectrum, the composition and location of aggregates are useful 
for defining distinct disease subtypes that often reflect the diverse genetic 
underpinnings of these two related disorders (Thomas et al., 2013). The most prevalent 
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aggregations in ALS are ubiquitinated, cytoplasmic inclusions containing TDP-43, 
which occur in the brain and spinal cord of virtually all ALS patients, with the exception 
of SOD1 and FUS ALS cases. Thus far, the only aggregates unique to C9 are 
p62/ubiquitin-positive, TDP-43-negative cytoplasmic and nuclear inclusions containing 
DPRs derived from non-ATG translation of expanded C9 transcripts (Blokhuis et al., 
2013). Such DPRs can display neurotoxic properties (Mizielinska et al., 2014; Wen et 
al., 2014), consistent with a role in MN death in ALS. However, it has been reported 
that they are enriched in non-vulnerable brain regions and largely absent from the 
spinal cord of C9ALS patients, raising questions regarding their exact role in motor 
neuron degeneration (Davidson et al., 2015). While foci containing expanded C9 RNA 
have been referred to as aggregates (Lee et al., 2013; Reddy et al., 2013; Zamiri et al., 
2014), whether this is in fact the case had not been previously investigated. Our 
experiments thus provide the first evidence that G-Q expansions bound to hnRNP H 
indeed form insoluble aggregates, and are present in disease-relevant regions of the 
brain. While we have focused on the consequences of hnRNP H sequestration on 
splicing, it remains to be seen if these aggregates also have dominant neurotoxic 
properties. 
The insights we provide here into the behavior of the C9 G-Qs suggest a 
possible therapeutic approach that specifically targets the C9 G-Qs and interferes with 
hnRNP H binding. Many G-Q-interacting compounds exist that have the potential to 
disrupt hnRNP H/G-Q interactions generically (Patel et al., 2007; Balasubramanian and 
Neidle, 2009). However, such compounds would likely also interfere with the normal 
binding of hnRNP H to intronic G-Qs and thereby exacerbate the splicing defects 
arising from hnRNP H sequestration. It may be possible however to exploit the high 
stability, compactness, and symmetry of the C9 G-Q to design drugs that selectively 
disrupt the pathogenic binding of hnRNP H and thus restore proper hnRNP H 
stoichiometry and ameliorate disease-relevant splicing changes. 
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Materials and Methods 
In vitro transcription and probe purification: In vitro transcription reactions were 
mixed to final concentrations of 1X transcription buffer (supplied by manufacturer, 
Thermo Scientific), 10 mM DTT, 1 U/ul RNAse inhibitor, 500 uM each ATP, CTP, UTP, 
20 uM total GTP including 16 pmol α-32P-GTP (3,000 Ci/mmol, Perkin Elmer), 2 ug 
double stranded T7 promoter containing template (Integrated DNA Technologies, 
Supp. File 3), and 1 U/ul T7 RNA polymerase (Promega). Reactions were incubated at 
37O C for 5 hr. Alternatively, RNA was transcribed cold using the same conditions, 
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except with 500 uM each unlabeled XTP. At the end of the incubation DNAse RQ1 was 
added to a concentration of one unit/ug of starting DNA template, with DNAse RQ1 
buffer (Promega), and incubated for 20 min at 37O C. The reaction mixture was then 
adjusted to 200 ul, extracted with phenol/chloroform, and the aqueous phase 
precipitated with NH4OAc, isopropanol and linear polyacrylamide (LPA) (Sigma) for 1 
hr-overnight at -20O C. RNA was pelleted in an Eppendorf for 15 min at 21,000xg at 4O 
C, dried, and resuspended in a 1:1 mixture of 50% glycerol and 2X RNA load dye 
(Ambion). Samples were then boiled and loaded onto an 8M Urea/8% acrylamide gel 
and electrophoresed at 200V for 2 hr. The gel was transferred to Whatman paper, 
wrapped in plastic, and exposed to X-ray film for up to 1 hr. Bands corresponding to 
the desired products were excised and eluted into a solution of 0.75 NH4OAc and 0.1% 
SDS for at least 16 hr at 4O C. The elution mixture was then precipitated with 
approximately 1.5 volumes of cold isopropanol, 1 ul LPA, incubated at -20O C, pelleted 
as above, dried, and resuspended in 20 ul H20. Yield was determined by liquid 
scintillation counts (MicroBeta Trilux) of 1 ul of the final product in H20 compared to 
reference of 1 ul of α-32P-CTP or GTP (Perkin Elmer).   
Purification of BG4 from E. coli: The pSang10 vector encoding the BG4 antibody was 
a generous gift from Dr. Balasubramanian (Cambridge, UK). BG4 antibody was purified 
by the following protocol: Plasmid was transformed into BL21 Rosetta Cells and a 2 
mL culture was grown with 2% glucose, 50 ug/ml Kanamycin, and 35 ug/ml 
chloramphenicol overnight at 200 rpm and 30O C. This culture was then diluted to 200 
mL in 2XYT containing kanamycin and chloramphenicol, and mixed with 100 mL auto-
induction media (Supp. File 4), grown at 250 rpm and 37O C for 6 hrs, and then 
overnight at 280 rpm and 25O C. The culture was pelleted, lysed in TES buffer (50mM 
Tris/HCl pH 8.0, 1 mM EDTA pH 8.0, 20% sucrose), purified Ni-NTA Agarose beads 
(Qiagen) with two washes (PBS + 100 mM NaCl + 10 mM imidazole, pH 8.0), eluted 
into PBS with 300 mM imidazole, dialyzed against nuclear extract buffer D (Kataoka 
and Dreyfuss, 2008), aliquoted, and stored at -80O C. 
Immunoprecipitation with BG4: FLAG-M2 coated magnetic beads (Sigma) were 
equilibrated three times with IP buffer (150 mM NaCl, 50 mM Tris pH 7.5, 1 mM EDTA, 
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10% glycerol, 0.5% NP-40) before rocking with ~5 ug BG4 (described above) or 
without for 1 hr at 4O C, followed again by three washes with IP buffer. Meanwhile, 
approximately 0.1 pmoles in vitro transcribed 10R-C was incubated at room 
temperature for 10 min in either DePC-treated H2O or 200 mM KCl and 500 uM 
Pyridostatin (PDS) (Sigma).  Equal amounts of RNA in water and KCl were then 
incubated with either BG4-caoted beads or beads alone for 1.5 hrs at 4O C, followed by 
three washes with IP buffer adjusted to 250 mM NaCl. After the final wash, input and 
beads were incubated with 2X RNA load dye (Ambion) at 95O C for 5 min, rapidly 
cooled on ice, separated on a magnetic stand, and the supernantant loaded onto a 
12% 8M Urea gel and electrophoresed for 2.5 hr at 400V. For SDS PAGE, samples 
were prepared identically, except the beads were heated at 95O C for 5 min in 2X SDS 
PAGE buffer and loaded onto a 10% SDS gel and electrophoresed for 120 min at 
100V. Gels were then dried on Whatman paper, wrapped in plastic, and analyzed by 
phosphorimager (Molecular Dynamics Storm 860). 
UV Crosslinking: U87 glioblastoma cells were acquired from previous Manley lab 
members. The cell line was not authenticated, and was not tested for mycoplasma. 
Cells were cultured in DMEM with 10% FBS in 140mm dishes. Nuclear extract (NE) 
was prepared from confluent cells according to (Kataoka and Dreyfuss, 2008).  
Approximately 1 nM RNA in H2O was incubated in microcentrifuge tubes with buffer D 
with KCl adjusted to a final concentration of 100 mM (or otherwise, where indicated) in 
a total reaction volume of ~10 ul. For denaturation (where applicable), RNA was heated 
as indicated in a circulating water bath prior to incubation with protein.  Four ul of NE 
was added last, or buffer D in the case of probe alone. Mixtures were incubated on ice 
for 15-30 min, then crosslinked in a UV stratalinker 1800 (Stratagene) for two 90-sec 
periods with 180-degree rotation in between. The mixtures were crosslinked at a 
distance of 8-12 cm from the UV source to the top of an open tube. Next, 1 ul of 
RNAse A (2 ug/ul) or T1 (10U/ul), or both, was added and reactions mixtures incubated 
at 37O C for 15 min. Equal volume of 2X SDS sample buffer was then added and 
reactions were boiled and then loaded onto 12% SDS PAGE gels and run at 90V for 
100 min. Gels were then dried and analyzed by phosphorimager as described above. 
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Immunoprecipitation of crosslinked protein-RNA complexes: For 
immunoprecipitations, crosslinking was performed as above. Protein A Dynabeads 
(Invitrogen), 10 ul per reaction, were equilibrated by washing 3X with NE buffer A 
(Kataoka and Dreyfuss, 2008), then incubated with end-over-end rotation for 1 hr at 4O 
C with or without 1.5 ug polyclonal rabbit hnRNP H antibody per reaction (Bethyl or 
ThermoFisher). Beads were then washed three more times with buffer A, resuspended 
in 100 ul buffer A with 0.1% Triton X-100, and mixed with crosslinking reactions, 
following RNAse treatment. Reaction mixtures were incubated for 30 min at 4O C with 
end over end rotation, then washed 3X with buffer A with 0.1% Triton X-100 adjusted 
to 300 mM KCl. After the third wash, isolated beads were resuspended in a 50/50 mix 
of buffer A and 2X SDS sample buffer (less than 20 ul total) and boiled. Tubes were 
placed on a magnetized stand to separate the beads, and supernatants were 
subjected to SDS-PAGE and bands visualized as described above. 
Purification of hnRNP H1 from E. coli: The cDNA sequence of hnRNP H1 was cloned 
in between BamHI and PstI sites of the pRSET-C vector (Invitrogen). Plasmid-
containing cells were inoculated in LB medium containing 1 ug/mL ampicillin and 35 
ug/mL chloramphenicol, and a 250 mL culture was grown at 200 rpm at 37O C until 
reaching an OD of 0.5. The culture was then induced with 1 mM IPTG for 6 hrs. 
Cultures were lysed in lysis buffer (1M NaCl, 50mM NaH2PO4, 0.5mM phenylmethyl 
sulphonyl fluoride (PMSF), pH 8.0) containing 0.1% Triton X-100 by sonication, then 
centrifuged at 8,000xg for 15 min at 4O C. The supernatant was passed through a 0.2 
um filter, then mixed with 0.5 mL Ni-NTA Agarose beads that were pre-washed in lysis 
buffer, and rocked for 30 min at 4O C before being loaded onto a Poly-prep 
chromatography column (Bio-Rad) at 4O C. The column was washed once with 50 mL 
of lysis buffer, once with 25 mL lysis buffer with 8mM imidazole, once with 20 mL lysis 
buffer with 40 mM imidazole, then ten times with 10 mL NaCl solution, starting with 1M 
and decreasing the concentration by 100 mM each time until reaching 100 mM. The 
column was then eluted up to five times with 500 mM imidazole, and dialyzed against 
buffer D overnight.  Protein was aliquoted and stored at -80O C. 
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Gel Shift Assays: Purified H1 concentration was estimated using the A280/260 
method of the NanoDrop 2000 spectrophotometer (Thermo Scientific) and diluted with 
binding buffer (50 mM Tris, pH 8, 50 mM NaCl, 2mM EDTA, 0.5% BSA, 0.2% CHAPS). 
Reactions were mixed to a final concentration of 0.3 nM in vitro transcribed RNA, 30 
nM tRNA and 0-640 nM H1 in binding buffer to a final volume of 5 ul, and incubated for 
30 min at 37O C. Reactions were instantly placed on ice and 1 ul 50% glycerol was 
added before loading onto a pre-run native 6% acrylamide gel, and electrophoresed 
for 100 min at 200V. Gels were dried, imaged by phosphorimager, quantified using 
ImageQuant, and plotted and analyzed using Graphpad for Prism. 
Patient information and ethics statement: Human fibroblasts were isolated and 
grown from C9 ALS patients and normal controls under a protocol approved by the 
Institutional Review Board (IRB) of Columbia University. Presence of C9 repeat 
expansion was confirmed in Columbia University’s CLIA approved molecular pathology 
laboratory by repeat-primed PCR. Protocols for obtaining skin biopsies and their use 
were approved by the IRB and all patients have signed their informed consent, 
including consent to publish. The procedure to culture astrocytes from post-mortem 
tissue had IRB approval, with the written informed consent given by the patient 
families.     
Skin biopsy and fibroblast culture: A skin punch kit was used to obtain biopsy 
samples. Once the skin had been prepared with alcohol, the area to be biopsied was 
anesthetized by injecting a Lidocaine solution (HCL1% and Epinephrine 1:100,000). 
After the skin was anesthetized, the biopsy was performed using a sterile 3mm skin 
punch. A ‘drilling’ motion was applied by pressure and twisting until the blade of the 
skin punch had pierced the epidermis of the skin. Then the skin area was removed 
carefully into a 2ml sterile tube with culture medium, and transferred to a laminar flow 
hood for culture. After the skin biopsy was rinsed with PBS, the adipose tissue was 
removed. Then the skin sample was cut into 6 smaller pieces, and each piece was 
cultured in a well from a 6 well plate using fibroblast culture medium (Supp. File 4). In 
general, around one week, the fibroblasts come out of the skin biopsy, and were 
passaged into a larger flask or frozen down.  
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Astrocyte culture: Human astrocyte cultures were made as described (Re et al., 
2014). Autopsied brain tissue samples of motor cortex were collected and transferred 
to a laminar flow hood with a dissection microscope. Prior to cell isolation, meninges 
and visible blood vessels were removed, and tissue was cut into 5 mm3 cubes. The 
tissue was then digested for 20 min at 37O C with dissociation medium (Supp. File 4), 
quenched with culture medium (Supp. File 4), and triturated harshly with a 10 ml sterile 
pipette for 10 times.  The solution was centrifuged at 1,000xg for 3 min and the pellet 
was cultured into a T75 cm2 flask for 2 hr in an incubator. The cell suspension was then 
moved to a new T75 cm2 flask coated with poly-L-lysine (15 μg/ml, Sigma). Flasks were 
incubated in a humidified atmosphere of 5% CO2 and 95% air at 37O C for 48 hr, after 
which the culture medium was changed so as to remove unattached cells and myelin 
debris. Culture medium was changed once a week. When cultures reached confluency, 
the astrocytes were passaged or frozen down. 
Immunofluorescence: Fibroblasts and astrocytes (described above) were grown in 
their respective culture medium (Supp. File 4) up to, but not exceeding, passage four. 
For immunofluorescence, cells were plated on Poly-L-Lysine coated 12mm coverslips 
(Corning BioCoat). Cells were fixed with 3% paraformaldehyde in PBS for 15 minutes, 
permeabilized with 0.15% Triton X-100 in PBS for 15 min, and blocked with 1% BSA in 
PBS (filtered) with at least two PBS 5-10 min washes between each step. Prior to BSA, 
cells were, where indicated, treated with RNAse A or T1 by incubating coverslips at 37O 
C for 1 hr with either 200 ug RNAse A/mL or 1,000 units RNAse T1/mL in PBS. Cells 
were then washed 3 times with PBS prior to incubation with 75 ul of 1.5 ug/ml BG4 for 
16-18 hr at RT, then washed with PBS and blocked again with 1% BSA prior to 
incubation with 1ug/ml each of hnRNP H (rabbit, Bethyl) and FLAG (mouse, Sigma) 
antibodies in 75 ul PBS for 3-4 hr at 37O C. One ul each of mouse-568 AlexaFluor and 
rabbit-488 AlexaFluor (Invitrogen) were diluted 1:1,000 in 0.2% BSA in PBS, vortexed, 
and centrifuged for 3 min at 16,000xg.  The upper 500 ul were then added, dropwise, 
to the coverslips, which were incubated for 2.5-3 hr at 37O C.  Cells were washed, 
stained with DAPI, and then mounted onto microscope slides, using ProLong Gold 
Antifade Reagent (Invitrogen). Cells were imaged using a Zeiss LSM 700 confocal 
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microscope with a 40X objective, and pictures were taken using Zen Lite software. 
Each experiment used cells from patient and control cell lines, and within each 
experiment all cells were imaged with identical gain settings (DAPI=690, 568=600, 
488=420), and manually focused until the green (488) channel appeared at its brightest 
so as to minimize variation in images. Images were converted to TIF files using Image J 
in order to be read by the BG4 count Matlab program.  
BG4 Count: BG4 Count is a script written in Matlab (MATLAB and Statistics Toolbox 
Release 2014b, The MathWorks, Inc., Natick, Massachusetts, United States) that 
works by reading a multichannel image (given as .tif). The program first prompts the 
user to set a variable threshold value between 0 and 1 for the intensity of the staining 
to be analyzed in the red channel, which corresponds to BG4 staining. We used a 
threshold of 0.1 for every image. The script then removes all staining in the red channel 
below the threshold intensity and removes any red channel staining that does not 
overlap with the staining in the blue channel (nucleus, or DAPI-stained cytoplasm). It 
then proceeds to utilize the regionprops function to measure the parameters of each 
continuous object in the image and then sums the area parameter of each object in the 
image, AreaTotal. Then a trimmed mean of areas is taken where the top and bottom 
10% of area data is removed from the data set and the remainder of the area data is 
averaged. This provides the average area of a single stained object. Taking the 
AreaTotal and dividing by this average area gives a trimmed mean approximated 
object count, or foci count, referred to here.  
Immunohistochemistry of spinal cord sections: Spinal cord sections were acquired 
from the Columbia Brain Bank and embedded in optimum cutting temperature (O.C.T.) 
compound (Sakura, Torrance, CA) and frozen at −80°C. Consecutive sections (25μ 
thick) were cut using a freezing microtome (Leica CM 3050S), mounted onto 
microscope slides, and stored at −80°C. Prior to fixation sections were briefly thawed 
and rinsed with PBS, then fixed in 4% paraformaldehyde in PBS for 15 min blocked 
and washed three times with PBS for 5 min each. Sections were blocked with 5% 
normal donkey serum diluted in Tris buffered saline (pH 7.4) with 0.2% Triton X-100 
(TBS-T) and incubated with hnRNP H antibody (Bethyl) diluted in TBS-T with 5% 
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normal donkey serum overnight at 4O C. After washing with TBS-T, tissue sections 
were incubated for 4 hrs at RT with species-specific secondary antibody coupled to 
Alexa 568 (1:1,000; Life Technologies, Carlsbad, CA, USA). After washing with TBS-T, 
coverslips were applied with Flouromount G (Southern Biotech, Birmingham, AL, USA) 
and imaged in a blinded fashion using an SP5 Leica confocal microscope (Leica 
Microsystems, Wetzlar, Germany).  Images were converted into z-stack max 
projections and individual foci were measured using ImageJ. 
siRNA Transfection: U87 cells were grown as described. Cells were grown in 10mM 
dishes and transfected with 25 nM si-hnRNP H (Xiao et al., 2009) or 25 nM negative 
control siRNA (Shanghai Gene Pharma) using RNAiMax (Invitrogen) as per 
manufacturer’s instructions at 80-90% confluency. Cells were split 24 hr later, then 
harvested 48 hr after, and split in two fractions of 75% and 25%. The 25% fraction was 
subject to sonication and boiling with SDS sample buffer for western blot analysis. The 
75% fraction was extracted with TriZol reagent as per the manufacturer’s instructions 
(Invitrogen), then treated with DNAse RQI for RNA analysis. 
Western Blot: Proteins were resolved on SDS-PAGE and westerns were carried out 
with the following antibodies: polyclonal rabbit anti-hnRNP H (Bethyl), mouse anti-Actin 
(Sigma), mouse mAb104. As secondary antibodies we used HRP-conjugated anti-
rabbit and anti-mouse (Sigma), and signal was detected with ECL western blotting 
system (GE Healthcare). 
RNA extraction from human patient cerebellum: Pulverized human brain samples 
were acquired from the Columbia Brain Bank. 50-70 mg of tissue was extracted on ice 
with 1 mL TriZol reagent by first passing through a 18 gauge needle 4-6 times, and 
then passing through a 22 gauge needle 3 times. The insoluble material was then 
pelleted at 9,400xg for 5 min at 4O C and discarded. The TriZol layer was then mixed 
with 200 ul chloroform, and incubated on ice for 5 min before centrifuging at 21,000xg 
for 15 min at 4O C. The aqueous layer was removed and 0.5 volumes TriZol and an 
additional 200 uL chloroform were added before centrifuging again at 21,000xg for 15 
min at 4O C. The resulting aqueous phase was mixed with equal volume chloroform, 
centrifuged, and the final upper phase precipitated with 1/10th volume 7.5 M NH4OAc, 
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1.5 volumes cold isopropanol, and LPA by incubating at -20O C for at least 30 min, and 
then centrifuging at 21,000xg for 15 min at 4O C. The pellet was washed with 70% 
EtOH, air dried and resuspended in H2O with 1 mM sodium citrate, pH 6.4. RNA quality 
was determined by electrophoresis of 1 ul of the resulting RNA on a 1% TAE agarose 
gel; RNA that was sufficiently intact based on the ratio of the 28S and 18S rRNA bands 
(approximately 2:1) was then subject to polyA selection. RNA was stored at -80O C. 
PolyA Selection: 20 uL of oligo(dT)25 Magnetight (Novagen) beads were equilibrated 
with binding buffer (0.5 M NaCl, 10 mM Tris/HCl, pH 8) 4 times, then mixed with 18 uL 
undegraded RNA and 2 uL 5 M NaCl and denatured at 65O C for 10 min, followed by 
incubation at RT for 10 min. The supernatant was removed and the beads were 
washed 3 times with wash buffer (150 mM NaCl, 10 mM Tris/HCl, pH 8). The beads 
were then incubated with elution buffer (10 mM Tris/HCl, pH 8) for 10 min at 65O C, and 
separated from the beads on a magnetic stand. The elutant was precipitated with 
NH4OAc, isopropanol and LPA, dried, resuspended, and the concentration was 
measured using the NanoDrop 2000 spectrophotometer (Thermo Scientific). RNA was 
stored at -80O C. 
RT-PCR: Equal amounts of siRNA (negative control and hnRNP H) treated U87 RNA 
(100-300 ng), and equal amounts of patient cerebellum polyA RNA (50 ng) were reverse 
transcribed using Maxima Reverse Transcriptase according to manufacturer’s 
instructions (Fermentas) with 4 uM random pentamer (Invitrogen).  The resulting cDNAs 
were then diluted (1:10 for siNC/H and 1:2 for polyA cerebellum) and used in PCR with 
1X standard Taq reaction buffer, 1.5mM MgCl2, 200 uM dNTPs, including 0.4 pmol α-
32P dCTP, (3,000 Ci/mmol, Perkin Elmer), 0.8 uM each forward and reverse primer 
(Supp. File 3), and .3U/25ul reaction recombinant Taq polymerase (Invitrogen).  PCR 
was performed using a Biometra T Gradient thermo cycler programmed for 33 cycles 
of 20 sec denaturation at 95O C, 30 sec annealing at 55 O C, and 80 sec extension at 
72O C, with an initial 2 min denaturation step at 95O C and a final 5 min extension at 72O 
C.  6X DNA load dye was added and PCR products were loaded onto a 6% native 
acrylamide gel, run for 2h at 200V, transferred to Whatman paper, dried, and exposed 
to phosphorimager. Bands were quanitifed using ImageQuant, and mean percent 
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inclusions (3-4 replicates per patient) were graphed, and statistically analyzed by t test, 
using Graphpad for Prism software.  
Computational Analysis of RNA-Seq Data:  Published RNA sequencing data were 
obtained from GSE67196 for healthy patients and c9ALS patients (Prudencio et 
al.,2015), and GSE16642 for siCtrl and sihnRNPH1 (Xiao et al., 2009). To identify 
differential AS events between healthy and c9ALS, or siCtrl and sihnRNPH1, we used 
rMATs (v3.0.8) (Shen et al., 2014) software. Statistical parameters for significant 
splicing change were defined as FDR <0.05 and p value <0.05. CLIPseq data of hnRNP 
H was obtained from GSE23694 (Katz et al., 2010). We mapped CLIP reads to the 
human genome using the software bowtie (v1.0.0) allowing up to 2 mismatches per 
read. After trimming CLIP short reads to 22 bp, 15487924 reads of CLIP tags were 
mapped uniquely to the human genome (hg38).   
Subcellular fractionation of human brain tissue: This protocol was adapted from Jo 
et al. (2014). 30-60 mg of pulverized human brain from cerebellum or motor cortex was 
aliquoted and weighed. For every mg of tissue, we added 18 ul of ice-cold soluble 
buffer (0.1 M MES (pH 7), 1 mM EDTA, 0.5 mM MgSO4, 1 M sucrose) containing 50 
mM N-ethylmaleimide (NEM), 1 mM NaF, 1 mM Na3VO4, 1 mM PMSF and 10 ug/ml 
each of aprotinin, leupeptin and pepstatin. Tissue was homogenized by 3-5 passages 
through a 21-gauge needle, followed by 3-5 passages through a 23-gauge needle. An 
equivalent volume of homogenate was then collected from each sample and 
centrifuged at 50,000xg for 20 min at 4O C, and the remainder was stored at -80O C. 
The supernatant was removed and saved at -80 O C as the soluble fraction, and each 
pellet was resuspended in 700 ul RAB buffer (100 mM MES (pH6.8), 10% sucrose, 2 
mM EGTA, 0.5 mM MgSO4, 500 mM NaCl, 1 mM MgCl2, 10 mM NaH2PO4, 20 mM NaF) 
containing 1% N-lauroylsarcosine (Sarkosyl) and protease inhibitors (1 mM PMSF, 50 
mM NEM and 10 ug/ml each of aprotinin, leupeptin and pepstatin), vortexed for 1 min 
at RT, and then incubated at 4O C overnight with end-over-end rotation. The samples 
were then centrifuged at 180,000xg for 30 min at 12O C, and the supernatant collected 
as the sarkosyl-soluble fraction. The pellet was resuspended in 700 ul RAB buffer and 
passed through a 26-gauge needle until the pellet was evenly dispersed, creating a 
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sarkosyl insoluble fraction. Equivalent portions of sarkosyl soluble and insoluble 
fractions were then aliquoted and to equal volumes 2X SDS sample buffer were added 
to each followed by heating to 90O C. Equal volumes of each fraction were then loaded 
onto a 10% SDS gel and electrophoresed for 100 min at 100V followed by western 
blotting for hnRNP H. Densitometry was performed using ImageJ. The ratios of 
soluble:insoluble hnRNP H were plotted and statistically analyzed using GraphPad for 
Prism. 
Co-immunoprecipitation  of BG4 from insoluble fraction: 40 ul of resuspended 
insoluble pellet prepared from motor cortex (as described in the previous section) was 
incubated with 100 ul  IP buffer containing FLAG-M2 beads that were pre-incubated 
with BG4 antibody or without. Immunoprecipitation, washing and SDS PAGE were 
carried out as described above, followed by western blotting.  Densitometry was 
performed using ImageJ. The amount of co-immunoprecipitatied hnRNP H was plotted 
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Figure 1: The GGGGCC expansion forms stable multimeric G-quadruplexes (G-
Qs). a) 10R UV crosslinked to U87 nuclear extract (NE) and digested with RNAse A (0.5 
ug) (lane 3), RNAse T1 (10U) (lane 4), both (0.5ug RNAse A/10U RNAse T1) (lane 5), or 
nothing (lane 2), and separated by 10% SDS-PAGE. b) 0.1 pmoles of 10R in water 
(lanes 1, 2 and 4) or 200 mM KCl and 500 uM pyridostatin (PDS) (lanes 3 and 5), IPed 
with BG4 antibody (lanes 4 and 5) or beads alone (lanes 2 and 3). Products were 
separated by 10% SDS-PAGE (top) and by 8M Urea/10% PAGE (bottom). c) 
Representative G-Q folding conformations of 10 repeats of GGGGCC RNA. Numbers 
indicate G-tracts that participate in GQs or linear fragments. The right most 
conformation represents 8 consecutive G-tracts forming an octamer. Beneath, a 
depiction of one quartet, with the N7 (replaced with C in 7-deaza GTP) position 
surrounded by red dashed oval d) 10R (lanes 1 and 3) and 10R-7dG (lanes 2 and 4) 
heated to 95 OC (lanes 3 and 4) or left on ice (lanes 1 and 2), crosslinked to NE, 
digested with RNAse A/T1 (.5 ug/10U) and separated by 10% SDS-PAGE. e) 10R-G 
(lanes 1, 3, 5 and 7) and 10R-G7dG (lanes 2, 4, 6 and 8) heated to 95 O C in water 
(lanes 5 and 6) or 100 mM KCl (lanes 7 and 8) or left on ice (lanes 3 and 4), crosslinked 
to NE, digested with RNAse A/T1 (0.5 ug/10U) and separated by 10% SDS-PAGE. This 
gel was cropped to remove two intervening lanes between lanes 6 and 7. 
 
Figure 2: hnRNP H associates with ten G4C2 repeat RNA in vitro.  a) IP of 10R-G 
(lane 5) and 10R-7dG (lane 10) crosslinked to U87 nuclear extract (NE), digested with 
RNAse A/T1 (0.5 ug/10U) and separated by 10% SDS-PAGE. b) IP of 10R (lane 4) and 
10R-G7dG (lane 8) crosslinked to U87 NE, digested with RNAse A/T1 (.5 ug/10U) and 
separated by 10% SDS-PAGE. c) 6X-HIS tagged hnRNP H1 (H1) produced in E. coli. 
	   104	  
d) 10R-G heated to 95 OC in 50 mM KCl and crosslinked to purified H1 (lanes 1 and 2) 
or NE (lanes 3 and 4) and digested with RNAse A/T1 (.5 ug/10U) (lanes 1 and 3) or 
nothing  (lanes 2 and 4), and separated by 10% SDS-PAGE. e) 10R-G heated to 100 OC 
in H2O and crosslinked to NE (lane 3) or purified H1 (4) and digested with RNAse A/T1 
(0.5 ug/10U) (lanes 3 and 4). f) (Left panel)10R-G crosslinked to NE prepared from U87 
cells treated with negative control siRNA (siNC) or siRNA against hnRNP H (siH), 
digested with RNAse A/T1 (.5 ug/10U) and separated by 10% SDS-PAGE. (Right panel, 
upper) Western blot of hnRNP H in siNC and siH nuclear extracts. (Right panel, lower) 
Silver stain of siNC and siH nuclear extracts. (Lower panel) Quantification of 
crosslinked doublet from three experiments with siNC and siH nuclear extracts. 
 
Figure 3: Quantification of BG4 stained foci and area in fibroblasts and astrocytes 
from C9 ALS/FTD patients and controls. Representative nonALS and C9ALS 
fibroblasts (a) and astrocytes (b) showing the projection created by “BG4 Count” that 
represents all stained area above the determined threshold (0.1) in red, with areas of 
particularly dense staining in white. Inset depicts source image showing only the red 
(BG4-FLAG) channel. c) Number of foci and total stained area (d) as fold change over 
the average number of foci, or area, respectively, per control cell for C9 fibroblasts (n 
replicates=16), control fibroblasts (n replicates=12), C9 astrocytes (n replicates=3), and 
control astrocytes (n replicates=3) (*p<.05, **p<.01, ***p<.001). Error bars are plotted to 
SEM. 
 
Figure 4: Visualization of nuclear and cytoplasmic BG4/hnRNP H colocalization in 
C9 patient cells and controls.  C9 patient astrocytes with nuclear hnRNP H/BG4 foci 
(a, c) nuclear redistribution of hnRNP H towards high BG4 staining (b) and large 
cytoplasmic foci (d). e) Percentage of control and C9 patient astrocytes containing 
nuclear and cytoplasmic hnRNP H colocalization events.  f) The single, small nuclear 
hnRNP H/BG4 nuclear foci in control astrocyte. g) Nuclear hnRNP H/BG4 inclusion in 
C9 patient fibroblasts. h) C9 patient fibroblasts with cytoplasmic hnRNP H/BG4 foci in 
DAPI-positive cytoplasm. i) Summary of all fibroblasts counted and the number of 
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colocalization event. All objects are indicated with arrow or dashed box (c), and all 
scale bars =3 microns with the exception of h), 10 microns. 
 
Figure 5: Missplicing of hnRNP H target exons in C9 ALS patient brains.  a) 
Western blot of hnRNP H knockdown in U87 cells.  b) (Left) Diagram of representative 
hnRNP H target exons with small blue rectangles depicting the relative locations of 
inclusion-enhacing intronic (upper) and repressive exonic (lower) G-Q binding motifs, 
listed at right. c-l) Representative hnRNP H target exons perturbed in C9ALS patient 
brains. (Left) 32P-RT-PCR across alternatively spliced exon for siRNA-treated U87 cells 
(lanes 1 and 2), nonALS control cerebellum (lanes 3-7, 13 and 14) and C9ALS 
cerebellum (lanes 8-12, 15 and 16). Star symbols (k and l) denote non-specific PCR 
artifact bands. (Right) Graph depicting the average percent inclusion of each target 
exon, all values listed in Supp. Table 2. PEI= percent exon inclusion. For lanes 4 and 7, 
see sample quality note in Supp. Fig. 1 (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). 
Error bars are plotted to SEM. m) Linear regression of percent inclusion values for each 
of the 18 significantly affected (p< 0.05) target exons as a function of the average 
percent inclusion of these genes in each C9ALS sample. Solid lines are used for genes 
with positive slopes, dashed lines for genes with negative slopes. Error bars are plotted 
to SEM. 
 
Figure 6: C9ALS brains are enriched with insoluble G-Q bound hnRNP H. a) 
Western blot analysis of hnRNP H in each of three fractions (soluble, sarkosyl soluble, 
sarkosyl insoluble). b) Graph of the percentage of insoluble hnRNP H in each of the 14 
patients c) IP with BG4 (IP-BG4) from the resuspended sarkosyl insoluble fraction of 
motor cortex (BA4). (Left) Western blots of input unfractionated tissue probed with anti-
GAPDH, hnRNP H and SR protein antibodies. (Right) Western blot of IP-BG4 probed 
with anti-hnRNP H and SR protein antibodies. HC and LC refer to IgG heavy chain and 
light chain, respectively. d) Quantification of hnRNP H co-IPed with BG4 (n= 3 
replicates) in each of ten non-ALS and C9ALS samples.  (*p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001). Error bars are plotted to SEM. 
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Supplemental Figure Legends 
 
Figure 1, fig. Supp. 1: Immunoprecipitation of 10R with BG4. Dark exposure of Fig. 
1b (top) depicting recovery of 10R in water (lane 4) using the BG4 antibody. 
 
Figure 2, fig. Supp. 1: Gel shift assays with 4R and 4R-7dG. (Top, left) Native gel 
with 1.5 fmoles 4R-7dG incubated with H1 diluted to a range of concentrations from 0 
to 160 nM. (Top, right) Native gel with 1.5 fmoles 4R incubated with H1 diluted to a 
range of concentrations from 0 to 640 nM. Multimeric complexes are indicated with 
roman numerals II and III. (Bottom) Binding curve for 4R and 4R-7dG based upon three 
independent repeats. Error bars are plotted to the SEM. 
 
Figure 3, fig. Supp. 1: Immunofluorescence with FLAG antibody without prior BG4 
incubation.  nonALS and C9ALS astrocytes lacking BG4 antibody incubation. DAP1= 
blue; hnRNP H= green; FLAG-BG4= red. 
  
Figure 3, fig. Supp. 2: BG4 quantification of RNAse A treated astrocytes. (Left) 
Immunofluorescence and BG4 count depiction of nonALS control and C9ALS 
astrocytes. (Right) Quantification of BG4 foci with and without RNAse A treatment, 
normalized to the average control, untreated cell. DAP1= blue; hnRNP H= green; 
FLAG-BG4= red. Scale bar= 10 microns. 
 
Figure 4, fig. Supp. 1: hnRNP H/BG4 colocalization in events in RNAse A treated 
astrocytes. Percentage of cells with hnRNP H/BG4 colocalization without treatment 
and after RNAse A treatment. 
 
Figure 4, fig. Supp. 2: hnRNP H foci in post-mortem human spinal motor neurons. 
(Top) Representative motor neurons (MNs) from C9ALS patients (upper panel) and from 
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nonALS patients (lower panel). DAPI=blue; hnRNP H=red, scale bar= 25 microns. 
Arrows indicate foci larger than 0.5 microns, dashed lines indicate lipofuscin. (Bottom) 
Table summarizing motor neurons counted, number of hnRNP H foci, and average foci 
size. 
 
Figure 5, fig. Supp. 1: (Left) 32P-RT-PCR across alternatively spliced exons for siRNA-
treated U87 cells (a-h lanes 1 and 2), nonALS control cerebellum (a,b lanes 3-9; c-f  
lanes 3-7, 13 and 14; g,h lanes 3-7) and C9ALS cerebellum (a,b 10-16; c-f lanes 8-12, 
15 and 16; g,h lanes 8-12). (Right) Graph depicting the average percent inclusion of 
each target exon, all values listed in Supp. Table 2. PEI= percent exon inclusion. 
(*p<0.05, **p<0.01, ***p<0.001), ****p<0.0001). Error bars are plotted to SEM.  
 
 Figure 5, fig. Supp. 2: (Left) 32P-RT-PCR across alternatively spliced exons for 
nonALS control cerebellum (lanes 1-7) and C9ALS cerebellum (lanes 8-14). (Right) 
Graph depicting the average percent inclusion of each target exon, all values listed in 
Supp. Table 2. PEI= percent exon inclusion. (*p<0.05, **p<0.01, ***p<0.001), 
****p<0.0001). Error bars are plotted to SEM. 
 
Figure 5, fig. Supp. 3: (Left) 32P-RT-PCR across alternatively spliced exons for nonALS 
control cerebellum (lanes 1-7) and C9ALS cerebellum (lanes 8-14). (Right) Graph 
depicting the average percent inclusion of each target exon, all values listed in Supp. 
Table 2. PEI= percent exon inclusion. Downward arrows in (f) indicate lanes with 
abnormal PCR products; these samples were omitted from t test for this gene. 
(*p<0.05, **p<0.01, ***p<0.001), ****p<0.0001). Error bars are plotted to SEM. 
 
Figure 5, fig. Supp. 4: CLIP-seq of hnRNP A1 and representative hnRNP H target 
exons. hnRNP H CLIP-seq reads of exons tested by PCR, mapped to hg38. Name of 
gene is followed by (+) or (-) to indicate forward or reverse strand, respectively. 
Regulated exon is surrounded by red box. Bars are drawn to indicate the number of 
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basepairs specified. hnRNP A1 targets are shown in (a) and hnRNP H targets are 
shown in (b). 
 
Figure 6, fig. Supp. 1: Co-immunoprecipitation of BG4 from the Sarkosyl insoluble 
fraction of patient motor cortex (BA4). Western blot of BG4 pulldown (IP-BG4) and 
FLAG-beads alone control IP, probed with anti-hnRNP H antibody. 
  
Supp. File 1: Patient and control information. CBL=cerebellum, BA4= Brodmann 
Area 4, SC= spinal cord, LE=lower extremity, UE=upper extremity, MND=motor neuron 
disease, COPD= chronic obstructive pulmonary disease, ***minimal clinical information 
available 
  
Supp. File 2: Genes analyzed. Names and genomic locations of genes with cassette 
exon inclusion/exclusion analyzed by RT-PCR (*p<0.05, **p<0.01, ***p<0.001), 
****p<0.0001).  
 
Supp. File 3: Template, siRNA and primer sequences. 
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Patient # MNs hnRNP H foci Ave. foci size (microns)
04 9 1 0.9
78 10 2 0.7
14 12 6 1.5
292 24 40 1.1
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Type Name/Gene Sequence (5'-3')
siRNA Negative control (siNC) UUCUCCGAACGUGUCACGUTT
ACGUGACACGUUCGGAGAATT
hnRNP H (siH) Phosphate-AACUUGAAUCAGAAGAUGAAGUCAA
UUGACUUCAUCUUCUGAUUCAAGUUCA




primer (cloning) hnRNP H1 BamHI F ATATATTTGGATCCGACCTATGATGTTGGGCACGGAAGGTGGAGA
hnRNP H1 HindIII R CGGGGATCAAGCTTCTATGCAATGTTTGATTGAAAATCAC














MTA1 F AAAGTGGTGTGCTTCTACCGG 







































Huelga et al. 2012 NRCAM F TCAAACCATACAGCAGAAGCA 
NRCAM R ACTTGCATTGCCTTCTGGAG 
NF1 F CGAAGTGTGTGCCACTGTTT 
NF1 R GGTGAGACAATGGCAGGATT 
NEXN F AACGCAGAATTGAGCAGGAT 
NEXN R TCCTTGAGAGATGGTCGTTG 
ZCCHC17 F AAGGCCTGAGACCATGGAA 
ZCCHC17 R GCCCCATAGTCTGTCACCAT 
G2AD F AGCTGGCCAAACTGCTCTAC 
G2AD R CAGGTCTCGGCACATCTCA 
USPL1 F ACGTTGCAACTAGGGTGGAG 
USPL1 R CAAGCAGGGCAATACTCATCT 
Supp. File 3: Template, siRNA, and Primer sequences
















ZY Medium 1% (w/v) N-Z amine AS
.5% (w/v) Yeast Extract
50X 5052 25% (w/v) glycerol
2.5% (w/v) glucose
10% (w/v) α-lactose
50X M 1.25 M KH2PO4
2.5 M NH4Cl
0.25 M Na2SO4

















Supp. File 4 Growth Medium Components 
DNase I
Human astrocytes culture medium DMEM 
F10
Fibroblast culture medium DMEM 
FBS 
0.25% trypsin
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Abstract 
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) represent two 
ends of a disease spectrum with shared clinical, genetic and pathological features. 
These include near ubiquitous pathological inclusions of the RNA binding protein (RBP) 
TDP-43, and often the presence of a GGGGCC expansion in the C9ORF72 (C9) gene. 
Here we show unexpectedly that the signature of hnRNP H sequestration and altered 
splicing of target transcripts we identified in C9ALS patients also occurs in fully half of 
50 post-mortem sporadic, non-C9 ALS/FTD post-mortem brains. Furthermore, and 
equally surprisingly, these “like-C9” brains also contained correspondingly high 
amounts of insoluble TDP-43, as well as several other disease-related RBPs, and this 
correlates with widespread global splicing defects. Finally, we show that the like-C9 
sporadic patients were, like actual C9ALS patients, much more likely to have 
developed FTD. We propose that these unexpected links between C9 and sporadic 
ALS/FTD define a common mechanism in this disease spectrum. 
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Introduction 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that 
afflicts approximately 1 in 400 people worldwide (Alonso et al. 2009). Diagnosis is 
predicated on symptoms of motor neuron (MN) loss from both the primary motor 
cortex (upper MNs), brainstem and spinal cord (lower MNs), which results in 
progressive weakness and loss of motor control, and eventually paralysis and death 
(Rowland and Shneider 2001).  While predominantly a motor disorder, many ALS 
patients experience cognitive and behavioral changes, and ~10-15% of ALS patients 
meet formal criteria for a diagnosis of frontotemporal dementia (FTD;  Lattante et al. 
2015; Ling et al. 2013).  FTD is a heterogeneous condition marked by the degeneration 
of neurons in the frontal cortex, and patients exhibit a range of cognitive, behavioral 
and language deficits (Seelaar et al. 2011).    
The co-occurrence of ALS and FTD is genetically determined in some cases, 
most often by the dominantly inherited C9ORF72 (C9) hexanucleotide expansion 
(DeJesus-Hernandez et al. 2011; Renton et al. 2011). The presence of a single copy of 
expanded C9 increases sharply the chance that an ALS-afflicted individual will be 
diagnosed with FTD, from 10 to ~50% (Byrne et al. 2012). While consensus on 
precisely how the expanded sequence acts as a pathological unit has remained 
elusive, we have shown that the repeat-containing RNA can directly sequester the RNA 
binding protein (RBP) hnRNP H, leading to dysregulation of pre-mRNA splicing (Conlon 
et al. 2016). Generally, our and others’ evidence for proteinaceous aggregates, seeded 
by RNAs and which are prone to undergo phase transitions (Fay et al. 2017; Jain and 
Vale 2017; Schwartz et al. 2013), may offer a bridge from aggregation-as a classical 
observation of neurodegenerative disease (Ginsberg et al. 1998; Ross and Poirier 
2004)-to a biophysical mechanism at the origins of ALS/FTD in cases with and without 
disease-associated mutations (Alberti and Hyman 2016; Conlon and Manley 2017; 
Mackenzie et al. 2017; Murakami et al. 2015) 
Histopathologic similarities also link ALS and FTD on this disease spectrum. In 
almost all ALS and over half of FTD patients, the distributions of pathological 
cytoplasmic accumulation of the hnRNP-like DNA/RNA binding protein TDP-43 tend to 
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correlate with areas of neurodegeneration (Baloh 2011). Although the observed 
aggregates of TDP-43 come in several forms (Scotter et al. 2015), translocation and 
nuclear clearance events are of particular interest, as they have suggested a loss-of-
function (LOF) mechanism (Vanden Broeck et al. 2014), predicted to impact mRNA 
processing and transport (Humphrey et al. 2017; Ling et al. 2015; Polymenidou et al. 
2011; Tollervey et al. 2011). While the relationship between TDP-43 aggregation and 
neurodegeneration could reflect the downstream effects of cell death rather than the 
cause, the existence of ALS-causing mutations in the gene that encodes TDB-43 
(TARDBP) suggests that the protein has a deterministic role in the ALS/FTD spectrum 
(Scotter et al. 2015). Between the extremes of bystander and instigator, it is possible 
that changes to TDP-43 reflect an important indicator of upstream processes that 
influence RBPs more pervasively. 
In all ALS/FTD cases with TDP-43 pathology, aggregation may be driven by any 
number of factors that impact the protein’s ability to form stoichiometrically correct 
interactions with itself or with other nuclear proteins and RNAs. For example, disease-
linked changes affecting the solubility properties of other RBPs (Harrison and Shorter 
2017), including hnRNP H (Conlon et al. 2016), have the potential to affect solubility of 
RBPs they interact with, like TDP-43 (Freibaum et al. 2010; Ling et al. 2010), although 
whether this occurs in ALS/FTD patient brains is unknown. Extending this idea, 
downstream changes to the transcriptome, particularly splicing patterns, may result 
from combinatorial deficiencies of several RBPs (Huelga et al. 2012; Mohagheghi et al. 
2016), making it difficult to pinpoint the initiating event or distinguish specific effects of 
TDP-43 LOF.  
 In this study, we have investigated whether the biochemical “signature” we 
described previously for C9ALS might extend to a broader spectrum of ALS/FTD 
patients. For this, we analyzed splicing and RBP solubility in 50 post-mortem human 
brains from patients with sporadic ALS, FTD with motor neuron disease (MND) and 
ALS-FTD (collectively, sALS/FTD), all of which were negative for known disease 
mutations, including C9. Unexpectedly, we identified splicing dysregulation of known 
hnRNP H targets (Conlon et al. 2016) in a large fraction of patients, and used the extent 
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of splicing dysregulation to divide the patients into two groups, like-control and like-
C9. Notably, we found that the like-C9 patients also had higher amounts of insoluble 
hnRNP H, the amount of which directly correlated with the magnitude of splicing 
dysregulation. Importantly, several other abundant RBPs linked to ALS, including TDP-
43, showed the same patterns of insolubility as hnRNP H. Consistent with this, we 
found pervasive splicing dysregulation genome wide, with the majority of events found 
in like-C9 also observed in authentic C9ALS patients. Intriguingly, the like-control 
cases with lowest hnRNP H/TDP-43 insolubility displayed almost no splicing 
dysregulation, despite the ubiquitous presence of histopathological TDP-43 inclusions. 
Finally, and importantly, we show that like-C9 patients, similar to actual C9ALS 
patients, were much more prone to develop dementia than were like-control patients. 
Together, our data define unanticipated biochemical similarities between a large 
fraction of sALS/FTD cases and C9ALS/FTD, suggesting a common mechanism 
underlying disease pathogenesis. 
 
Results 
Patient stratification based on graded inclusion of hnRNP H-regulated exons  
 C9 expansion is the most common known cause of ALS/FTD. However, a large 
majority of cases, especially amongst the 90% that are sporadic in origin, are of 
unknown etiology. When initially characterizing hnRNP H-dependent splicing events, 
we compared C9ALS/FTD patients to neurological controls and SOD1 ALS (not 
believed to proceed through a mechanism of RBP dysfunction or aggregation; Ling et 
al. 2013), but not to sALS/FTD (Conlon et al. 2016). Indeed, sALS/FTD is a mechanistic 
unknown, and may constitute a wide range of molecular subtypes. Given that TDP-43 
and hnRNP H have been reported to interact (Appocher et al. 2017; Ling et al. 2010; 
Sephton et al. 2011) in a manner that is largely, but perhaps not entirely, RNA 
dependent (Freibaum et al. 2010), it is reasonable to speculate that changes in RNA 
binding and/or solubility of one might impact the other.  
In an attempt to distinguish splicing patterns specific to C9ALS/FTD from those 
related to ALS/FTD more generally, we analyzed whether sALS/FTD patients display 
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splicing changes similar to those we described in C9 patients (Conlon et al. 2016) (Fig. 
1a). To this end, we measured alternative exon inclusion by 32P-RT-PCR of oligo(dT)-
selected RNA samples purified from post-mortem cerebellum from 50 sporadic 
patients: 32 classified as ALS (without cognitive/behavioral involvement), seven as 
ALS-FTD (symptoms of both disorders during the patient’s life), and 11 as FTD with 
motor neuron disease (FTD-MND) defined by a lack of clinical ALS symptoms yet the 
presence of pathological MN degeneration at autopsy. We also included two patients 
carrying pathogenic SOD1 variants, and four patients carrying C9 repeat expansions, 
for a total of 56 cases (Supp. Table 1). 
To assay hnRNP H-dependent splicing changes, we selected 18 known hnRNP 
H target exons that we previously found are differentially included in C9ALS/FTD 
compared to individuals without neurological symptoms and SOD1 ALS controls (Fig. 
1a). Four of the targets were hnRNP H-repressed exons, meaning hnRNP H normally 
represses inclusion when physiological levels of the protein are high, and the other 14 
were hnRNP H-enhanced exons, which respond with decreased inclusion when hnRNP 
H levels are low (Fig. 1b). Results obtained with two enhanced exons (from ARRB2 and 
PPP1R12C) and one repressed exon (from OS9) are shown in Fig. 1c-e. Representative 
gels for all other genes analyzed are shown in Supp. Fig. 1. The data revealed dramatic 
differences across many of the patient samples. We observed several patients that 
consistently had the lowest levels of enhanced exon inclusion for all 14 exons, and 
noticed that these same patients had the highest levels of repressed exon inclusion 
(e.g., boxed FTD-MND samples 9-13; Fig. 1c-e). Other patients consistently displayed 
the opposite trend, or a milder version of both.  
We next wished to classify the patients as either having or not having hnRNP H-
dependent splicing changes. For this, we first averaged the percent inclusion of all the 
enhanced exons to define a single composite splicing score (CSS). We then compared 
the CSS values of sporadics to those of a set of neurological normal and SOD1-ALS 
controls, and to C9ALS/FTD patients. Interestingly, we noticed that for these same 14 
exons, the controls had a very close range of values, while the C9+ range was 
centered significantly lower and with a wider distribution (Fig. 1f). Only a single control 
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point deviated significantly from the mean; this point corresponds to the second 
SOD1-ALS patient and is likely due to poor RNA quality. Due to the rarity of SOD1-ALS 
post-mortem samples, we decided against discarding this patient. This is the only 
sample in the entire set where RNA quality was compromised.  
The wide range of CSS values of the C9+ group in theory made it impossible to 
judge with certainty whether or not a patient is C9+ based on a CSS similar to a control 
value. The converse however was not true: control samples had a close range of 
observed values, and all of the patients with significantly lowered values were disease 
afflicted. Thus we defined “like-control” as any patient with a CSS within 3 standard 
deviations (SD) of the nonALS mean, since this range should encompass 99.7% of 
values within a normally distributed population. “Like-C9” was then defined as all of the 
patients with CSS values lower than this value. These two categories split the 50 
patients into two groups of roughly equal size (Fig. 1f). Comparison of like-control 
(n=24) and like-C9 (n=26) revealed a significant difference (p<0.05) between these two 
categories for each of the 18 genes, with only one exception, RPL10 (p=0.09) (Fig. 1h). 
We also wished to determine if each individual hnRNP H-regulated exon 
recapitulates the trend of the average of all other exon inclusion values. To this end, we 
re-calculated the CSS for each combination of 13 enhanced exons and plotted a best-
fit line for each gene in the case where it is excluded from the average, by using each 
patient’s percent exon inclusion value for that gene as a Y-coordinate. Indeed, we 
found that each individual gene followed the trend of the patients’ average CSS (Fig. 
2a; simplified to show three best- and one worst-fit lines), with the same patients 
consistently showing the most severe changes, and others consistently showing the 
most mild. Some genes had extremely good fit to a linear model (GABBR1, r-squared= 
0.90, ARRB2, r-squared=0.88), while others displayed the trend without as good a fit 
(PAN2, r-squared=0.40). We also averaged the four hnRNP H repressed exons, and 
plotted this value as a Y coordinate (Fig. 2b). As expected, the patients with the lowest 
values of hnRNP H enhanced exon CSS had the highest levels of average repressed 
exon inclusion, as the data fit well to an inverse linear relationship (r-square=0.75).  
Like C9 sALS/FTD display increased hnRNP H insolubility  
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 The above results defined a cohort of patients that displayed graded splicing 
dysregulation similar to what we observed in C9ALS patients.  We next asked whether 
these patients also display increased levels of sarkosyl-insoluble hnRNP H, indicative 
of functional sequestration (see Conlon et al. 2016). To this end we performed 
biochemical fractionation of motor cortex from all cases where tissue was available, 
with two independent replicates per case (Fig. 2c). While we performed RNA analysis 
with cerebellum for abundance and RNA quality reasons, for fractionation we used 
motor cortex as it is a primary site of disease-specific degeneration. Given the 
historical range of our cohort, for some samples motor cortex was unavailable, and 
thus we omitted those cases from analysis. We then analyzed equivalent amounts of 
each fraction, soluble, sarkosyl soluble, and sarkosyl insoluble, by Western blot (WB), 
and calculated the percentage of insoluble hnRNP H in each case. Using 39 samples 
(18 like-control and 21 like-C9), we found that the average percent insoluble hnRNP H 
was 69.2 in like-C9s, and 38.9 in like-control, or 1.78 times higher in like-C9, a highly 
significant increase in aggregated protein (p<0.0001) (Fig. 2d). This enrichment closely 
resembles the 1.9-fold increase we previously reported in seven C9ALS/FTD (56.1% 
insoluble) compared to controls (30.0% insoluble).  
 We next wished to quantify the relationship, if any, between splicing severity and 
hnRNP H insolubility. We therefore performed the same regression analysis as we did 
above with splicing changes, except with percent sarkosyl-insoluble hnRNP H. We 
found that the general trend was for patients with large changes in splicing to have 
high insoluble hnRNP H (Fig. 2e; r-square= 0.58). These observations suggest that 
hnRNP H is differentially sequestered, with patients showing a gradient of decreasing 
soluble hnRNP H that correlates with increasing splicing dysfunction. The 
correspondence between hnRNP H’s biochemical solubility and its predicted 
transcriptomic effects across distal brain regions from the same patients supports the 
notion that this is an intrinsic, brain-wide property of each patient. 
Insolubility of hnRNP H correlates with that of the ALS-linked RBPs TDP-43 and 
FUS 
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 We previously provided evidence that the insolubility of hnRNP H in C9ALS 
brains was due to formation of aggregated assemblies with long, repetitive, G 
quadruplex-forming RNA (Conlon et al. 2016). However, in the sporadic cases analyzed 
here, the source of hnRNP H insolubility/aggregation is unknown. To investigate this 
question, and to understand the significance of the observed gradient of hnRNP H 
insolubility and splicing dysregulation, we considered the possibility that it is related to 
insolubilities of other proteins with similar functions and/or domain structures. For 
example, as mentioned above, TDP-43 displays histopathological evidence of 
cytoplasmic accumulation/aggregation in virtually all ALS cases. Is this relevant to the 
biochemical insolubility we observed with hnRNP H?  
To measure insolubilities of more protein targets, including TDP-43, we selected 
a subset of 20 patients: the 10 most like-control and the 10 most like-C9, based on 
highest and lowest CSS, respectively (and omitting cases where motor cortex was 
unavailable for fractionation) (Fig. 3a). First, to demonstrate clearly the gradient pattern 
of these samples for hnRNP H insolubility we performed simultaneous WB of all 20 
samples and each of the three fractions (soluble, sarkosyl soluble and sarkosyl 
insoluble) (Fig. 3b). We also performed splicing analysis of a new hnRNP H-regulated 
target, ACHE (Nazim et al. 2017), further illustrating the relationship between hnRNP H 
insolubility and splicing dysregulation. 
 Having established these 20 cases as representative of the hnRNP H gradient, 
we used the motor cortex fractions derived from them for WB for three other ALS/FTD-
implicated hnRNPs: TDP-43, FUS (also known as hnRNP P2), and hnRNP A1 (Fig. 3d). 
These proteins all belong to a common yet dynamic interactome (Markmiller et al. 
2018); FUS has been reported to interact with hnRNP H (Reber et al. 2016) and hnRNP 
A1 (Kim et al. 2013), while hnRNP A1 has been reported to interact cooperatively with 
hnRNP H to modulate splice site selection (Fisette et al. 2010). Likewise, TDP-43 was 
shown to interact with the structurally related hnRNP A1 to repress exon inclusion 
(Buratti et al. 2005), and has also been suggested to self-associate (Polymenidou et al. 
2011; Tollervey et al. 2011) to influence a set of targets it shares with FUS (Lagier-
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Tourenne et al. 2012). As a control, we also blotted for GAPDH, which seemed unlikely 
to be insoluble. 
Strikingly, for each RBP target we found significant increases in insoluble 
protein in the like-C9s, matched by significant decreases in soluble protein (Fig. 3e). 
Indeed, no insoluble FUS could be detected in any like-control patient, while it was 
present in all of the like-C9s (between 6.1-69.1%). Intriguingly, we found that the 
correlations between CSS and percentage insoluble protein for hnRNP H, TDP-43, 
FUS and hnRNP A1 each fit remarkably well to a line (r-squared= 0.89, 0.79 .80 and 
0.90, respectively) (Fig. 3f). Analysis of GAPDH revealed no insoluble protein in any of 
the 20 cases (Fig. 3e) confirming that insolubility of these RBPs was not due to an 
artifact of fractionation or global protein insolubility in like-C9s. 
The above results were unanticipated, and we therefore wished to examine 
properties of the insoluble fractions further. One possibility was that the high force 
(180,000xG) used to generate the sarkosyl-insoluble fractions might have resulted in an 
artificial enrichment of RBPs in the pellet of some patients, and thus the similar 
insolubilities of these targets may not reflect physiological interactions. To examine 
this, we decreased the sedimentation force we used to isolate the aggregated proteins, 
by separating the sarkosyl-insoluble pellet at 21,000xG for 15 minutes instead of 
180,000xG for 30 minutes. We performed simultaneous fractionation and WB of the 20 
cases described above, and expanded our targets beyond hnRNP H, TDP-43, hnRNP 
A1 and FUS to include three additional proteins that we would not expect a priori to be 
insoluble: Histone H3, C9ORF72 itself and splicing factor U2AF65. We also included 
one more target protein with broad relevance to MN disease, SMN, which has been 
reported to interact with RBPs in the context of RNA transport granules (Hua and Zhou 
2004; Murakami et al. 2015; Thomas et al. 2011).  
The results of this analysis confirm and extend the observations we made with 
the 180,000xG fractionation. They support the idea that the insolubility we initially 
described for hnRNP H (Fig. 4a) extends to other MN disease-related proteins (Fig. 4b-
e), but is not a general property of like-C9 brains. The non-disease associated proteins 
(Fig. 4f and g) did not display any insolubility, except for U2AF65 (Fig. 4h), which had 
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low levels of insoluble protein in six of ten like-C9s, or 9.2% on average (Fig. 4i). 
Intriguingly, a fraction of SMN was insoluble in all of the like-C9 cases with a range 
from 8.1-61.8%, or 31.1% on average, but in none of the like-controls. For 
comparison, hnRNP H and hnRNP A1 were insoluble in like-C9s with a range from 
16.0-77.5% and 29.4-94.7% (Fig. 4i). Despite the important role of SMN in snRNP 
assembly, and thus in splicing per se, its relatively low average insolubility in like-C9s 
suggests it is only partially deficient and thus present at levels sufficient to facilitate 
snRNP assembly, and far higher than levels seen in SMA (Lefebvre et al. 1997). The 
low levels of U2AF65 and presence of the four abundant hnRNP proteins in the 
insoluble fraction is supportive of the like-C9s having alterations in the soluble 
concentration of a limited set of auxiliary splicing factors, yet maintaining sufficient 
concentrations of the core factors necessary for splicing.  
Reciprocal insolubilities of hnRNP H and TDP-43 reveal TDP-43 LOF is exclusive 
to like-C9s 
The similarity between hnRNP H and TDP-43 insolubilities in the like-C9 
samples suggests that a common process or factor may be functioning to bring about 
their aggregation to correspondingly severe degrees. Supporting this idea, insolubility 
of each protein displayed an inverse relationship with CSS (Fig. 4j), and correlation 
analysis of the measured insolubilities of all of these RBPs (at both 180,000 and 21,000 
xG) amongst this set of 20 patients revealed highly significant correlation for each 
pairwise combination (Fig. 4k). The top pairwise combinations between different 
proteins were between hnRNP H and TDP-43 at both 180,000 and 21,000 xG (Fig. 4k; 
Spearman r= 0.95 for both). As support that primary insolubility of hnRNP H can drive 
insolubility of these other factors, we performed fractionation at 21,000xG with 13 C9 
patients and found similar correlation between hnRNP H and TDP-43 (Spearman r= 
0.71) (Supp. Fig. 3).  
 The possibility that a reciprocal relationship exists between hnRNP H and TDP-
43 prompted us to consider that insoluble TDP-43 is upstream of hnRNP H insolubility 
in like-C9s cases. Etiologically, this is appealing, since hallmark TDP-43 histopathology 
is presumed to reflect underlying biochemical insolubility, and polymerization of TDP-
	   137	  
43 into this non-functional and/or mislocalized state is often given as a rationale for 
mechanistic studies that have sought evidence for TDP-43 LOF (Lagier-Tourenne et al. 
2012; Ling et al. 2015; Polymenidou et al. 2011). However, our data present a 
significant contradiction of this tenet, as 21,000xG fractionation revealed TDP-43 to be, 
on average, only 5.3% insoluble in the 10 like-control patients. Meanwhile, 10 patients 
that were on the same clinical and pathological spectrum yet classified as like-C9 had 
on average almost eight times as much insoluble TDP-43 (40.8 versus 5.3%, t test 
p<0.0001) (Fig. 4j). Fractionation of the same samples at 180,000xG revealed a majority 
of TDP-43 to be insoluble in like-C9s (68.2%) compared to a minority in like-controls 
(25.2%; p<0.0001; Fig. 3e).  
The above differential TDP-43 insolubility is in sharp contrast with the much 
more uniform histopathology. Of the 17 sporadic cases for which we possessed data 
for pathological analysis by immunohistochemistry with TDP-43 antibodies, only two 
were found to lack detectable TDP-43 inclusions in motor regions (Supp. Table 1). One 
of these, s30, was a like-control case, while the other, F10, was the most like-C9 case 
(lowest CSS), and had an average of 61.8% insoluble TDP-43 based upon two 
measurements at 180,000 and 21,000 xG each (Fig. 3f and 4i, respectively). 
Conversely, case 36 had only 2.3% insoluble TDP-43 based upon two measurements 
at 180,000 and 21,000 xG each (Fig. 3f and 4i, respectively), yet TDP-43 pathology was 
indeed evident (Supp. Table 1). 
The above observation suggests that insolubility of TDP-43, and relatedly, 
hnRNP H, is not related to TDP-43 histopathology. Given that hnRNP H insolubility is 
correlated with splicing dysfunction of a set of validated targets, we wished to ask if 
TDP-43 LOF-associated splicing changes also occurred more in the like-C9 cases than 
in like-controls. To assay TDP-43 dependent splicing, we selected targets from 
previously published TDP-43 knockdown (KD) and CLIP studies (Tollervey et al. 2011) 
and analyzed them as above by 32P RT-PCR (Supp. Fig. 4). For 18 targets that 
produced appropriate products, we compared the percent inclusion values from the six 
most like-control and six most like-C9 patients (six highest and lowest CSS, 
respectively). Using a t-test for each event, we found that ten of the 18 events 
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displayed significant changes (p<0.10). Of these events, eight were as predicted 
consistent with the like-C9 group having lower concentrations of functional TDP-43, 
while the other two displayed the opposite trend. These results suggest that TDP-43-
regulated splicing events demonstrate differential exon inclusion amongst sALS/FTD 
patients with TDP-43 pathology, with the patients demonstrating biochemically 
insoluble TDP-43 displaying greater TDP-43 LOF. 
RNA-sequencing reveals widespread splicing defects that correlate with protein 
insolubility 
Our investigation into splicing dysfunction initially focused specifically on hnRNP 
H splicing targets. However, the results described thus far imply that the splicing 
changes due to decreased levels of functional hnRNP H are complemented by 
shortages of other RBPs such as TDP-43. We therefore next analyzed splicing on a 
global scale, and with a larger cohort of patients. We performed RNA-sequencing of 
RNA purified from cerebellum of 28 of the sALS/FTD cases described above for which 
hnRNP H solubility and clinical data was available, 16 like-C9 and 12 like-control, as 
well as 13 confirmed C9ALS/FTD cases. As controls, we used a combined group of six 
neurologically normal individuals and five SOD1-ALS individuals, with only two of these 
11 samples coming from our previously categorized control group (Supp. Table 1). The 
decision to include SOD1 in the control group reflects the fact that SOD1-ALS 
represents the only known form of ALS marked by the absence of TDP-43 (or FUS) 
inclusions (Mackenzie et al. 2007).  
The definitions “like-C9” and “like-control” were derived from changes in hnRNP 
H splicing targets. As we now wished to analyze splicing patterns globally and without 
bias, we regrouped the patients in a manner independent of measured splicing. We 
divided the 28 sALS/FTD patients into three groups based on clinical diagnosis and 
insolubility: ALS-hnRNP H low insolubility (ALSlow; 7 patients), ALS-hnRNP H high 
insolubility (ALShigh; 13 patients) and FTD (FTD; 8 patients) (Supp. Table 1). The first 
two groups consisted of patients with ALS only, and with measured hnRNP H 
insolubility being below or above 50%, respectively (Fig. 5a). The FTD group consisted 
of those patients with clinical diagnoses of FTD. Interestingly, this group contained the 
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five most severely like-C9 patients; of the 13 FTD-MND patients in our cohort, only 
one, F7, had insolubility below 50%, and was not included in this analysis. A fourth 
patient group consisted of C9ALS and ALS/FTD patients (C9). The average percentage 
insoluble hnRNP H (180,000xG) in each group was 26.4 in ALSlow, 59.4 in C9, 67.3 in 
ALShigh and 79.6 in FTD (Fig. 5b). In order to rule out differential hnRNP H levels in the 
cerebellum of these patients, we performed WB of tissue from 26 of the samples, and 
observed that there were no changes in overall hnRNP H abundance between these 
groups (Fig. 5c). 
We next compared differential splicing (DS) events in each of the four patient 
groups to the controls. For this analysis, we used the annotation-free method 
Leafcutter (Li et al. 2018). Variations in intron splicing were considered significant in 
ALS/FTD when the Percentage Spliced Index (PSI) compared to control differed by 
more than 10% (|∆PSI|≥0.1) with a 10% FDR cutoff (see Experimental Procedures). To 
confirm our assumption that neurological normal and SOD1 ALS could be grouped as 
one, we compared these two groups and indeed found very few (23) detectable 
splicing differences (|∆PSI|≥0.1). The paucity of splicing defects in these patients 
contrasted with 1,300-1,400 DS events in ALShigh and C9 groups and several 
thousand in the FTD groups (Fig. 5d; events listed in Supp. Table 2), with 488 events 
overlapping between C9, FTD and ALShigh. Comparison of events without filtering for 
the magnitude of the change in PSI revealed an even greater proportion of overlapping 
events between the FTD, C9 and ALShigh groups (Supp. Fig. 5). As validation of our 
like-C9 nomenclature, with or without filtering respectively, only 27 or 8% of all events 
detected in C9 were unique to that group; the remainder were detected in ALShigh, 
FTD or both (like-C9 collectively). Furthermore, the ALSlow group had an essentially 
insignificant number of events, even without filtering, upholding our definition of like-
control for splicing in general.  
To visualize the degree of change of all events by patient, we produced 
heatmaps of the normalized difference in PSI for all the events that differed significantly 
between control and any other group (|∆PSI|≥0.1), excluding the very large number of 
events that differed exclusively between control and FTD (Fig. 5d). Patients were 
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organized according to the above groupings, and within each group they were further 
arranged by increasing hnRNP H insolubility from left to right (Fig. 5e, gray-scale). To 
extend our analysis, we also included 23 additional samples from C9, ALS and FTD 
patients that were not included in one of the groups above (Supp. Table 1), creating an 
additional group of ALS patients (ALS) not categorized as ALSlow or ALShigh.  
Hierarchical clustering of splice junctions revealed two distinct groups of events 
that displayed opposite directions of normalized PSI change in the controls versus the 
FTDs (Fig. 5e). As expected, the ALSlow group was found to be most similar to 
controls, and the FTD the most different, reflecting the extreme ends of the insolubility 
spectrum. Within the C9 and ALShigh groups, the patients displayed a gradient of 
patterns from low to high insolubility that generally mirrored the pattern of PSI from 
control to FTD. 
We next sought to isolate significant splicing changes in our dataset that best 
correlate with hnRNP H insolubility. Thus, we ranked events according to their 
correlation to insolubility (Supp. Table 3; 100 most correlated events) and plotted 
several. The results (Fig. 6a) demonstrate that splicing of these transcripts was as 
expected vulnerable to variations in functional hnRNP H levels. Amongst these 
correlated events, the relationship to hnRNP H insolubility varied; for example, splicing 
changes at hnRNPA3 followed a linear relationship similar to BBS, GABRG2 and 
CCDC136; in turn, splicing changes at hnRNPH1 occurred only when hnRNP H 
insolubility was above 60%, primarily in FTD patients and some C9 patients. RIOK3 
and several of the top 100 most correlated events with hnRNP H insolubility presented 
exponential trends similar to hnRNPH1 splicing defects. Perhaps this is indicative of 
the fact that some events are regulated in compensatory fashions by many factors (see 
below), and only undergo change in inclusion when soluble levels of multiple RBPs are 
severely compromised.  
Broadly, the 100 events with the highest correlation with hnRNP H insolubility 
display variable splicing strength (intron exclusion ratios) across the cohort (Fig. 6b), 
analogous to the pattern seen for all events (Fig. 5e). Notably, among the DS events 
were many in transcripts encoding splicing regulators, which generally followed the 
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same pattern of PSI changes relative to insolubility in each group (Fig. 6c; events listed 
in Supp. Table 4). Interestingly, several of the events found to affect RBPs (FUS, 
hnRNP A1, hnRNP D and TIA-1) have been the subjects of intensive inquiry for their 
potential roles in disease (Deshaies et al. 2018; Zhou et al. 2013) as well regulating 
splicing and interactions with other hnRNPs (Gueroussov et al. 2017; Izquierdo and 
Valcarcel 2007). This observation raises the possibility that insolubility of the disease-
associated RBPs leads to specific alterations in RNA splicing that compound defects in 
those same RBPs and others, thereby exacerbating the magnitude and extent of 
splicing dysregulation (see Discussion).  
We next recapitulated this stratification of patient groups using hierarchical 
clustering. Using the 489 differential events that were common to all groups (488 
common to ALShigh, C9 and FTD, and one common to ALSlow as well) (Supp. Fig. 6), 
patients with similar insolubility measurements were grouped close to one another. To 
further support the hypothesis that all DS events are due to insolubility and not 
particular clinical distinctions, clustering of patients based on the top events that were 
unique to each grouping (20 from each ALShigh, C9 and FTD, and all three events in 
ALSlow) also ordered the patients according to insolubility (Supp Fig. 7). Regardless of 
whether clustering was performed with either the most shared (Supp. Fig. 6) or the 
most divergent (Supp. Fig. 7) events, the two groups separated by the farthest distance 
contained almost exactly the same patients, whereas the controls (neurological normal 
and SOD1) clustered together with the patients with the lowest insolubility, including 
samples not in the original AHL group. In summary, we conclude that widespread, 
global splicing differences occur in ALS and FTD, and these can be explained by 
biochemical insolubility of RBPs, with corresponding severity across distinct brain 
regions. 
Like-C9 patients have a higher incidence of FTD 
In the above analysis based on solubility groupings, the FTD samples were 
noteworthy in that they displayed the highest hnRNP H insolubility, as well as the most 
numerous and acute PSI changes. However, several sporadic and C9 ALS patients 
with high insolubility had similar DS patterns, implying that the excessive events were 
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not somehow specific to the FTD clinical diagnosis, but rather the result of 
exceptionally high insolubility of RBPs, which occurs at a greater rate in FTD than ALS. 
This suggests a possible relationship between patients identified as like-C9 and FTD.  
 To determine if like C9-patients were indeed more likely to be diagnosed with 
FTD, we returned to our initial assignments of like-C9 and like-control. Of the 50 
patients in this analysis, 18 had symptoms of FTD, and were clinically diagnosed with 
either ALS-FTD or pure FTD, while the remaining 32 patients were diagnosed with ALS 
without cognitive or behavioral impairment. The majority (13/18; 72%) of the patients 
characterized by symptoms of FTD were like-C9, while only five of the patients with 
FTD symptoms were like-control. We compared these ratios using a Fisher’s exact 
test, and found that patients like-C9 were on average 3.8 times more likely to have 
symptoms of FTD versus like-control patients (Fig. 6d, p=0.032). Strikingly, these 
findings mirror what has been reported for C9 patients, who are approximately four 
times more likely than the ALS population at large to receive a diagnosis of FTD (Byrne 
et al. 2012). Thus we conclude that this distinction of like-C9 based upon splicing and 
accompanying biochemical insolubility confers clinical susceptibility to FTD, just as is 
occurs in authentic C9ALS patients. 
 
Discussion 
 In this study we have characterized a diverse cohort of ALS/FTD patient brains 
and identified a signature of graded splicing dysregulation that correlates in magnitude 
with insolubility of several abundant and disease-relevant RBPs. Our work provides 
evidence that aberrant alternative splicing is a common molecular feature of 
C9ALS/FTD and sporadic ALS/FTD patients, and importantly, that these changes 
reflect underlying biochemical changes that manifest in RBP aggregation. A unified 
vision of what causes ALS and FTD at the molecular levels has remained highly 
speculative despite great advances in our understanding of the genetics that contribute 
to this disease spectrum (Taylor et al. 2016). Thus our work is significant in that it 
provides a compelling case for the existence of a shared biochemical mechanism that 
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occurs in ALS, FTD and ALS/FTD, and which can be rationalized in the context of other 
known disease mutations and pathologies. 
RNA splicing defects have previously been reported in C9ALS (Conlon et al. 
2016) and sporadic ALS/FTD (Ling et al. 2015; Prudencio et al. 2015). However in the 
absence of mechanistic insights into the origins of these defects in sporadic patients, 
the assumed culprit has been TDP-43 deficiency, reflecting the almost universal 
observation of TDP-43 histopathology (Lagier-Tourenne et al. 2012; Ling et al. 2015; 
Polymenidou et al. 2011). Through stratification of patient samples based on 
biochemical insolubility of hnRNP H, and by extension TDP-43, we found that TDP-43 
pathology is not sufficient to confer detectable splicing differences relative to 
neurologically normal controls or SOD1 ALS patients. Thus our data suggest a model 
(Fig. 7) in which TDP-43 is just one of several affected RBPs. Our finding that 
biochemical insolubility of TDP-43 correlates with splicing defects as well as with 
insolubility of several other RBPs casts doubt on the TDP-43-centric view of ALS 
(Lagier-Tourenne and Cleveland 2009; Scotter et al. 2015). Given the decoupling of 
visible pathology from biochemical insolubility, with only the latter correlated with 
splicing dysregulation, our results strongly suggest that ALS/FTD should be considered 
a multiRBP proteinopathy rather than a TDP-43 proteinopathy.  
The fact that approximately half of sporadic ALS/FTD patient brains do not 
display significant splicing defects or insoluble protein seemingly contradicts our 
assertion that this is the common mechanism underlying disease. One possibility is 
that an entirely distinct mechanism drives neurodegeneration in these patients, 
perhaps one similar to SOD1ALS in which we detect no insolubility or aberrant splicing. 
Alternatively, the range of abnormality in sALS patients we observed may reflect what 
we detected in C9ALS/FTD (Conlon et al 2016). Specifically, some C9 patients 
displayed severe splicing changes, while others were indistinguishable from normal 
controls. One possible explanation for this is that in both C9s and sporadic cases, 
some patients display these changes only on a limited scale. For instance, detectable 
splicing changes and highly insoluble protein levels may only become evident in the 
later stages of a progressive coalescence of RBPs (Lin et al. 2015; Murakami et al. 
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2015; Patel et al. 2015). In such a model, splicing changes, while undoubtedly 
contributory, may not be the sole, or critical, event driving disease onset or 
progression, but rather a consequence of perturbations in the equilibrium of soluble 
versus aggregated RBPs (Fig. 7). 
Many studies of ALS/FTD disease mechanisms have focused on a complex 
equilibrium between differentially concentrated RBPs in physically distinct phases. 
Importantly, many factors, including mutations known to cause disease (Fay et al. 
2017; Kim et al. 2013; Mackenzie et al. 2017; Martinez et al. 2016; Murakami et al. 
2015; Patel et al. 2015 ), are capable of influencing the balance between protein 
concentrations in each phase over time (Ramaswami et al. 2013). Our model (Fig. 7) 
proposes that all ALS/FTD patients fall at varying points beyond a hypothetical “toxicity 
boundary” that would be analogous to the phase boundaries that describe 
physiological granule formation ( Elbaum-Garfinkle et al. 2015; Weber and Brangwynne 
2012), only unidirectional. The magnitude of this imbalance, or position past a 
theoretical tipping point, would thus be related to increased abundance of 
biochemically insoluble protein and decreased levels of functional RBPs, leading to 
disruption of alternative splicing.  
The above model depicts RBP insolubility as lying upstream of splicing defects. 
However, it is worth considering the possibility that splicing changes lead to, or at least 
contribute to, insolubility. Notably, two events found to affect the RBPs hnRNP D and 
hnRNP A1 (exon 7 and 8, respectively) have been shown to cause inclusion of glycine-
tyrosine (GY)-rich intrinsically disordered regions (IDRs) in their respective proteins 
(Gueroussov et al. 2017). In our analysis we observed increased inclusion of hnRNP D 
exon 7, leading to an isoform with an extended GY-rich region that makes increased 
contacts with other hnRNPs, thereby potentially promoting overly stable RBP 
complexes. Inclusion of hnRNP A1 exon 8 also extends its IDR, although the difference 
in the number of GY-repeats is not as strong as for hnRNP D (Gueroussov et al. 2017). 
Somewhat surprisingly, this exon was found in our data to be more skipped as RBP 
insolubility increased, which seems to contradict a recent study suggesting that 
reduced levels of TDP-43 promote inclusion of this exon (Deshaies et al. 2018). In 
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contrast, loss of soluble FUS may explain the increased inclusion of FUS exon 7 seen 
in our data (Zhou et al. 2013). Normally, FUS represses inclusion of exon 7, leading to 
an isoform that undergoes nonsense-mediated decay, allowing FUS to auto-regulate 
its expression. Thus it may be that reduced levels of soluble FUS lead to increased 
exon 7 inclusion, thereby resulting in excess levels of FUS that either seed RBP 
aggregates or “pile on” to existing ones. Such a mechanism, whereby splicing changes 
affecting one or a few RBPs act as “drivers” of RBP aggregation, can also be 
envisioned for other events in our analysis, e.g., hnRNP H1, which we found undergoes 
differential splicing in its gly-rich IRD. Regardless of whether insolubility is upstream of 
splicing changes, or splicing changes precipitate insolubility, these events, and likely 
others, highlight how the two processes may reinforce one another in a vicious cycle, 
ultimately leading to the severe insolubility/ splicing dysregulation we have 
documented in the like-C9 ALS and FTD cases. 
If all ALS-FTD indeed converges on the same mechanism, then what factors 
dictate the onset and progression of disease at the clinical level? This is not 
straightforward, even when a known mutation underlies disease. In the case of C9, 
understanding how a single genetic polymorphism can lead to two different disorders, 
or a combination of the two, is perplexing. Further complicating matters, the C9 
expansion has been associated with scarce disease incidence in a wide spectrum of 
neurodegenerative and psychiatric conditions, including Huntington’s Disease, 
Parkinson’s Disease, and Schizophrenia (Hensman Moss et al. 2014; Lesage et al. 
2013; McLaughlin et al. 2017). It is unclear if these different patterns of neuronal 
degeneration reflect intra-patient variation in toxic burden across cell types/brain 
regions (Mackenzie et al. 2014), or if particular cell-types have inherently lower 
tolerance to toxic threats that are uniform across an individual (Nijssen et al. 2017). It 
may be that a combination of burden mosaicism and varying toxicity thresholds of 
distinct cell types converge to affect disease progression, such that mutation alone 
cannot predict the disease course of a given individual (Van Mossevelde et al. 2017). In 
our C9 model, these hypothetical burdens may be manifested and/or enhanced by 
transcriptional activity of the expanded locus (Liu et al. 2014), heightened ratio of 
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aggregated to soluble hnRNP H, and increasingly severe splicing changes. For 
sALS/FTD, we know the latter two occur, but as of yet, what triggers this remains a 
mystery. 
The variation in disease severity implied in our model also suggests a natural 
progression of disease from ALS to FTD along this clinical spectrum. Our results 
suggest that FTD patients are further past this hypothetical boundary than are patients 
with pure ALS, as reflected by the highest values RBP insolubility, and most global 
splicing changes. Given that all of the patients in our cohort with FTD also displayed 
MN loss, but not all ALS patients displayed signs of frontal cortex deterioration, we 
propose that the distinct neuronal populations affected by this disease spectrum have 
differential vulnerabilities to the alterations in granule dynamics that define the toxicity 
boundary. The heightened sensitivity of spinal MNs implied by this gradient parallels 
what is known about SMA, a disease where subtle alterations in the concentration of 
the protein SMN cause highly specific degeneration of spinal MNs, with further 
increasing deficiency in SMN resulting in wider systemic dysfunction (Tu et al. 2017). In 
both cases, disease mechanisms have been suggested to converge on perturbations 
of granule dynamics (Ishihara et al. 2013; Shan et al. 2010; Zhang et al. 2006) and RNA 
splicing (Tsuiji et al. 2013; Zhang et al. 2008).  
The observation that defects in mRNA splicing may have relevance to ALS was 
made 20 years ago, through examination of the disease-relevant EAAT2 gene product 
(Lin et al. 1998). In retrospect, our findings shed new light on the observation that 
splicing changes could be found region-specifically, and in most, but not all, sporadic 
patients. In addition to providing a potential mechanistic basis for this observation, our 
data can fit it into a broader mechanistic context that correlates changes in mRNA 
splicing with changes in RBP solubility. While the ubiquity of TDP-43 pathology to 
ALS/FTD, and the protein’s known roles in RNA processing, brought RNA biology to 
the forefront of research on these diseases, we now conclude that RNA processing 
defects are not simply correlated to visible pathology. Nonetheless, the microscopically 
invisible fluctuations in RBP concentration that we have described biochemically imply 
that this complex spectrum of disease states can be reached through many paths, 
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some genetically-mediated, some potentially driven by environment and experience. 
Our discovery that a large fraction of all ALS/FTD is characterized by a “like-C9” 
signature and reflects a “multiRBP proteinopathy” thus provides a unifying theme for 
these complex and lethal diseases.   
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Acquisition of Patient Materials: Human patient brains were donated for research by 
next of kin. Samples were acquired from the New York Brain Bank. C9 expansion 
testing was performed by repeat-primed PCR in the Clinical Pathology lab of Columbia 
University Medical Center. All available clinical and pathological records were collected 
and used to summarize patient demographics and disease features. Additional 
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samples were obtained by the New York Genome Center as part of the Target ALS 
post-mortem core. 
RT-PCR: High-quality total RNA was extracted from patient cerebellum, polyA 
selected, reverse-transcribed, and amplified by 32P-PCR for 33 cycles with established 
primers as previously described (Conlon et al. 2016). Products were electrophoresed 
side-by-side on 6% native PAGE and quantified using ImageQuant. Percent inclusions 
were measured using ImageQuant, and graphed and analyzed with Graphpad for 
Prism. All primer sequences for hnRNP H targets (Conlon et al. 2016), and TDP-43 
targets (Tollervey et al. 2011) were previously published. Primer sequences (5’-3’) for 
ACHE are as follows: 4F: GAACCGCTTCCTCCCCAAATT; 5aR: 
CAGCCTCCCCATGGGTGAA; 5bR: GTGGAACTCGGCCTTCCACT 
Biochemical Fractionation: Biochemical fractionation using Sarkosyl-containing 
buffers was performed as previously described (Conlon et al. 2016), with 15 minutes of 
21,000 xG centrifugation substituted for 180,000 xG where indicated. All three 
fractions, soluble, sarkosyl soluble and sarkosyl insoluble, were western blotted 
simultaneously, and the band intensities of each fraction were quantified using ImageJ 
from a single exposure. 
Western Blotting: Western blotting was performed as previously described (Conlon et 
al. 2016). Antibodies used in include Actin (Sigma, A2066), hnRNP H (Bethyl, A300-
511), TDP-43 (Proteintech, 10782-2-AP), FUS (Santa Cruz Biotechnologies, H-6), 
GAPDH (Sigma, G9545), hnRNP A1 (Sigma, 4B10), Histone H3 (Abcam, 1791), SMN 
(Sigma, S2944), U2AF65 (Sigma, U4758), C9ORF72 (Novus). All primary antibodies 
were incubated in Pierce Protein-free blocking buffer.  
RNA-sequencing 
Total RNA was extracted from flash-frozen post-mortem cerebellum tissue in 
Trizol/Chloroform and purified using a Qiagen RNeasy minikit column. Starting form 
500 ng total RNA input, rRNA depletion and library preparation were performed 
according to the manufacturer’s conditions using the KAPA Stranded RNA-Seq Kit 
with RiboErase and unique Illumina-compatible indexes (NEXTflex RNA-seq Barcodes, 
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BioScientific). Multiplexed libraries 550bp in length were sequenced PE 125 (Illumina 
HiSeq 2500). 
Computational methods: 
40-60 million filtered reads were aligned to GRCh38 using STAR (2.5.2a) (Dobin and 
Gingeras 2015). Differential splicing analysis was performed using the LeafCutter 
annotation-free algorithm (Li et al. 2018). The package was implemented with default 
parameter settings per the author’s recommendations: at least 50 split reads must 
support the cluster with introns up to 500kb. Only clusters with p-adjusted <0.1 were 
considered for further analysis (a lower p-adjusted cutoff proved to be too stringent, 
with no significant clusters listing for the ALSlow analysis). We used gender as an 
additional co-variate to prevent events attributable to gender from cluttering the 
results. Variations in intron splicing were considered significant in ALS/FTD when the 
Percentage Spliced Index (PSI) compared to control differed by more than 10% 
(|∆PSI|≥0.1) with 10% FDR cutoff. Differential splicing events were then mapped to 
gene names to identify events of interest using Gencode version 25. 
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Figure 1: Patient stratification into like-control and like-C9 groups by aberrant 
splicing of known hnRNP H-target exons. 
(a) List of hnRNP H target exons, separated into enhanced and repressed categories. 
(b) (Top) Simplified diagram of enhanced and repressed exons with relative binding of 
hnRNP H (H1). (Bottom) Depiction of expected product when H1 levels are high (left) 
and low (right). (c-e) Representative PCR gels of all patient samples for two enhanced 
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exons (ARRB2 and PPP1R12C) and one repressed exon (OS9). Pink boxes show 
samples F09-F13 that consistently show large magnitudes of change in inclusion. (f) 
Graph of CSS by group: nonALS, C9ALS, like-control and like-C9. Each point 
represents the CSS of an individual patient. Red dashed line marks the cutoff of 3 
standard deviations below the control mean. Error bars are plotted to the SEM. (g) 
Comparison of percent exon inclusion of 18 hnRNP H-target exons between like-
control and like-C9 patient replicate values. Exons are ordered by enhanced exons 
(KIF1C-PCBP2) followed by repressed exons (RPL10-HNRPDL). Error bars are plotted 
to the SEM. (t test p value: *= 0.05, **=<0.01, ***= <0.0001, ****= <0.0001). 
Figure 2: Differential concentration of hnRNP H due to insolubility explains graded 
splicing dysregulation in patient brains. 
(a) Linear regression of percent exon inclusion for each enhanced target exon 
compared to the average inclusion of all other enhanced exons. Clockwise from upper 
left: GABBR1, DOLPP1, PAN2, ARRB2, with r-square= 0.90, 0.86, 0.40, 0.88, 
respectively. (b) Linear regression of percent exon inclusion for the average of four 
repressed target exons compared to the average inclusion of all enhanced exons. R-
square=0.75. (c) (Upper) Diagram of biochemical fractionation and resultant fractions. 
(Lower) Representative example of 6 like-control and 6 like-C9 samples, western 
blotted for actin (cortex homogenate fraction) and hnRNP H (SOL, SS, SI). (d) 
Summary graph percent insoluble hnRNP H in motor cortex of like-controls versus like-
C9s. Samples for which motor cortex was unavailable were excluded from this 
analysis. Each point represents a single patient with replicate values. Error bars are 
plotted to the SEM. (t test p value: *= 0.05, **=<0.01, ***= <0.0001, ****= <0.0001). (e). 
Linear regression of percent insoluble hnRNP H compared to CSS, r-square=0.58. 
Figure 3: Insolubility of hnRNP H correlates with insolubility of additional RBPs. 
(a) CSS scores and identifiers for 10 most like-control and 10 most like-C9 patients for 
which motor cortex was available. These patients were loaded in this descending order 
for all parts of this figure. (b) Fractionation (180,000xG) of 20 sALS-FTD patients 
blotted for hnRNP H. SOL=soluble, SS=sarkosyl soluble and SI=sarkosyl insoluble. (c) 
Top: gel of ACHE alternative splicing in 20 sALS-FTD patients, loaded in order of 
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highest to lowest CSS. PCR products are identified at right. Bottom: diagram of 
primers used and hnRNP H binding motif. (d) Fractionation shown in (b) with western 
blotting for the following targets (clockwise from upper-left): TDP-43, FUS, GAPDH, 
hnRNP A1. (e) Quantification of percent insoluble protein (180,000xG) in these 20 
cases, with replicate values.  Error bars are plotted to the SEM. (t test p value: *= 0.05, 
**=<0.01, ***= <0.0001, ****= <0.0001).  (f) Linear regression of percent insoluble 
hnRNP H, TDP-43, FUS, hnRNP A1 and GAPDH for 20 sALS-FTD patients, plotted 
against CSS. R-square is listed. 
Figure 4 : Like-control ALS/FTD patients have undetectable levels of insoluble 
RBPs after low-speed fractionation. 
(a-h) Low-speed (21,000xG) fractionation experiment with 20 patients listed in Fig. 3a. 
Western blot hnRNP H (a),  TDP-43 (b), FUS (c), hnRNP A1 (d), SMN (e), Histone H3 (f), 
C9ORF72 (g), U2AF65 (h). SOL=soluble, SS=sarkosyl soluble, SI=sarkosyl insoluble 
and HMW=high molecular weight.  (i) Quantification of low-speed centrifugation of 20 
patients with replicate values. Error bars are plotted to the SEM. (j) Linear regression of 
percent insoluble protein for targets in (a-h) plotted against CSS. R-square is listed.  (k) 
Heatmap spearman correlation coefficient for comparison of percent insoluble protein 
at 180,000 or 21,000xG (180k and21k, respectively).  
Figure 5: hnRNP H insolubility defines patient groupings for RNA-sequencing 
analysis. 
(a) Percent insoluble hnRNP H of 28 samples in RNA-seq analysis reveals 50% as a 
natural boundary between ALSlow and ALShigh samples. (b) RNA-seq groups plotted 
by CSS and percent insoluble hnRNP H. (c) Western blot of whole tissue homogenate 
from cerebellum of 26/28 samples used in RNA-seq analysis. Two ALShigh cases (s01 
and s20) were excluded in order to fit all samples on one gel. Grayscale heatmap 
displays percent insoluble hnRNP H. (d) Venn diagram of all events found to be 
significantly different between each group and the combined control/SOD1ALS group 
with PSI magnitude filtering (|∆PSI|≥0.1). (e) Heatmap of all events in Fig. (d), except for 
the 6,576 events found to have significant DS exclusively in FTD. Blue-red color scale 
represents Z-score for normalized difference in PSI. Four rows above heatmap display 
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whether each sample was included in the groupings used for the identification of DS 
events (In analysis; black/white), gender (pink= female blue= male), Patient subtype 
(see key), and percent insolubility hnRNP H (180,000xG), ranging from light (low 
insolubility) to dark (high insolubility) gray. Yellow is shown for cases without insolubility 
data. Patients are arranged by subtype, with increasing insolubility from right to left, 
where data is available. 
Figure 6: Global splicing differences correlate to hnRNP H insolubility. 
(a) Examples of events amongst the 100-most correlated to insolubility, with Leafcutter 
(LC) PSI plotted on the X-axis and insolubility (%) on the Y-axis. (b) Heatmap of 100 
events most correlated/anti-correlated (absolute value Spearman coefficient) with 
hnRNP H insolubility. Blue-red color scale represents Z-score for normalized difference 
in PSI. Four rows above heatmap display whether each sample was included in the 
groupings used for the identification of DS events (In analysis; black/white), gender 
(pink= female blue= male), Patient subtype (see key), and percent insolubility hnRNP H 
(180,000xG), ranging from light (low insolubility) to dark (high insolubility) gray. Yellow 
is shown for cases without insolubility data. Patients are arranged by subtype, with 
increasing insolubility from right to left, where data is available. (c) Heatmap of 
significant DS events that occur in a set of common splicing factor genes, simplified to 
the single most changed event per gene (hnRNPs, SR proteins, ALS-related RBPs or 
SMN; events listed in Supp. table 3). The same four rows apply as in (b). (d) Bar graph 
depicting that patients like-C9 are 3.8-times more likely to have symptoms of FTD than 
patients like-control (Fisher’s exact test, p=0.032). 
Figure 7: A model for a multi-RBP proteinopathy and splicing dysregulation as a 
common mechanism underling ALS/FTD pathogenesis. 
A model of a multi-RBP proteinopathy, where several disease-related proteins (hnRNP 
H, TDP-43, FUS, hnRNP A1) can exist in different states: free/soluble, phase separated 
into reversible granules, and trapped in overly mature granules or aggregated 
RNA/protein assemblies. The relative balance of these states can be influenced by 
known ALS/FTD mutations, or normal fluctuations due to experience, thus altering the 
cellular distribution of RBPs between diffuse and localized/sequestered states. We 
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envision a theoretical “toxicity boundary” beyond which RBPs are disproportionately in 
the highly concentrated state, and functional levels of soluble protein are low. We 
propose that the distance past this boundary, or magnitude of the imbalance between 
free and local RBP concentrations, is correlated to a greater involvement of cortical 
neuron dysfunction, whereas mild imbalance is sufficient only to cause MN death. Thus 
our model implies a gradient in vulnerability, with spinal MNs being more sensitive to 
this imbalance than cortical MNs, which are more vulnerable than neurons (such as 
spindle) that are predominantly affected in FTD. 
Supplemental figure 1: RT-PCR of hnRNP H target genes. 
(a-q) Representative PCR gels from all genes that are significantly altered between 
like-control and like-C9. In some instances, single samples failed to amplify thus 
leading to blank lanes. These reactions were repeated and re-run individually or in 
small groups (data not shown). Loading convention is gel 1: sALS 1-28, gel 2: sALS 29-
41; FTD 1-15. Sample information can be found in Supplemental table 1. 
Supplemental figure 2: Linear regression of hnRNP H enhanced exons. 
(a-j) Linear regression all remaining genes not shown in Fig. 2a. Percent exon inclusion 
for each hnRNP H-target exon is plotted as a Y-coordinate compared to the average 
percent inclusion of all other hnRNP H-enhanced exons. R-square values are 
displayed. 
Supplemental figure 3: Insoluble hnRNP H and TDP-43 correlate in C9 patient 
brains. 
Representative western blot of 21,000 xG motor cortex fractionation from eight control 
(six nonALS and two SOD1 ALS) and 14 C9+ ALS/FTD patients. Membranes are shown 
from top-bottom: cortex homogenate (western blot actin), Sarkosyl insoluble fraction 
(western blot hnRNP H), and same membrane (western blot TDP-43), with arrows 
differentiating TDP-43 from residual hnRNP H signal. 
Supplemental figure 4: Quanitification of TDP-43 splicing targets. 
Summary quantification of rt-PCR of 18 TDP-43 splicing targets with six most like-
control (highest CSS) and six most like-C9 (lowest CSS) patients. Signifcant events 
(p<0.10, t test) are indicated with a bracket that is pink if the direction of change 
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indicates TDP-43 LOF in like-C9, or blue and dashed if the direction of change 
indicates TDP-43 LOF in like-control.  (p value: *= 0.05, **=<0.01, ***= <0.0001, ****= 
<0.0001; values between 0.05 and 0.10 are displayed).  
Supplemental figure 5: DS events without filtering 
Venn diagram of all events found to be significantly different between each group and 
the combined control/SOD1ALS group with no PSI magnitude filtering. 
Supplemental figure 6: Heatmap of intersecting events 
Heatmap of 489 (488 between FTD, C9 and ALShigh plus one between all four groups) 
overlapping events from Fig. 6d, with hierarchical clustering. Blue-red color scale 
represents Z-score for normalized difference in PSI. Four rows above heatmap display 
whether each sample was included in the groupings used for the identification of DS 
events (In analysis; black/white), gender (pink= female blue= male), Patient subtype 
(see key), and percent insolubility hnRNP H (180,000xG), ranging from light (low 
insolubility) to dark (high insolubility) gray. Yellow is shown for cases without insolubility 
data. 
Supplemental figure 7: Heatmap of subtype-specific DS events. 
Heatmap of non-intersecting events comprised of the top 20 events (magnitude |∆PSI|) 
from each group (FTD, C9, ALShigh), and all three events from ALSlow. Side color bar 
represents which group the event derived from. Patients are arranged according to 
vertical dendogram. Blue-red color scale represents Z-score for normalized difference 
in PSI. Four rows above heatmap display whether each sample was included in the 
groupings used for the identification of DS events (In analysis; black/white), gender 
(pink= female blue= male), Patient subtype (see key), and percent insolubility hnRNP H 
(180,000xG), ranging from light (low insolubility) to dark (high insolubility) gray. Yellow 
is shown for cases without insolubility data.  
Supplemental Table 1: Patient clinical information. 
Supplemental Table 2: All significant DS events with greater than 10% difference 
in PSI in any group. 
All events found to be significantly different between each patient group (FTD, 
ALShigh, ALSlow, C9) and control (|∆PSI|≥0.1). Events are arranged from greatest to 
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smallest difference. Events without significant change in a given group are denoted 
with zeroes. All coordinates are mapped to GRCh38/hg18. 
Supplemental Table 3: Significant DS events most correlated to hnRNP H 
insolubility 
Events and spearman rank correlation coefficients are provided. All coordinates are 
mapped to GRCh38/hg18. 
Supplemental Table 4: Significant DS events occurring in common RBP genes. 
All events occurring in a set of common splicing factor genes (hnRNPs, SR proteins, 
ALS-related RBPs or SMN; heatmap in Supp. Fig. 5) amongst the events found to be 
significantly different between each patient group (FTD, ALShigh, ALSlow, C9) and 
control (no PSI filter). Events without significant change in a given group are denoted 
with zeroes. All coordinates are mapped to GRCh38/hg18. 
Supplemental Table 5: NYGC ALS Consortium Members. 
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Sample # Tissue Sex Clinical diagnosis Age at death Disease duration Like-C9? TDP-43 Pathology Known Mutation RNA-seq Seq Group Key
s01 CBL, BA4 F ALS 53 9 years No UNA n/a Yes ALShigh Sporadic ALS
s02 CBL, BA4 F ALS 64 2.5 years Yes Confirmed n/a Yes ALShigh FTD-MND
s03 CBL, BA4 F ALS 79 2 years Yes UNA n/a Yes ALShigh nonALS
s04 CBL, BA4 M ALS 67 1.5 years No UNA n/a Yes ALShigh SOD1ALS
s05 CBL, BA4 F ALS 77 2-2.5 years Yes UNA n/a Yes ungrouped ALS C9+
s06 CBL, BA4 M ALS 54 2-3 years No UNA n/a Yes ALSlow
s07 CBL, BA4 M ALS 60 unknown No UNA n/a Yes ALShigh
s08 CBL, BA4 F ALS 77 1.5 years Yes UNA n/a Yes ALShigh
s09 CBL, BA4 F ALS 69 1.5 years Yes UNA n/a Yes ALShigh
s10 CBL, BA4 M ALS 73 2.5-3 years Yes UNA n/a Yes ALShigh
s11 CBL, BA4 M ALS 56 1.5 years Yes UNA n/a Yes ALShigh
s12 CBL F ALS 79 3 years No UNA n/a Yes ungrouped ALS
s13 CBL, BA4 M ALS 52 6.5 years Yes Confirmed n/a Yes ALShigh
s14 CBL F ALS 74 2 years No UNA n/a Yes ungrouped ALS
s15 CBL M ALS 76 unknown No UNA n/a Yes ungrouped ALS
s16 CBL, BA4 M ALS 60 2 years Yes UNA n/a Yes ALShigh
s17 CBL M ALS 63 2 years Yes UNA n/a Yes ungrouped ALS
s18 CBL, BA4 M ALS-FTD 58 1.5-2 years Yes UNA n/a Yes ungrouped ALS
s19 CBL, BA4 M FTD-MND 50 4 years Yes UNA n/a Yes FTD
s20 CBL F ALS 78 unknown No UNA n/a Yes ALShigh
s21 CBL M ALS 75 unknown Yes UNA n/a Yes ungrouped ALS
s22 CBL M ALS 73 3 years n/a UNA n/a Yes ungrouped ALS
s24 CBL, BA4 F ALS 69 2 years Yes UNA n/a Yes ALSlow
s25 CBL M ALS-FTD 75 9 years No UNA n/a Yes ungrouped ALS
s26 CBL M ALS-FTD, PD 85 2 years No UNA I70V ANG Yes ungrouped ALS
s27 CBL F ALS-FTD 59 unknown No UNA n/a
s28 CBL, BA4 F ALS 76 unknown No UNA n/a Yes ALShigh
s29 CBL, BA4 F ALS 67 10 years No UNA n/a Yes ALSlow
s30 CBL, BA4 M ALS 69 12 years No Not observed n/a Yes ALShigh
s31 CBL, BA4 F ALS 71 2 years No UNA n/a Yes ALSlow
s32 CBL, BA4 F ALS 72 unknown No UNA n/a Yes ALSlow
s33 CBL, BA4 F ALS 71 unknown No UNA n/a Yes ungrouped ALS
s34 CBL, BA4 M ALS 56 2 years No Confirmed n/a Yes ALSlow
s35 CBL, BA4 F ALS 55 3 years No Confirmed n/a
s36 CBL, BA4 M ALS 44 2-2.5 years No Confirmed n/a
s38 CBL, BA4 M ALS 80 0.5-1 years No UNA n/a Yes ALSlow
s39 CBL, BA4 F ALS 32 2-3 years n/a UNA A3V SOD1
s40 CBL, BA4 F ALS 65 2 years No Confirmed n/a
s42 CBL M ALS 80 unknown n/a UNA n/a Yes ungrouped ALS
s43 CBL M ALS 74 unknown n/a UNA n/a Yes ungrouped ALS
s44 CBL M ALS 65 unknown n/a UNA n/a Yes ungrouped ALS
F02 CBL, BA4 M ALS-FTD 78 3 years Yes Confirmed n/a Yes FTD
F03 CBL, BA4 F ALS-FTD 55 4 years No Confirmed n/a Yes ungrouped FTD
F05 CBL, BA4 F FTD-MND 67 14 years Yes Confirmed n/a Yes FTD
F06 CBL, BA4 F ALS-FTD 52 3 years Yes UNA n/a
F07 CBL, BA4 M FTD-MND 54 4 years No UNA n/a Yes ungrouped FTD
F08 CBL, BA4 M FTD-MND 74 11 years Yes UNA n/a
F09 CBL, BA4 M FTD-MND 69 9 years Yes Confirmed n/a Yes FTD
F10 CBL, BA4 M FTD-MND 57 6 years Yes TDP-43 negative MNI n/a Yes FTD
F11 CBL, BA4 M FTD-MND 64 3 years Yes Confirmed n/a Yes FTD
F12 CBL, BA4 M FTD-MND 58 10 years Yes Confirmed n/a Yes FTD
F13 CBL, BA4 F FTD-MND 66 8 years Yes Confirmed n/a Yes FTD
F14 CBL, BA4 F FTD-MND 79 8 years Yes Confirmed n/a
F15 CBL, BA4 F FTD-MND 66 3 years Yes Confirmed n/a Yes ungrouped FTD
non1 CBL, BA4 M Non-neurological control 60 n/a n/a n/a n/a
non2 CBL, BA4 F Non-neurological control 62 n/a n/a n/a n/a
non3 CBL, BA4 F Non-neurological control 54 n/a n/a n/a n/a
non4 CBL, BA4 M Non-neurological control 89 n/a n/a n/a n/a
non5 CBL M Non-neurological control 84 n/a n/a n/a n/a
non6 CBL, BA4 F Non-neurological control 54 n/a n/a n/a n/a Yes Control
non7 BA4 M Non-neurological control 62 n/a n/a n/a n/a
non8 CBL F Non-neurological control 57 n/ n/a n/a n/a
non9 CBL F Non-neurological control 90+ n/a n/a n/a n/a Yes Control
non10 CBL F Non-neurological control 90+ n/a n/a n/a n/a Yes Control
non11 CBL F Non-neurological control 70 n/a n/a n/a n/a Yes Control
non12 CBL F Non-neurological control 52 n/a n/a n/a n/a Yes Control
non13 CBL M Non-neurological control 89 n/a n/a n/a n/a Yes Control
23=SOD1 CBL, BA4 F ALS 52 unknown n/a UNA L144F SOD1 Yes SOD1
SOD2 CBL M ALS 58 unknown n/a UNA unknown Yes SOD1
SOD3 CBL M ALS 47 unknown n/a UNA unknown Yes SOD1
SOD4 CBL M ALS 49 unknown n/a UNA unknown Yes SOD1
SOD5 CBL M ALS 68 unknown n/a UNA A4V SOD1 Yes SOD1
C91 CBL, BA4 F ALS 64 1-1.5 years n/a UNA C9ORF72 Yes C9
C92 CBL, BA4 F ALS 64 0.5 years n/a UNA C9ORF72 Yes C9
C93 CBL, BA4 F ALS 58 1-1.5 years n/a UNA C9ORF72 Yes C9
C94 CBL, BA4 M ALS-FTD 60 0.5-1 years n/a Confirmed C9ORF72 Yes C9
C95 CBL, BA4 F ALS 65 7-7.5 years n/a UNA C9ORF72 Yes C9
C96 CBL, BA4 M ALS 73 4.5 years n/a UNA C9ORF72 Yes C9
C97 CBL M ALS 53 4 years n/a UNA C9ORF72 Yes C9
C98 CBL, BA4 M ALS 59 1 year n/a UNA C9ORF72 Yes C9
C99=s37 CBL, BA4 M ALS 70 <2 years n/a UNA C9ORF72 Yes C9
C910=F04 CBL, BA4 F FTD 75 9 years n/a UNA C9ORF72 Yes ungrouped FTD
C911 CBL, BA4 M ALS-FTD 73 2 years n/a UNA C9ORF72 Yes C9
C912 CBL, BA4 F ALS 57 1 year n/a UNA C9ORF72 Yes C9
C913=s41 CBL, BA4 F ALS-FTD 68 6 years n/a Confirmed C9ORF72 Yes C9
C914 CBL, BA4 M ALS-FTD 59 2 years n/a UNA C9ORF72
C915 BA4 M ALS 44 4 years n/a UNA C9ORF72
C916=F01 CBL, BA4 F ALS-FTD 68 6 years n/a UNA C9ORF72 Yes ungrouped FTD
C920 CBL F ALS unknown unknown n/a UNA C9ORF72 Yes C9
C921 CBL M ALS 67 unknown n/a UNA C9ORF72 Yes ungrouped ALS
C922 CBL F FTD, AD 72 unknown n/a UNA C9ORF72 Yes ungrouped FTD
C923 CBL F ALS 61 unknown n/a UNA C9ORF72 Yes ungrouped ALS
Note: CBL= cerebellum; BA4= Brodmann Area 4, motor cortex; MND= motor neuron disease; PD= Parkinson's Disease; AD= Alzheimer's Disease; n/a= not applicable; UNA= unavailable; MNI= 
motor neuron inclusion
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Junction ALShigh ALSlow C9 FTD
chr2:159762993:159767284 MARCH7 -0.2093031 0 -0.2593248 -0.8076951
chr14:69769251:69770467 SRSF5 0.292486 0 0.1993165 0.7368784
chr12:88053746:88055576 CEP290 -0.2711763 0 -0.2856626 -0.7103373
chr3:5208263:5211120 EDEM1 -0.3782185 0 -0.4290132 -0.7090368
chr8:106270367:106359476 RP11-395G23.3,OXR1 0.2165793 0 0.2663979 0.6836862
chr5:172057473:172060967 STK10 0 0 0 -0.6649246
chr5:172057473:172061139 STK10 0 0 0 0.6649246
chr2:241723271:241724989 ING5 0.1906485 0 0.2180641 0.6385333
chr1:95117617:95143891 TMEM56,TMEM56-RWDD3 0.1718147 0 0.3353733 0.635388
chr1:95118091:95143891 TMEM56,TMEM56-RWDD3 -0.1718147 0 -0.3353733 -0.635388
chr16:15086258:15091315 RRN3 -0.3104967 0 -0.3037044 -0.6295771
chr2:97164311:97167577 ANKRD36 -0.215944 0 -0.295349 -0.6195404
chr19:2037829:2040134 MKNK2 -0.2315354 0 -0.291921 -0.6136257
chr19:2039856:2040134 MKNK2 0.2315354 0 0.291921 0.6136257
chr8:38279681:38281467 WHSC1L1 -0.3164902 0 -0.3481403 -0.6066549
chr8:38279681:38281500 WHSC1L1 0.3164902 0 0.3481403 0.6066549
chr19:1272051:1274307 CIRBP -0.121998 0 -0.1782213 -0.6060536
chr7:96688966:96694798 SHFM1 0.2122536 0 0.2465435 0.5995879
chrY:2975654:2977940 ZFY -0.342369 0 -0.282679 -0.5961299
chr17:37519071:37520538 SYNRG -0.1906326 0 -0.2730224 -0.5894998
chr10:119751156:119781635 INPP5F 0.1344533 0 0.1845643 0.5884316
chr17:67736754:67737508 NOL11 -0.170375 0 -0.1618927 -0.5824124
chr2:60794191:60794964 PAPOLG -0.2491594 0 -0.2037599 -0.5812447
chr12:6678460:6678946 ZNF384 -0.1905728 0 -0.1905157 -0.5768025
chrX:55722285:55729294 RRAGB -0.1504872 0 -0.2113395 -0.5763866
chr10:22318306:22318959 COMMD3,COMMD3-BMI1 -0.1310928 0 -0.1057778 -0.5757921
chr4:116928452:116952660 NA 0 0 -0.2506764 -0.5706627
chrX:135577295:135579788 INTS6L 0.260508 0 0 0.5702235
chrX:135577427:135579788 INTS6L -0.260508 0 0 -0.5702235
chr14:77243056:77245940 TMEM63C 0 0 -0.1069189 -0.5687804
chr19:1272051:1272427 CIRBP 0.1304314 0 0.1738531 0.5661333
chr15:50592626:50593617 TRPM7 0 0 0.2746636 0.5617528
chr6:33441759:33442889 SYNGAP1 -0.1183126 0 -0.165749 -0.5584326
chr8:109339390:109340444 ENY2 -0.2130514 0 -0.1854085 -0.5571594
chr5:178618778:178623256 CLK4 0 0 -0.1738208 -0.550645
chr1:113700949:113704081 PHTF1 0.3121309 0 0.1751024 0.549871
chr14:64950414:64950943 RAB15 0 0 0 -0.5493265
chr14:64950414:64951074 RAB15 0 0 0 0.5493265
chr1:7785586:7788045 PER3 -0.1459899 0 -0.1251588 -0.5477927
chr9:37854982:37860048 DCAF10 0 0 0 -0.5475635
chr22:38248019:38272884 TMEM184B 0.1340114 0 0.24719 0.543644
chr10:15109215:15109702 NMT2 0.1495934 0 0 0.5402647
chr1:156236483:156242553 PMF1,PMF1-BGLAP,BGLAP -0.1881973 0 -0.2525965 -0.5385178
chr11:63819002:63826928 C11orf84 0.2591332 0 0.2920658 0.5353865
chr18:79904183:79919184 PQLC1 0.2862282 0 0.216636 0.5345057
chrX:40071159:40072349 BCOR -0.3118868 0 -0.3051058 -0.5337643
chr17:64822393:64824625 PLEKHM1P1 0 0 0.1467982 0.5291802
chr3:121807443:121826051 IQCB1 -0.107538 0 -0.1535473 -0.5288424
chr3:38236961:38242743 OXSR1 0 0 0.1871552 0.5278695
chr8:109339390:109340489 ENY2 0.2211882 0 0.1858027 0.5277093
chr8:106270367:106271806 RP11-395G23.3,OXR1 -0.1324397 0 -0.119216 -0.5259532
chr4:145110444:145112239 ABCE1 -0.100343 0 -0.1371457 -0.5252379
chr2:61311910:61314585 USP34 0.2026248 0 0.2650166 0.5251242
chr16:67169101:67169631 HSF4 0 0 0 -0.5229977
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chr19:7981186:7991644 ELAVL1 0.1270339 0 0.1265292 0.5213002
chr5:6620298:6623214 NSUN2 -0.1943824 0 -0.1768199 -0.520978
chr11:63905043:63908877 MARK2 -0.223806 0 -0.1996201 -0.5173715
chr17:60075833:60076130 HEATR6 0 0 -0.1999749 -0.5163374
chr1:160283109:160285055 PEX19,RP11-574F21.3 -0.1833119 0 -0.1833441 -0.5139792
chr7:143854142:143857074 TCAF1 -0.2037445 0 -0.209066 -0.51362
chr7:143854142:143857100 TCAF1 0.2037445 0 0.209066 0.51362
chr1:70228555:70232268 SRSF11 -0.1750707 0 -0.1651599 -0.512832
chr3:113008430:113011045 NEPRO -0.1853988 0 -0.1635501 -0.5125543
chr12:111457359:111470108 ATXN2 -0.1876744 0 -0.1978171 -0.5121052
chr16:57213946:57216904 RSPRY1 -0.1167117 0 0 -0.5115303
chr7:11062085:11111350 PHF14 -0.1392366 0 -0.2226782 -0.511524
chr6:143462997:143470961 PEX3 -0.1281757 0 -0.1272813 -0.509568
chr7:11062085:11102486 PHF14 0.1590716 0 0.2369845 0.5083484
chr2:24275849:24286212 ITSN2 -0.1698704 0 -0.2478657 -0.5039847
chr11:6218150:6218558 FAM160A2 -0.124235 0 -0.1068186 -0.5010418
chr11:6218150:6218600 FAM160A2 0.124235 0 0.1068186 0.5010418
chr1:156236483:156239548 PMF1,PMF1-BGLAP,BGLAP 0.1871657 0 0.2537111 0.4997835
chr3:9433950:9434277 SETD5 -0.2547691 0 -0.247646 -0.4992417
chr17:73203793:73206154 COG1 -0.08096239 0 -0.100714 -0.4991115
chr9:97326669:97330154 RP11-23J9.4,CCDC180 -0.1969384 0 -0.1315002 -0.4986107
chr4:109717713:109729602 PLA2G12A -0.1937302 0 -0.13938 -0.496625
chr4:101026061:101032267 PPP3CA -0.1798113 0 -0.1628078 -0.4954774
chr10:122228008:122237395 TACC2 0 0 -0.1488087 -0.4929638
chr4:43763775:43764462 NA 0.1945873 0 0 0.4910598
chr20:37236709:37241303 RPN2 0 0 -0.1925915 -0.4909359
chr8:73027052:73032042 TERF1 0 0 0 -0.4908164
chr22:31449531:31454144 EIF4ENIF1 -0.09412199 0 -0.1001572 -0.4874325
chr3:97788119:97798024 ARL6 -0.1615866 0 -0.1924283 -0.4845114
chr2:97560860:97584944 ANKRD36B -0.173568 0 -0.1192494 -0.4834879
chr3:65357132:65361199 MAGI1 0 0 0 -0.4818477
chr9:34614768:34617885 DCTN3 0 0 0 -0.4814187
chr1:203045987:203048227 PPFIA4 0 0 -0.09833003 -0.4780724
chr4:82424883:82426037 HNRNPDL 0.2160315 0 0.1952651 0.4773015
chr19:10830378:10832304 DNM2 0 0 0 -0.4755351
chr9:97685040:97693649 XPA -0.1144811 0 -0.1062378 -0.4755341
chr12:122489463:122492715 ZCCHC8 -0.1048191 0 -0.1217043 -0.4752821
chr4:15686462:15687001 FAM200B 0.1400746 0 0 0.4741603
chrX:16832742:16837593 TXLNG -0.02196749 0 -0.05165822 -0.4737091
chr2:159759335:159762880 MARCH7 0.113477 0 0.1743984 0.473536
chr2:159759358:159762880 MARCH7 -0.113477 0 -0.1743984 -0.473536
chr1:85258722:85259358 C1orf52 -0.2005793 0 -0.1772084 -0.4730738
chr3:15052633:15053291 MRPS25 -0.1026309 0 -0.1514435 -0.4726416
chr3:15052633:15053380 MRPS25 0.1026309 0 0.1514435 0.4726416
chr4:82894847:82900077 THAP9-AS1,SEC31A -0.1402634 0 0 -0.47149
chr3:184386159:184386845 CHRD -0.1250208 0 -0.1493622 -0.4685457
chr15:40389929:40391949 KNSTRN 0 0 0 -0.4679159
chr13:102766580:102768260 TEX30 0 0 -0.1443739 -0.4674513
chr18:63403826:63410290 VPS4B -0.09815919 0 -0.1666822 -0.4652656
chr13:31141259:31145563 HSPH1 -0.07857944 0 -0.1965439 -0.464435
chr3:113506605:113514897 SPICE1 -0.1812176 0 -0.2440828 -0.4641754
chr3:113506605:113515080 SPICE1 0.1812176 0 0.2440828 0.4641754
chr2:70989816:70993696 AC007040.11,TEX261 -0.06807734 0 -0.08636002 -0.462861
chr14:66965325:67023633 GPHN -0.1474842 0 -0.1619891 -0.4583843
chr3:33576275:33581821 CLASP2 -0.1788514 0 -0.1493741 -0.4578169
chr1:16315435:16316437 FBXO42 -0.1996742 0 -0.2408567 -0.4563388
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chr13:19670363:19671206 MPHOSPH8 0.27256 0 0.2026964 0.454043
chr15:99690428:99706729 MEF2A 0 0 0 -0.4528047
chr19:14480778:14491656 GIPC1 -0.09811639 0 0 -0.4524476
chr9:146158:152034 CBWD1 0 0 0 0.4523252
chr1:204532246:204538209 MDM4 -0.1053629 0 0 -0.4521426
chr6:116571655:116580295 RWDD1 -0.1405239 0 -0.1142628 -0.4519766
chr16:3532841:3536122 CLUAP1 0 0 -0.1930366 -0.4504836
chr11:43889828:43901516 ALKBH3 -0.2236413 0 0 -0.4480016
chr13:110642521:110644385 CARS2 -0.2165189 0 -0.2166474 -0.445368
chr3:43081536:43105836 POMGNT2 -0.1891991 0 -0.1461154 -0.4448914
chr5:87394484:87395044 CCNH 0.279434 0 0.2788884 0.4437127
chr2:95935644:95938987 ANKRD36C -0.1825195 0 -0.2024004 -0.4431701
chr15:56704267:56707263 ZNF280D -0.2132597 0 -0.2184595 -0.4419803
chr6:56463764:56466078 DST -0.1276521 0 -0.1565136 -0.4414927
chr3:33402904:33409236 UBP1 0 0 -0.1673612 -0.441431
chr4:122274436:122279775 KIAA1109 -0.1386298 0 -0.1344693 -0.4408058
chr2:159762993:159764626 MARCH7 0.1773464 0 0.1395318 0.4393244
chr3:9433950:9434334 SETD5 0.2223661 0 0.2187296 0.4392679
chr3:142183049:142185929 GK5 -0.03454436 0 -0.1620572 -0.4379037
chr10:37971807:37976072 ZNF25 -0.1695317 0 -0.1859087 -0.4372473
chr3:45826332:45828439 LZTFL1 0 0 -0.0743918 -0.4368774
chr9:121090405:121096422 CNTRL -0.1865798 0 -0.2323191 -0.4367816
chr7:99909660:99919009 TRIM4 -0.1780919 0 -0.1702429 -0.4362799
chr11:113827360:113829197 USP28 -0.2215702 0 -0.2145137 -0.4359079
chr3:142185989:142186452 GK5 0 0 0 -0.4356965
chr4:13587771:13590386 BOD1L1 -0.07312433 0 -0.08583821 -0.4349862
chr2:39035310:39051144 SOS1 -0.04851248 0 -0.1164228 -0.4347315
chr10:123162828:123163820 BUB3 0.2093534 0 0.2254254 0.4344839
chr10:123162828:123165047 BUB3 -0.2093534 0 -0.2254254 -0.4344839
chr22:19975757:19977415 ARVCF -0.0803601 0 -0.1030001 -0.4339467
chr1:16315435:16352255 FBXO42 0.2045255 0 0.240637 0.4335216
chr3:5210248:5211120 EDEM1 0.2515436 0 0.264043 0.4334807
chr14:100137644:100141180 EVL -0.1128262 0 -0.1391831 -0.4332343
chr8:42338685:42344953 POLB 0 0 0 -0.4331259
chr1:155727738:155729208 DAP3 -0.06754543 0 -0.06834082 -0.4316706
chr1:203045987:203046248 PPFIA4 0 0 0.1295395 0.4310374
chr9:113178801:113182766 FKBP15 0 0 0 -0.4306874
chr9:113178801:113182796 FKBP15 0 0 0 0.4306874
chr17:27306882:27307744 WSB1 0 0 0.1086706 0.4305613
chr1:1402256:1405809 MRPL20 0 0 0.1311535 0.4303576
chr20:3800498:3800971 CDC25B -0.05554811 0 -0.05757662 -0.4299799
chr13:51379572:51383329 INTS6 -0.1475064 0 -0.1772572 -0.4296753
chr4:2639859:2646685 FAM193A 0.1041097 0 0.1490571 0.4284794
chr1:86354859:86358787 ODF2L -0.0948291 0 -0.1393182 -0.4279648
chr7:72829783:72831602 SBDSP1 -0.1402279 0 -0.1540736 -0.4277701
chr16:11768501:11770783 ZC3H7A -0.1290994 0 -0.1295782 -0.4227774
chr2:219228053:219229535 ATG9A -0.1339708 0 -0.08980866 -0.422727
chr1:25243633:25245150 RSRP1 -0.3092706 0 -0.2522382 -0.4204912
chr5:87392904:87395044 CCNH -0.2508941 0 -0.2223907 -0.4202968
chr7:92042771:92045008 AKAP9 -0.1547366 0 -0.2159661 -0.4200433
chr17:17215316:17217069 RP11-45M22.4,FLCN -0.09921965 0 -0.1499636 -0.4199116
chr17:58305643:58306342 TSPOAP1 0 0 -0.08350496 -0.4196885
chr3:141876910:141903620 ATP1B3 -0.1413278 0 -0.1602 -0.4194772
chr20:35632025:35632311 CPNE1 -0.08896689 0 -0.1133149 -0.4187685
chr11:64360592:64360821 RPS6KA4 -0.1486559 0 0 -0.4175314
chr11:64360592:64361134 RPS6KA4 0.1486559 0 0 0.4175314
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chr15:25078995:25081091 SNHG14 -0.1191778 0 -0.1510702 -0.4173284
chr22:38248019:38272499 TMEM184B -0.1021527 0 -0.1936259 -0.4173164
chr22:31327309:31335692 PATZ1 0 0 0 -0.4168809
chr1:160224549:160225591 DCAF8,RP11-574F21.3 -0.1258842 0 0 -0.4162038
chr2:97154741:97162099 ANKRD36 -0.04065158 0 -0.08859193 -0.4159914
chr6:83120791:83122863 DOPEY1 -0.04437815 0 -0.1029827 -0.4156974
chr3:197624197:197627780 AC024560.3 0 0 -0.00263095 0.4156368
chr19:7981186:7982672 ELAVL1 -0.1288841 0 -0.1032002 -0.4155844
chr1:2391958:2395784 RER1 0 0 0 0.4144641
chr12:72255774:72271823 TRHDE-AS1 -0.155269 0 -0.122812 -0.4142804
chr3:52617538:52627273 PBRM1 0 0 0 -0.4127812
chr15:61945882:61947193 VPS13C -0.133695 0 -0.1227175 -0.4124307
chr14:30559272:30586718 G2E3 -0.1470741 0 -0.1627684 -0.4109358
chr2:151468756:151469711 RIF1 -0.180142 0 -0.232278 -0.4092211
chr1:219173981:219179147 LYPLAL1 0.1351572 0 0 0.409112
chr1:219174304:219179147 LYPLAL1 -0.1351572 0 0 -0.409112
chrX:11760937:11762130 MSL3 -0.0812542 0 -0.1213323 -0.408877
chr9:127682560:127690775 STXBP1 -0.1603725 0 -0.1596084 -0.4087278
chr8:56211837:56214598 CHCHD7 -0.2358048 0 -0.1430324 -0.4086599
chr3:32530328:32532986 DYNC1LI1 -0.07287181 0 -0.07715484 -0.4084375
chr2:233354674:233388257 DGKD 0.05961097 0 0.1437337 0.4081815
chr15:78971934:78980620 RASGRF1 0 0 0 -0.4074148
chr14:69769251:69769511 SRSF5 -0.1442252 0 -0.1276911 -0.4073615
chr17:60073886:60076130 HEATR6 0 0 0.1362239 0.4070894
chr18:47136449:47137235 HDHD2,RP11-49K24.6 0 0 -0.1594341 -0.4069785
chr13:19677823:19730239 PSPC1 -0.1361307 0 0 -0.4064708
chr5:103104846:103108569 GIN1 -0.08831051 0 -0.1217054 -0.4062034
chr2:148483436:148485742 MBD5 0 0 0 0.4047805
chr2:148484135:148485742 MBD5 0 0 0 -0.4047805
chr19:53122743:53132749 ZNF415 0 0 -0.1299162 -0.4040467
chr2:134946146:134947736 CCNT2 0.1872058 0 0 0.4034054
chr2:134946465:134947736 CCNT2 -0.1872058 0 0 -0.4034054
chr11:113805046:113808298 USP28 -0.0684078 0 -0.1298509 -0.402954
chr10:68483588:68487144 DNA2,SLC25A16 0.1152514 0 0.1625471 0.4027667
chr14:45096228:45096887 PRPF39 -0.1604207 0 -0.1972946 -0.4017947
chr6:112081207:112086556 TUBE1 -0.1148776 0 0 -0.401403
chr8:78666164:78678563 ZC2HC1A -0.04060417 0 -0.07883482 -0.4009571
chrX:153558303:153559729 ATP2B3 0.1698459 0 0.1306888 0.4007276
chr9:35790340:35799618 NPR2 -0.1285349 0 -0.1572356 -0.3989126
chr9:35794103:35799618 NPR2 0.1285349 0 0.1572356 0.3989126
chrX:48575667:48576314 RBM3 0.1892198 0 0.2267299 0.3988183
chr10:35071339:35089896 CUL2 -0.1193838 0 -0.1832067 -0.3987537
chr14:23566419:23567111 AP1G2 0 0 -0.1202755 -0.3976895
chr8:42319421:42320735 IKBKB 0 0 -0.1697194 -0.3976785
chr3:53673126:53702641 CACNA1D 0 0 0 0.3971733
chr3:53673816:53702641 CACNA1D 0 0 0 -0.3971733
chr4:169561554:169561832 NEK1 -0.1226909 0 -0.0938043 -0.3967538
chr1:39459249:39460632 MACF1 -0.2076109 0 -0.2251027 -0.3963747
chr4:119455133:119460183 RP11-33B1.1 0.07329915 0 0.1013102 0.3953151
chr4:119212873:119217550 USP53 0 0 -0.1250628 -0.3952451
chr3:58130908:58132808 FLNB -0.1966018 0 0 -0.3951095
chr1:46572167:46576575 MKNK1 -0.1114132 0 -0.1569438 -0.3934491
chr5:126832801:126836223 LMNB1 0.1397728 0 0.1643194 0.3933366
chr5:126832801:126853562 LMNB1 -0.1397728 0 -0.1643194 -0.3933366
chr17:44759897:44771584 ADAM11 0 0 0 -0.3933243
chr9:4722625:4740937 AK3 0.1813192 0 0.2299663 0.3929408
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chr20:3167181:3173455 RP5-1187M17.10 -0.06645489 0 -0.06613072 -0.3927094
chr3:15560897:15563358 HACL1,COLQ 0.2873231 0 0 0.3925221
chr16:2181929:2184777 CASKIN1 0 0 0 -0.3919842
chr14:90923196:90943078 RPS6KA5 0.1299501 0 0.1641599 0.3919135
chr11:34115884:34118396 NAT10 -0.04658438 0 0 -0.3916141
chr2:29157347:29160333 CLIP4 0.05354037 0 0.100109 0.3912426
chr2:29157402:29160333 CLIP4 -0.05354037 0 -0.100109 -0.3912426
chr3:33573354:33576169 CLASP2 -0.1206724 0 -0.1548359 -0.3905625
chr10:119781242:119781635 INPP5F -0.1018755 0 -0.1146103 -0.3893509
chr1:114397860:114399457 TRIM33 -0.2083045 0 -0.1971957 -0.3889639
chr2:218650526:218656150 ZNF142 0 0 0 -0.3884384
chr17:54962915:54963306 COX11 0.1749445 0 0.2104098 0.3882826
chr1:110047869:110050343 STRIP1 -0.03267587 0 0 -0.3877105
chr9:4722625:4726083 AK3 -0.1899688 0 -0.2255977 -0.3870273
chr6:25610181:25619447 LRRC16A 0 0 -0.1581009 -0.3867496
chr18:47136449:47150378 HDHD2,RP11-49K24.6 0 0 0.1750605 0.3866416
chr8:22589741:22593733 PDLIM2,AC037459.4,C8orf58 0 0 0 -0.3864376
chr10:49752248:49752638 OGDHL 0 0 0.1083482 0.3855623
chr10:49752372:49752638 OGDHL 0 0 -0.1083482 -0.3855623
chr18:2656261:2666870 SMCHD1 -0.1372512 0 -0.1074765 -0.3852895
chr11:103236539:103243693 DYNC2H1 0 0 -0.1735119 -0.3851441
chr3:98573570:98585441 CPOX 0 0 -0.1447448 -0.3846425
chr3:98581511:98585441 CPOX 0 0 0.1447448 0.3846425
chr7:151240522:151241492 SMARCD3 0.07742723 0 0.08609203 0.3841054
chr1:245929937:246327201 SMYD3 0.07219736 0 0.09847122 0.3837534
chr11:57791673:57795577 CTNND1,RP11-691N7.6 -0.2229604 0 -0.108085 -0.3837508
chr16:30852322:30888860 BCL7C -0.08522953 0 -0.1095987 -0.38361
chr2:253115:256207 SH3YL1 -0.1754772 0 -0.1239628 -0.3831715
chr22:50286287:50287667 PLXNB2 -0.04569239 0 -0.04695058 -0.3829264
chr3:195681666:195683752 LINC00969,SDHAP2 0 0 0 0.382365
chr3:195682217:195683752 LINC00969,SDHAP2 0 0 0 -0.382365
chr16:67169101:67169279 HSF4 0 0 0 0.381262
chr7:117745930:117756555 CTTNBP2 -0.09456804 0 -0.1375 -0.3807612
chr14:96291682:96294960 ATG2B -0.04469521 0 -0.06786555 -0.379444
chr7:88171561:88181505 ADAM22 -0.1603657 0 -0.1610472 -0.3791092
chr15:101430063:101431990 PCSK6 0 0 -0.04935663 -0.378639
chr5:87401772:87407976 CCNH -0.1085046 0 -0.1368058 -0.3779542
chr15:82859135:82864167 HOMER2 0.1521819 0 0.1280877 0.377074
chr15:82859168:82864167 HOMER2 -0.1521819 0 -0.1280877 -0.377074
chr1:144448916:144456537 NBPF15 -0.1203707 0 -0.1573489 -0.3768461
chr3:197624197:197627572 AC024560.3 0 0 -0.09302763 -0.3761044
chr15:55389433:55407847 CCPG1,DYX1C1-CCPG1 -0.09950821 0 -0.1183705 -0.3760652
chr15:55389433:55408221 CCPG1,DYX1C1-CCPG1 0.09950821 0 0.1183705 0.3760652
chr18:21741812:21765772 MIB1 0.0745156 0 0.1056607 0.3756994
chr2:230044:230547 SH3YL1 -0.1314541 0 0 -0.3749183
chr2:230044:231023 SH3YL1 0.1314541 0 0 0.3749183
chr6:57161152:57168423 ZNF451,BAG2 0.1414097 0 0.1500297 0.3746451
chr11:34137026:34139385 NAT10 -0.04577037 0 -0.04411373 -0.3737202
chr9:23762249:23825806 ELAVL2 -0.1693968 0 -0.1945192 -0.3734615
chr14:90906299:90920206 RPS6KA5 0.1823191 0 0.1503975 0.3725372
chr1:58685251:58690340 MYSM1 -0.1244623 0 -0.12032 -0.3723857
chr17:59930174:59931622 RPS6KB1 0.2080332 0 0.1824862 0.3714322
chr6:111259727:111262257 MFSD4B 0 0 0 0.3710439
chr3:136819628:136854443 SLC35G2 -0.1752702 0 -0.2093352 -0.3708533
chrY:2975654:2976670 ZFY 0.2095899 0 0.1649784 0.3706957
chr16:72044357:72088987 TXNL4B -0.1858705 0 0 -0.3705723
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Leafcutter:delta_psi Leafcutter:delta_psi Leafcutter:delta_psi Leafcutter:delta_psi
Junction ALShigh_vs_Control ALSlow_vs_Control C9_vs_Control FTD_vs_Control
chr12:54282874:54283079 HNRNPA1 -0.04464831 0 -0.04513898 -0.140054
chr12:54282874:54283812 HNRNPA1 0.06412829 0 0.0674213 0.1828857
chr12:54283234:54283812 HNRNPA1 -0.01947998 0 -0.02228232 -0.04283172
chr12:54284317:54284549 HNRNPA1 0 0 0 0.06833414
chr12:54284317:54286662 HNRNPA1 0 0 0 -0.06833414
chr10:68332197:68337199 HNRNPH3 0 0 0 0.000903326
chr10:68332216:68337199 HNRNPH3 0 0 0 0.108741
chr10:68332235:68337199 HNRNPH3 0 0 0 -0.1045583
chr10:68333102:68337199 HNRNPH3 0 0 0 -0.00508603
chr10:68338642:68339140 HNRNPH3 0.06993597 0 0.07497951 0.1116341
chr10:68338669:68339140 HNRNPH3 -0.000592127 0 0.002750076 -0.000942758
chr10:68338687:68339140 HNRNPH3 -0.06934385 0 -0.07772958 -0.1106914
chr10:68341680:68341759 HNRNPH3 0 0 0 0.009007517
chr10:68341680:68341783 HNRNPH3 0 0 0 -0.009007517
chr14:21234229:21262594 HNRNPC 0 0 0.001004408 0.001966559
chr14:21234229:21262601 HNRNPC 0 0 0.006830296 0.01558167
chr14:21234229:21263311 HNRNPC 0 0 -0.01562917 -0.00992176
chr14:21234229:21269298 HNRNPC 0 0 0.01983137 0.03716677
chr14:21263336:21269298 HNRNPC 0 0 -0.02919522 -0.05045077
chr14:21263829:21269298 HNRNPC 0 0 0.02154274 0.01961835
chr14:21268668:21269298 HNRNPC 0 0 -0.002728405 -0.008505303
chr19:8471427:8473664 HNRNPM 0 0 0 0.02472852
chr19:8471427:8474167 HNRNPM 0 0 0 -0.05833532
chr19:8473708:8474167 HNRNPM 0 0 0 0.0336068
chr19:8474244:8483158 HNRNPM 0 0 0 0.05050668
chr19:8474244:8485603 HNRNPM 0 0 0 -0.08675508
chr19:8483211:8485603 HNRNPM 0 0 0 0.03624841
chr19:38840559:38841613 HNRNPL 0.003078114 0 0 0.00344637
chr19:38840559:38843842 HNRNPL -0.01160962 0 0 -0.01428228
chr19:38841682:38843842 HNRNPL 0.008531503 0 0 0.01083591
chr19:41262582:41268223 HNRNPUL1 0 0 -0.01988851 0
chr19:41264692:41268223 HNRNPUL1 0 0 -0.04565816 0
chr19:41264798:41268223 HNRNPUL1 0 0 0.06554667 0
chr19:41279176:41281163 HNRNPUL1 0 0 0 -0.003143077
chr19:41279176:41292245 HNRNPUL1 0 0 0 -0.03712857
chr19:41281275:41292245 HNRNPUL1 0 0 0 0.04027164
chr7:26174782:26185199 HNRNPA2B1 0.00225761 0 0.001285982 0.003201048
chr7:26174782:26190993 HNRNPA2B1 0.000389151 0 0.00111101 0.001383017
chr7:26174782:26192495 HNRNPA2B1 0.006138756 0 0.00619904 0.009545154
chr7:26190460:26190993 HNRNPA2B1 -0.03739261 0 -0.01943532 0.001853332
chr7:26190460:26191056 HNRNPA2B1 0.009616658 0 0.01013851 0.01769525
chr7:26191128:26191422 HNRNPA2B1 -0.001991997 0 -0.005395542 0.002070724
chr7:26191128:26192495 HNRNPA2B1 0.01410078 0 0.003509516 0.01136614
chr7:26191650:26192495 HNRNPA2B1 -0.001415684 0 -0.001062325 0.004402625
chr7:26192338:26192495 HNRNPA2B1 0.008297334 0 0.003649138 -0.05151729
chr7:26197732:26197831 HNRNPA2B1 0 0 0 -0.04647113
chr7:26197732:26200572 HNRNPA2B1 0 0 0 0.06860273
chr7:26197866:26200572 HNRNPA2B1 0 0 0 -0.0221316
chr5:178209447:178210132 HNRNPAB 0 0 0 -0.1061539
chr5:178209447:178210553 HNRNPAB 0 0 0 0.0511404
chr5:178210272:178210553 HNRNPAB 0 0 0 0.05501353
chr5:179614959:179615546 HNRNPH1 0.02411877 0 0.02892536 0.1355606
chr5:179614959:179616126 HNRNPH1 -0.04861032 0 -0.05452836 -0.2458729
chr5:179615595:179616126 HNRNPH1 0.02449155 0 0.02560299 0.1103124
chr5:179616218:179616869 HNRNPH1 0.1102794 0 0.1308451 0.3490703
chr5:179616218:179617021 HNRNPH1 -0.1102794 0 -0.1308451 -0.3490703
chr5:179618323:179619269 HNRNPH1 -0.01562605 0 -0.01206289 0.01090368
chr5:179618323:179620892 HNRNPH1 -0.02699708 0 -0.02699267 -0.07513974
chr5:179619407:179620892 HNRNPH1 0.04262313 0 0.03905556 0.06423606
chr5:179621397:179621843 HNRNPH1 -0.01170553 0 -0.01876279 -0.03510356
chr5:179621397:179623037 HNRNPH1 0.02587008 0 0.0342435 0.07400717
chr5:179621976:179623037 HNRNPH1 -0.01416454 0 -0.01548072 -0.03890361
chr4:82357444:82358659 HNRNPD -0.01344012 0 0 -0.02294701
chr4:82357444:82373446 HNRNPD -0.003843055 0 0 -0.01090265
chr4:82358820:82359471 HNRNPD -0.000473315 0 0 0.02154779
chr4:82358820:82373446 HNRNPD -0.008399018 0 0 -0.02778621
chr4:82359639:82371528 HNRNPD 0.01247048 0 0 0.03990337
chr4:82359639:82373446 HNRNPD -0.009309969 0 0 -0.03712088
chr4:82371584:82373446 HNRNPD 0.02348858 0 0 0.03769744
chr4:82354154:82354895 HNRNPD 0 0 -0.03330129 -0.05565196
chr4:82354154:82355304 HNRNPD 0 0 0.06735783 0.1620619
chr4:82355001:82355304 HNRNPD 0 0 -0.03405655 -0.1064099
chr4:82355401:82356537 HNRNPD 0 0 0 0.06913354
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chr4:82355401:82356796 HNRNPD 0 0 0 -0.1036647
chr4:82356683:82356796 HNRNPD 0 0 0 0.03453111
chr4:82424883:82425563 HNRNPDL -0.04998467 0 -0.04805434 -0.1225465
chr4:82424883:82426037 HNRNPDL 0.2160315 0 0.1952651 0.4773015
chr4:82425667:82426037 HNRNPDL -0.1660468 0 -0.1472108 -0.3547549
chr4:82428179:82428278 HNRNPDL 0 0 0 0.0104638
chr4:82428201:82428278 HNRNPDL 0 0 0 -0.0104638
chr2:177212805:177215539 HNRNPA3 0.05868872 0 0.06022479 0.1042988
chr2:177212871:177215539 HNRNPA3 -0.05868872 0 -0.06022479 -0.1042988
chr2:177219314:177219408 HNRNPA3 0 0 0.06665894 0.07226273
chr2:177219314:177222060 HNRNPA3 0 0 -0.06705709 -0.1046481
chr2:177221976:177222060 HNRNPA3 0 0 0.000398152 0.03238533
chr1:23321663:23323556 HNRNPR 0 0 0 -0.000130248
chr1:23321663:23333518 HNRNPR 0 0 0 -0.01926056
chr1:23323732:23333518 HNRNPR 0 0 0 0.01046502
chr1:23323732:23337754 HNRNPR 0 0 0 0.000547867
chr1:23333631:23337754 HNRNPR 0 0 0 0.008377921
chr1:23338608:23340852 HNRNPR 0 0 0 0.0427875
chr1:23338608:23344211 HNRNPR 0 0 0 -0.05555288
chr1:23341017:23344211 HNRNPR 0 0 0 0.01790517
chr1:23341020:23344211 HNRNPR 0 0 0 -0.005139791
chr1:244846706:244847002 HNRNPU 0 0 0 -0.007980226
chr1:244846706:244848788 HNRNPU 0 0 0 -0.004143071
chr1:244846706:244854382 HNRNPU 0 0 0 0.001237134
chr1:244847101:244848788 HNRNPU 0 0 0 -0.008612575
chr1:244848856:244854219 HNRNPU 0 0 0 0.001835538
chr1:244848856:244854318 HNRNPU 0 0 0 -0.00214505
chr1:244848856:244854382 HNRNPU 0 0 0 0.0062707
chr1:244848856:244854973 HNRNPU 0 0 0 0.004860983
chr1:244854503:244854973 HNRNPU 0 0 0 0.008676567
chr1:244862730:244863617 HNRNPU 0 0 0 -0.1024127
chr1:244862730:244863674 HNRNPU 0 0 0 0.1024127
chr9:83970804:83970897 HNRNPK 0.01089113 0 0 0.01773865
chr9:83970819:83970897 HNRNPK -0.01089113 0 0 -0.01773865
chr9:83971356:83971672 HNRNPK -0.005866077 0 0 -0.01153652
chr9:83971356:83971882 HNRNPK -0.00208548 0 0 -0.001966999
chr9:83971726:83971882 HNRNPK 0.007951557 0 0 0.01350352
chr9:83973399:83973902 HNRNPK 0.02206079 0 0.02583382 0.07846091
chr9:83973399:83974517 HNRNPK -0.05122786 0 -0.0363434 -0.1902102
chr9:83973973:83974517 HNRNPK 0.02916708 0 0.01050958 0.1117493
chr9:83974589:83975462 HNRNPK 0 0 0 -0.005979376
chr9:83974589:83976995 HNRNPK 0 0 0 -0.01213191
chr9:83975505:83976995 HNRNPK 0 0 0 0.01811129
chr9:83978327:83980503 HNRNPK 0 0 0 -0.04339933
chr9:83978452:83979601 HNRNPK 0 0 0 0.000942393
chr9:83978452:83980119 HNRNPK 0 0 0 -0.07619985
chr9:83978452:83980153 HNRNPK 0 0 0 0.1390783
chr9:83978452:83980503 HNRNPK 0 0 0 -0.02042153
chr12:120464122:120464733 SRSF9 -0.03598087 0 -0.03753002 -0.03459227
chr12:120464122:120465627 SRSF9 0.04128246 0 0.05860602 0.05599814
chr12:120464822:120465627 SRSF9 -0.005301593 0 -0.021076 -0.02140587
chr17:58005041:58005398 SRSF1 0 0 0.00072668 0.006024137
chr17:58005041:58005414 SRSF1 0 0 0.06288708 0.1288102
chr17:58005041:58005801 SRSF1 0 0 0.002745195 0.009405069
chr17:58005600:58005732 SRSF1 0 0 -0.006529362 0.001603389
chr17:58005600:58005801 SRSF1 0 0 -0.05982959 -0.1458428
chr17:76735158:76735772 SRSF2 0 0 0.08377773 0.1580273
chr17:76735158:76736154 SRSF2 0 0 -0.1174178 -0.2878961
chr17:76735875:76736154 SRSF2 0 0 0.03364012 0.1298688
chr14:69767251:69768138 SRSF5 0.05800296 0 0.06673262 0.1650301
chr14:69767255:69768138 SRSF5 0.002204048 0 0.005542287 0.03759321
chr14:69767380:69768138 SRSF5 -0.05442127 0 -0.06291063 -0.1863507
chr14:69767987:69768138 SRSF5 -0.005785737 0 -0.009364278 -0.01627257
chr14:69769251:69769511 SRSF5 -0.1442252 0 -0.1276911 -0.4073615
chr14:69769251:69770467 SRSF5 0.292486 0 0.1993165 0.7368784
chr14:69770042:69770467 SRSF5 -0.1482607 0 -0.07162541 -0.3295169
chr14:69771105:69771194 SRSF5 0.03466918 0 0.03575948 0.07962102
chr14:69771105:69771197 SRSF5 -0.03466918 0 -0.03575948 -0.07962102
chr20:43458509:43459153 SRSF6 -0.01328844 0 0 -0.02144423
chr20:43458509:43459771 SRSF6 0.1705501 0 0 0.275081
chr20:43459420:43459771 SRSF6 -0.1572617 0 0 -0.2536368
chr2:38733616:38746144 SRSF7 -0.01008301 0 0 -0.03200694
chr2:38745187:38746144 SRSF7 0.01422441 0 0 0.03128002
chr2:38745187:38746694 SRSF7 0.01346313 0 0 0.0280257
chr2:38746179:38746694 SRSF7 -0.01760453 0 0 -0.02729878
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chr1:23967723:23971338 SRSF10 0.004860653 0 0.003777852 0.01279116
chr1:23967723:23971573 SRSF10 -0.01534323 0 -0.02562077 -0.03362377
chr1:23967723:23971850 SRSF10 -0.008556695 0 -0.003708238 -0.04179138
chr1:23967956:23971573 SRSF10 -0.03097418 0 -0.03930611 -0.1103303
chr1:23967956:23971850 SRSF10 0 0 0 -0.0123158
chr1:23971439:23971573 SRSF10 0.06915029 0 0.09747026 0.1620944
chr1:23971623:23971850 SRSF10 -0.01609075 0 -0.0033489 -0.002899866
chr1:23971626:23971850 SRSF10 -0.003046085 0 -0.0292641 0.02607551
chr1:29149226:29150103 SRSF4 0 0 0 0.03431194
chr1:29149226:29154696 SRSF4 0 0 0 -0.02742517
chr1:29150192:29154696 SRSF4 0 0 0 -0.006886772
chr1:29160517:29165890 SRSF4 0 0 0 0.08002993
chr1:29160517:29181646 SRSF4 0 0 0 -0.09394769
chr1:29168638:29181646 SRSF4 0 0 0 0.01391775
chr1:70221839:70228422 SRSF11 0 0 0 -0.01011727
chr1:70222798:70228422 SRSF11 0 0 0 0.01011727
chr1:70228555:70229210 SRSF11 0.000160739 0 -0.001947995 0.008730774
chr1:70228555:70230557 SRSF11 -0.000650996 0 -0.004126799 0.002662229
chr1:70228555:70231095 SRSF11 -0.002130903 0 -0.003798859 0.003024872
chr1:70228555:70231859 SRSF11 -0.009626917 0 -0.01948226 0.001357574
chr1:70228555:70232268 SRSF11 -0.1750707 0 -0.1651599 -0.512832
chr1:70230618:70231095 SRSF11 0.1229157 0 0.08676264 0.2060549
chr1:70231194:70231859 SRSF11 0.005886058 0 0.007947516 0.00955872
chr1:70231203:70231859 SRSF11 -0.01136764 0 0.01995147 0.04676499
chr1:70231975:70232268 SRSF11 0.06988468 0 0.07985421 0.234678
chr1:70246907:70247117 SRSF11 0.01497776 0 0.01295762 0.02056253
chr1:70246907:70249931 SRSF11 0.007355109 0 0.004603886 0.005635891
chr1:70246907:70249952 SRSF11 -0.04181558 0 -0.0324893 -0.04794115
chr1:70247149:70249952 SRSF11 0.0194827 0 0.01492779 0.02174273
chr1:70250503:70250608 SRSF11 0.04828937 0 0.06020454 0.1167388
chr1:70250503:70250611 SRSF11 -0.04828937 0 -0.06020454 -0.1167388
chr16:31185179:31186802 FUS 0.02241389 0 0.006426189 0.05543376
chr16:31185179:31188325 FUS -0.05549228 0 -0.02552221 -0.1082369
chr16:31186836:31188325 FUS 0.03307838 0 0.01909602 0.05280313
chr17:35809576:35817716 TAF15 0 0 0 0.04362362
chr17:35809576:35820024 TAF15 0 0 0 -0.01744908
chr17:35810063:35817716 TAF15 0 0 0 2.65723E-05
chr17:35817755:35820024 TAF15 0 0 0 -0.02620111
chr17:35820075:35820164 TAF15 0 0 0.0301249 0.05677004
chr17:35820075:35820332 TAF15 0 0 -0.02702432 -0.1045486
chr17:35820239:35820332 TAF15 0 0 -0.01100939 -0.03648611
chr17:35820248:35820332 TAF15 0 0 0.007908801 0.08426465
chr17:35824198:35833907 TAF15 0.03102347 0 0 0.08048068
chr17:35824198:35834566 TAF15 -0.04136121 0 0 -0.1541364
chr17:35833941:35834566 TAF15 0.01033774 0 0 0.0736557
chr22:29273864:29274265 EWSR1 0.0276785 0 0.02822827 0.06328028
chr22:29273864:29274268 EWSR1 -0.01143625 0 -0.01001866 -0.01973114
chr22:29273864:29278030 EWSR1 -0.06070072 0 -0.07310411 -0.127054
chr22:29274282:29278030 EWSR1 0.04445847 0 0.0548945 0.0835049
chr22:29278216:29282390 EWSR1 0 0 0 -0.03841
chr22:29278216:29286923 EWSR1 0 0 0 0.009752671
chr22:29282557:29286923 EWSR1 0 0 0 0.02865733
chr22:29288786:29291562 EWSR1 0.01937373 0 0.01939724 0.05946043
chr22:29288786:29291565 EWSR1 -0.008911275 0 -0.01943065 0.02043774
chr22:29288786:29292137 EWSR1 -0.02231327 0 -0.02279859 -0.1007332
chr22:29291599:29292137 EWSR1 0.01185081 0 0.022832 0.02083506
chr22:29298895:29299195 EWSR1 0 0 0 -0.02757129
chr22:29298895:29299234 EWSR1 0 0 0 0.02757129
chr22:29299280:29299599 EWSR1 0 0 0 0.01617563
chr22:29299331:29299599 EWSR1 0 0 0 -0.01617563
chr2:70215494:70216208 TIA1 0 0 0.006039033 0.06958403
chr2:70215494:70216404 TIA1 0 0 -0.01378345 -0.1330183
chr2:70216292:70216404 TIA1 0 0 0.007744422 0.06343423
chr2:70227822:70228344 TIA1 0.03146571 0 0.02088583 0.04373417
chr2:70227822:70229059 TIA1 0.04829671 0 0.01668254 0.03691394
chr2:70227822:70229264 TIA1 -0.1851315 0 -0.1304606 -0.2126159
chr2:70228462:70229059 TIA1 0.005072772 0 0.01430953 -0.003024882
chr2:70228462:70229264 TIA1 -0.005743333 0 0.004353118 -0.002388268
chr2:70229091:70229264 TIA1 0.1060397 0 0.07422953 0.1373809
chr10:110297728:110298648 SMNDC1 0 0 0.02939717 0.06097828
chr10:110297745:110298648 SMNDC1 0 0 -0.02939717 -0.06097828
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